"Analysis.group","Analysis.number","Analysis.name","Subgroup","Applicability","Study","Study.year","GIV.Mean","GIV.SE","Experimental.mean","Experimental.SD","Experimental.cases","Experimental.N","Control.mean","Control.SD","Control.cases","Control.N","O.E","Variance","Weight","Mean","CI.start","CI.end","Footnotes","review.url","review.doi","analysis_key","dataset_name","mismatch_type","direction_match","or_sig","rd_sig","log_or","rd","log_or_ci_lb","log_or_ci_ub","rd_ci_lb","rd_ci_ub","sparse_events","double_zero"
1,1,"FEV1 % predicted (absolute change from baseline)","At up to 1 month","SUBGROUP_AND_OVERALL","Boyle 2014","2014",0,0,-0.2,4.32615,0,40,1.7,4.174,0,21,0,0,100,-1.9,-4.132572,0.332572,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","1::overall","CD010966_pub4_data","significance_only",TRUE,FALSE,TRUE,-0.207750252671045,-0.0819815913269149,-0.673556970156986,0.258056464814896,-0.1207064162904,-0.0432567663634297,TRUE,TRUE
1,2,"Adverse effects: 100 mg and 200 mg lumacaftor groups (combined data) versus placebo at up to 1 month","Cough","SUBGROUP_AND_OVERALL","Clancy 2012","2012",0,0,0,0,17,36,0,0,7,17,0,0,100,1.278195,0.27588,5.92209,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
1,2,"Adverse effects: 100 mg and 200 mg lumacaftor groups (combined data) versus placebo at up to 1 month","Headache","SUBGROUP_AND_OVERALL","Clancy 2012","2012",0,0,0,0,7,36,0,0,3,17,0,0,100,1.126437,0.157838,8.038992,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
1,2,"Adverse effects: 100 mg and 200 mg lumacaftor groups (combined data) versus placebo at up to 1 month","Rales","SUBGROUP_AND_OVERALL","Clancy 2012","2012",0,0,0,0,6,36,0,0,1,17,0,0,100,3.2,0.177094,57.822561,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
1,2,"Adverse effects: 100 mg and 200 mg lumacaftor groups (combined data) versus placebo at up to 1 month","Productive cough","SUBGROUP_AND_OVERALL","Clancy 2012","2012",0,0,0,0,10,36,0,0,3,17,0,0,100,1.794872,0.268865,11.982113,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
1,2,"Adverse effects: 100 mg and 200 mg lumacaftor groups (combined data) versus placebo at up to 1 month","Dyspnoea","SUBGROUP_AND_OVERALL","Clancy 2012","2012",0,0,0,0,6,36,0,0,1,17,0,0,100,3.2,0.177094,57.822561,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
1,2,"Adverse effects: 100 mg and 200 mg lumacaftor groups (combined data) versus placebo at up to 1 month","Pulmonary exacerbation","SUBGROUP_AND_OVERALL","Clancy 2012","2012",0,0,0,0,6,36,0,0,2,17,0,0,100,1.5,0.15725,14.308424,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
1,2,"Adverse effects: 100 mg and 200 mg lumacaftor groups (combined data) versus placebo at up to 1 month","Fatigue","SUBGROUP_AND_OVERALL","Clancy 2012","2012",0,0,0,0,5,36,0,0,2,17,0,0,100,1.209677,0.120997,12.093845,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
1,2,"Adverse effects: 100 mg and 200 mg lumacaftor groups (combined data) versus placebo at up to 1 month","Fever","SUBGROUP_AND_OVERALL","Clancy 2012","2012",0,0,0,0,6,36,0,0,2,17,0,0,100,1.5,0.15725,14.308424,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
1,2,"Adverse effects: 100 mg and 200 mg lumacaftor groups (combined data) versus placebo at up to 1 month","Nasal congestion","SUBGROUP_AND_OVERALL","Clancy 2012","2012",0,0,0,0,4,36,0,0,3,17,0,0,100,0.583333,0.069083,4.925647,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
1,2,"Adverse effects: 100 mg and 200 mg lumacaftor groups (combined data) versus placebo at up to 1 month","Wheezing","SUBGROUP_AND_OVERALL","Clancy 2012","2012",0,0,0,0,1,36,0,0,3,17,0,0,100,0.133333,0.006104,2.912258,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
1,2,"Adverse effects: 100 mg and 200 mg lumacaftor groups (combined data) versus placebo at up to 1 month","Diarrhoea","SUBGROUP_AND_OVERALL","Clancy 2012","2012",0,0,0,0,2,36,0,0,3,17,0,0,100,0.27451,0.022769,3.309639,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
1,2,"Adverse effects: 100 mg and 200 mg lumacaftor groups (combined data) versus placebo at up to 1 month","Oropharyngeal pain","SUBGROUP_AND_OVERALL","Clancy 2012","2012",0,0,0,0,2,36,0,0,3,17,0,0,100,0.27451,0.022769,3.309639,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
1,2,"Adverse effects: 100 mg and 200 mg lumacaftor groups (combined data) versus placebo at up to 1 month","Upper respiratory tract infection","SUBGROUP_AND_OVERALL","Clancy 2012","2012",0,0,0,0,3,36,0,0,1,17,0,0,100,1.454545,0.067112,31.524761,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
1,2,"Adverse effects: 100 mg and 200 mg lumacaftor groups (combined data) versus placebo at up to 1 month","Sinus congestion","SUBGROUP_AND_OVERALL","Clancy 2012","2012",0,0,0,0,1,36,0,0,2,17,0,0,100,0.214286,0.008281,5.545007,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
1,2,"Adverse effects: 100 mg and 200 mg lumacaftor groups (combined data) versus placebo at up to 1 month","Respiration abnormal","SUBGROUP_AND_OVERALL","Clancy 2012","2012",0,0,0,0,4,36,0,0,0,17,0,0,100,4.846154,0.096632,243.038722,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
1,2,"Adverse effects: 100 mg and 200 mg lumacaftor groups (combined data) versus placebo at up to 1 month","Haemoptysis","SUBGROUP_AND_OVERALL","Clancy 2012","2012",0,0,0,0,2,36,0,0,2,17,0,0,100,0.441176,0.029747,6.543174,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
1,2,"Adverse effects: 100 mg and 200 mg lumacaftor groups (combined data) versus placebo at up to 1 month","Constipation","SUBGROUP_AND_OVERALL","Clancy 2012","2012",0,0,0,0,2,36,0,0,0,17,0,0,100,2.536232,0.043685,147.246545,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
1,2,"Adverse effects: 100 mg and 200 mg lumacaftor groups (combined data) versus placebo at up to 1 month","Abdominal pain","SUBGROUP_AND_OVERALL","Clancy 2012","2012",0,0,0,0,1,36,0,0,1,17,0,0,100,0.457143,0.011025,18.954252,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
1,2,"Adverse effects: 100 mg and 200 mg lumacaftor groups (combined data) versus placebo at up to 1 month","Myalgia","SUBGROUP_AND_OVERALL","Clancy 2012","2012",0,0,0,0,1,36,0,0,1,17,0,0,100,0.457143,0.011025,18.954252,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
1,2,"Adverse effects: 100 mg and 200 mg lumacaftor groups (combined data) versus placebo at up to 1 month","Post-tussive vomiting","SUBGROUP_AND_OVERALL","Clancy 2012","2012",0,0,0,0,2,36,0,0,0,17,0,0,100,2.536232,0.043685,147.246545,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
1,2,"Adverse effects: 100 mg and 200 mg lumacaftor groups (combined data) versus placebo at up to 1 month","Nausea","SUBGROUP_AND_OVERALL","Clancy 2012","2012",0,0,0,0,1,36,0,0,0,17,0,0,100,1.478873,0.020614,106.096226,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
1,2,"Adverse effects: 100 mg and 200 mg lumacaftor groups (combined data) versus placebo at up to 1 month","Nasopharyngitis","SUBGROUP_AND_OVERALL","Clancy 2012","2012",0,0,0,0,3,36,0,0,0,17,0,0,100,3.656716,0.069173,193.30498,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
1,2,"Adverse effects: 100 mg and 200 mg lumacaftor groups (combined data) versus placebo at up to 1 month","Dizziness","SUBGROUP_AND_OVERALL","Clancy 2012","2012",0,0,0,0,3,36,0,0,0,17,0,0,100,3.656716,0.069173,193.30498,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
1,2,"Adverse effects: 100 mg and 200 mg lumacaftor groups (combined data) versus placebo at up to 1 month","Back pain","SUBGROUP_AND_OVERALL","Clancy 2012","2012",0,0,0,0,1,36,0,0,0,17,0,0,100,1.478873,0.020614,106.096226,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
1,2,"Adverse effects: 100 mg and 200 mg lumacaftor groups (combined data) versus placebo at up to 1 month","Upper abdominal pain","SUBGROUP_AND_OVERALL","Clancy 2012","2012",0,0,0,0,3,36,0,0,1,17,0,0,100,1.454545,0.067112,31.524761,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
1,2,"Adverse effects: 100 mg and 200 mg lumacaftor groups (combined data) versus placebo at up to 1 month","Sputum abnormal","SUBGROUP_AND_OVERALL","Clancy 2012","2012",0,0,0,0,1,36,0,0,0,17,0,0,100,1.478873,0.020614,106.096226,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
1,2,"Adverse effects: 100 mg and 200 mg lumacaftor groups (combined data) versus placebo at up to 1 month","Epistaxis","SUBGROUP_AND_OVERALL","Clancy 2012","2012",0,0,0,0,2,36,0,0,1,17,0,0,100,0.941176,0.036495,24.272029,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
1,2,"Adverse effects: 100 mg and 200 mg lumacaftor groups (combined data) versus placebo at up to 1 month","C-reactive protein increased","SUBGROUP_AND_OVERALL","Clancy 2012","2012",0,0,0,0,2,36,0,0,0,17,0,0,100,2.536232,0.043685,147.246545,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
1,2,"Adverse effects: 100 mg and 200 mg lumacaftor groups (combined data) versus placebo at up to 1 month","Paranasal sinus hypersecretion","SUBGROUP_AND_OVERALL","Clancy 2012","2012",0,0,0,0,0,36,0,0,0,17,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
1,2,"Adverse effects: 100 mg and 200 mg lumacaftor groups (combined data) versus placebo at up to 1 month","Lung hyperinflation","SUBGROUP_AND_OVERALL","Clancy 2012","2012",0,0,0,0,2,36,0,0,0,17,0,0,100,2.536232,0.043685,147.246545,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
1,3,"Adverse effects: 200 mg lumacaftor group versus placebo at up to 1 month","Cough","SUBGROUP_AND_OVERALL","Boyle 2014","2014",0,0,0,0,6,41,0,0,1,21,0,0,100,3.428571,0.193548,60.734852,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
1,3,"Adverse effects: 200 mg lumacaftor group versus placebo at up to 1 month","Pulmonary exacerbation","SUBGROUP_AND_OVERALL","Boyle 2014","2014",0,0,0,0,2,41,0,0,0,21,0,0,100,2.721519,0.047428,156.166305,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
1,3,"Adverse effects: 200 mg lumacaftor group versus placebo at up to 1 month","Oropharyngeal pain","SUBGROUP_AND_OVERALL","Boyle 2014","2014",0,0,0,0,2,41,0,0,0,21,0,0,100,2.721519,0.047428,156.166305,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
1,3,"Adverse effects: 200 mg lumacaftor group versus placebo at up to 1 month","Nasal congestion","SUBGROUP_AND_OVERALL","Boyle 2014","2014",0,0,0,0,0,41,0,0,0,21,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
1,3,"Adverse effects: 200 mg lumacaftor group versus placebo at up to 1 month","Dizziness","SUBGROUP_AND_OVERALL","Boyle 2014","2014",0,0,0,0,0,41,0,0,0,21,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
1,3,"Adverse effects: 200 mg lumacaftor group versus placebo at up to 1 month","Prothrombin time prolonged","SUBGROUP_AND_OVERALL","Boyle 2014","2014",0,0,0,0,1,41,0,0,0,21,0,0,100,1.592593,0.022444,113.008334,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
1,3,"Adverse effects: 200 mg lumacaftor group versus placebo at up to 1 month","Upper respiratory tract infection","SUBGROUP_AND_OVERALL","Boyle 2014","2014",0,0,0,0,0,41,0,0,0,21,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
1,4,"Adverse effects requiring study drug discontinuation at up to 1 month","25 mg lumacaftor","SUBGROUP_AND_OVERALL","Clancy 2012","2012",0,0,0,0,1,18,0,0,0,17,0,0,100,3,0.114194,78.813557,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
1,4,"Adverse effects requiring study drug discontinuation at up to 1 month","50 mg lumacaftor","SUBGROUP_AND_OVERALL","Clancy 2012","2012",0,0,0,0,1,18,0,0,0,17,0,0,100,3,0.114194,78.813557,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
1,4,"Adverse effects requiring study drug discontinuation at up to 1 month","100 mg lumacaftor","SUBGROUP_AND_OVERALL","Clancy 2012","2012",0,0,0,0,1,17,0,0,0,17,0,0,100,3.181818,0.120868,83.760376,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
1,4,"Adverse effects requiring study drug discontinuation at up to 1 month","200 mg lumacaftor","SUBGROUP_AND_OVERALL","Clancy 2012","2012",0,0,0,0,1,19,0,0,0,17,0,0,100,2.837838,0.108217,74.418125,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
1,5,"Sweat chloride concentration (change from baseline at up to 1 month) [mmol/L]","100 mg lumacaftor","SUBGROUP_AND_OVERALL","Clancy 2012","2012",-6.13,3.1225,0,0,0,17,0,0,0,17,0,0,100,-6.13,-12.249988,-0.010012,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
1,5,"Sweat chloride concentration (change from baseline at up to 1 month) [mmol/L]","200 mg lumacaftor","SUBGROUP_AND_OVERALL","Clancy 2012","2012",-8.21,3.1072,0,0,0,19,0,0,0,17,0,0,100,-8.21,-14.3,-2.12,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
2,1,"CFQR respiratory domain: absolute change from baseline","At up to 1 month","SUBGROUP_AND_OVERALL","Donaldson 2017","2017",0,0,-0.8,16.6,0,12,-4.6,20.9,0,12,0,0,100,3.8,-11.301159,18.901159,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","1::overall","CD010966_pub4_data","significance_only",TRUE,FALSE,TRUE,-0.207750252671045,-0.0819815913269149,-0.673556970156986,0.258056464814896,-0.1207064162904,-0.0432567663634297,TRUE,TRUE
2,2,"CFQR eating domain: absolute change from baseline","At up to 1 month","SUBGROUP_AND_OVERALL","Donaldson 2017","2017",0,0,2.4,7.8,0,12,0,4.7,0,12,0,0,100,2.4,-2.752444,7.552444,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
2,3,"Adverse events occurring in > 10% of participants at up to 1 month","Cough","SUBGROUP_AND_OVERALL","Donaldson 2017","2017",0,0,0,0,6,14,0,0,5,12,0,0,100,1.05,0.134925,8.171223,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
2,3,"Adverse events occurring in > 10% of participants at up to 1 month","Pulmonary exacerbation","SUBGROUP_AND_OVERALL","Donaldson 2017","2017",0,0,0,0,0,14,0,0,1,12,0,0,100,0.264368,0.00349,20.027854,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
2,3,"Adverse events occurring in > 10% of participants at up to 1 month","Chest discomfort","SUBGROUP_AND_OVERALL","Donaldson 2017","2017",0,0,0,0,2,14,0,0,0,12,0,0,100,5,0.081115,308.204893,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
2,3,"Adverse events occurring in > 10% of participants at up to 1 month","Fatigue","SUBGROUP_AND_OVERALL","Donaldson 2017","2017",0,0,0,0,3,14,0,0,1,12,0,0,100,3,0.125932,71.467227,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
2,4,"Sweat chloride","At up to 1 month","SUBGROUP_AND_OVERALL","Donaldson 2017","2017",0,0,-4.1,5,0,12,-0.8,9,0,12,0,0,100,-3.3,-9.125194,2.525194,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
3,1,"FEV1 % predicted (relative change from baseline at up to 1 month)","5 mg/day N6022","SUBGROUP_AND_OVERALL","Donaldson 2014","2014",0,0,-0.5,4.72,0,10,1.5,3.44,0,19,0,0,100,-2,-5.309184,1.309184,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","1::overall","CD010966_pub4_data","significance_only",TRUE,FALSE,TRUE,-0.207750252671045,-0.0819815913269149,-0.673556970156986,0.258056464814896,-0.1207064162904,-0.0432567663634297,TRUE,TRUE
3,1,"FEV1 % predicted (relative change from baseline at up to 1 month)","10 mg/day N6022","SUBGROUP_AND_OVERALL","Donaldson 2014","2014",0,0,-0.2,3.99,0,9,1.5,3.44,0,19,0,0,100,-1.7,-4.731122,1.331122,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","1::overall","CD010966_pub4_data","significance_only",TRUE,FALSE,TRUE,-0.207750252671045,-0.0819815913269149,-0.673556970156986,0.258056464814896,-0.1207064162904,-0.0432567663634297,TRUE,TRUE
3,1,"FEV1 % predicted (relative change from baseline at up to 1 month)","20 mg/day N6022","SUBGROUP_AND_OVERALL","Donaldson 2014","2014",0,0,-0.7,4.08,0,9,1.5,3.44,0,19,0,0,100,-2.2,-5.281834,0.881834,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","1::overall","CD010966_pub4_data","significance_only",TRUE,FALSE,TRUE,-0.207750252671045,-0.0819815913269149,-0.673556970156986,0.258056464814896,-0.1207064162904,-0.0432567663634297,TRUE,TRUE
3,1,"FEV1 % predicted (relative change from baseline at up to 1 month)","40 mg/day N6022","SUBGROUP_AND_OVERALL","Donaldson 2014","2014",0,0,0.5,3.04,0,19,1.5,3.44,0,19,0,0,100,-1,-3.064226,1.064226,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","1::overall","CD010966_pub4_data","significance_only",TRUE,FALSE,TRUE,-0.207750252671045,-0.0819815913269149,-0.673556970156986,0.258056464814896,-0.1207064162904,-0.0432567663634297,TRUE,TRUE
3,2,"Treatment-emergent adverse events (mild) at up to 1 month","5 mg/day N6022","SUBGROUP_AND_OVERALL","Donaldson 2014","2014",0,0,0,0,4,10,0,0,11,19,0,0,100,0.484848,0.102001,2.304656,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
3,2,"Treatment-emergent adverse events (mild) at up to 1 month","10 mg/day N6022","SUBGROUP_AND_OVERALL","Donaldson 2014","2014",0,0,0,0,6,9,0,0,11,19,0,0,100,1.454545,0.277022,7.637319,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
3,2,"Treatment-emergent adverse events (mild) at up to 1 month","20 mg/day N6022","SUBGROUP_AND_OVERALL","Donaldson 2014","2014",0,0,0,0,4,9,0,0,11,19,0,0,100,0.581818,0.117538,2.88002,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
3,2,"Treatment-emergent adverse events (mild) at up to 1 month","40 mg/day N6022","SUBGROUP_AND_OVERALL","Donaldson 2014","2014",0,0,0,0,12,19,0,0,11,19,0,0,100,1.246753,0.338697,4.58933,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
3,3,"Treatment-emergent adverse events (moderate) at up to 1 month","5 mg/day N6022","SUBGROUP_AND_OVERALL","Donaldson 2014","2014",0,0,0,0,3,10,0,0,6,19,0,0,23.07883,0.928571,0.176059,4.89749,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
3,3,"Treatment-emergent adverse events (moderate) at up to 1 month","10 mg/day N6022","SUBGROUP_AND_OVERALL","Donaldson 2014","2014",0,0,0,0,3,9,0,0,6,19,0,0,20.488349,1.083333,0.199874,5.871746,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
3,3,"Treatment-emergent adverse events (moderate) at up to 1 month","20 mg/day N6022","SUBGROUP_AND_OVERALL","Donaldson 2014","2014",0,0,0,0,5,9,0,0,6,19,0,0,13.658899,2.708333,0.529425,13.854794,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
3,3,"Treatment-emergent adverse events (moderate) at up to 1 month","40 mg/day N6022","SUBGROUP_AND_OVERALL","Donaldson 2014","2014",0,0,0,0,2,19,0,0,6,19,0,0,42.773922,0.254902,0.044044,1.475226,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
3,4,"Treatment-emergent adverse events (serious or severe) at up to 1 month","5 mg/day N6022","SUBGROUP_AND_OVERALL","Donaldson 2014","2014",0,0,0,0,2,10,0,0,1,19,0,0,16.231513,4.5,0.354607,57.105537,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
3,4,"Treatment-emergent adverse events (serious or severe) at up to 1 month","10 mg/day N6022","SUBGROUP_AND_OVERALL","Donaldson 2014","2014",0,0,0,0,0,9,0,0,1,19,0,0,27.948636,0.649123,0.024066,17.508667,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
3,4,"Treatment-emergent adverse events (serious or severe) at up to 1 month","20 mg/day N6022","SUBGROUP_AND_OVERALL","Donaldson 2014","2014",0,0,0,0,0,9,0,0,1,19,0,0,27.948636,0.649123,0.024066,17.508667,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
3,4,"Treatment-emergent adverse events (serious or severe) at up to 1 month","40 mg/day N6022","SUBGROUP_AND_OVERALL","Donaldson 2014","2014",0,0,0,0,1,19,0,0,1,19,0,0,27.871216,1,0.057974,17.249129,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
4,1,"Mean change in CFQ-R respiratory domain","At up to 1 month","SUBGROUP_AND_OVERALL","Horsley 2017","2016",0,0,-0.46,7.0038,0,6,-5.55,7.3418,0,7,0,0,100,5.09,-2.719374,12.899374,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","1::overall","CD010966_pub4_data","significance_only",TRUE,FALSE,TRUE,-0.207750252671045,-0.0819815913269149,-0.673556970156986,0.258056464814896,-0.1207064162904,-0.0432567663634297,TRUE,TRUE
4,2,"FEV1 % predicted absolute change (% points)","At up to 1 month","SUBGROUP_AND_OVERALL","Horsley 2017","2016",0,0,1.65,4.0117,0,6,-3.03,4.3683,0,7,0,0,100,4.68,0.121958,9.238042,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
4,3,"Adverse events at up to 1 month","Serious adverse events","SUBGROUP_AND_OVERALL","Horsley 2017","2016",0,0,0,0,1,6,0,0,1,7,0,0,100,1.2,0.022815,63.115776,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
4,3,"Adverse events at up to 1 month","Headache","SUBGROUP_AND_OVERALL","Horsley 2017","2016",0,0,0,0,3,6,0,0,1,7,0,0,100,6,0.183429,196.261673,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
4,3,"Adverse events at up to 1 month","Nasopharyngitis","SUBGROUP_AND_OVERALL","Horsley 2017","2016",0,0,0,0,1,6,0,0,1,7,0,0,100,1.2,0.022815,63.115776,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
4,3,"Adverse events at up to 1 month","Fatigue","SUBGROUP_AND_OVERALL","Horsley 2017","2016",0,0,0,0,1,6,0,0,0,7,0,0,100,4.090909,0.047875,349.566669,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
4,3,"Adverse events at up to 1 month","Blood CK increase","SUBGROUP_AND_OVERALL","Horsley 2017","2016",0,0,0,0,1,6,0,0,0,7,0,0,100,4.090909,0.047875,349.566669,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
4,3,"Adverse events at up to 1 month","Cough","SUBGROUP_AND_OVERALL","Horsley 2017","2016",0,0,0,0,1,6,0,0,0,7,0,0,100,4.090909,0.047875,349.566669,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
4,3,"Adverse events at up to 1 month","Flatulence","SUBGROUP_AND_OVERALL","Horsley 2017","2016",0,0,0,0,0,6,0,0,0,7,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
4,3,"Adverse events at up to 1 month","Respiratory exacerbation","SUBGROUP_AND_OVERALL","Horsley 2017","2016",0,0,0,0,0,6,0,0,1,7,0,0,100,0.333333,0.003923,28.325088,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
4,3,"Adverse events at up to 1 month","Rhinorrhoea","SUBGROUP_AND_OVERALL","Horsley 2017","2016",0,0,0,0,1,6,0,0,1,7,0,0,100,1.2,0.022815,63.115776,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
4,3,"Adverse events at up to 1 month","Increased sputum","SUBGROUP_AND_OVERALL","Horsley 2017","2016",0,0,0,0,0,6,0,0,0,7,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
4,3,"Adverse events at up to 1 month","Abdominal pain","SUBGROUP_AND_OVERALL","Horsley 2017","2016",0,0,0,0,0,6,0,0,1,7,0,0,100,0.333333,0.003923,28.325088,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
4,3,"Adverse events at up to 1 month","Dry mouth","SUBGROUP_AND_OVERALL","Horsley 2017","2016",0,0,0,0,0,6,0,0,1,7,0,0,100,0.333333,0.003923,28.325088,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
4,3,"Adverse events at up to 1 month","Lethargy","SUBGROUP_AND_OVERALL","Horsley 2017","2016",0,0,0,0,0,6,0,0,2,7,0,0,100,0.169231,0.002389,11.9878,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
4,3,"Adverse events at up to 1 month","Myalgia","SUBGROUP_AND_OVERALL","Horsley 2017","2016",0,0,0,0,0,6,0,0,0,7,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
4,3,"Adverse events at up to 1 month","Nasal congestion","SUBGROUP_AND_OVERALL","Horsley 2017","2016",0,0,0,0,0,6,0,0,0,7,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
4,3,"Adverse events at up to 1 month","Nausea","SUBGROUP_AND_OVERALL","Horsley 2017","2016",0,0,0,0,0,6,0,0,0,7,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
4,3,"Adverse events at up to 1 month","Oropharyngeal pain","SUBGROUP_AND_OVERALL","Horsley 2017","2016",0,0,0,0,1,6,0,0,1,7,0,0,100,1.2,0.022815,63.115776,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
4,3,"Adverse events at up to 1 month","Productive cough","SUBGROUP_AND_OVERALL","Horsley 2017","2016",0,0,0,0,1,6,0,0,0,7,0,0,100,4.090909,0.047875,349.566669,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
4,3,"Adverse events at up to 1 month","Upper respiratory tract infection","SUBGROUP_AND_OVERALL","Horsley 2017","2016",0,0,0,0,0,6,0,0,1,7,0,0,100,0.333333,0.003923,28.325088,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
4,3,"Adverse events at up to 1 month","Total number of participants experiencing at least 1 adverse event","SUBGROUP_AND_OVERALL","Horsley 2017","2016",0,0,0,0,5,6,0,0,3,7,0,0,100,6.666667,0.213807,207.871725,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
4,4,"Sweat chloride change from baseline (mmol/L)","At up to 1 month","SUBGROUP_AND_OVERALL","Horsley 2017","2016",0,0,-3.5,6.108,0,6,-5.97,6.6606,0,7,0,0,100,2.47,-4.474913,9.414913,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
5,1,"Mean change in CFQ-R respiratory domain","At up to 1 month","SUBGROUP_AND_OVERALL","Horsley 2017","2016",0,0,-9.88,6.7846,0,6,-5.55,7.3418,0,7,0,0,100,-4.33,-12.014481,3.354481,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","1::overall","CD010966_pub4_data","significance_only",TRUE,FALSE,TRUE,-0.207750252671045,-0.0819815913269149,-0.673556970156986,0.258056464814896,-0.1207064162904,-0.0432567663634297,TRUE,TRUE
5,2,"FEV1 % predicted absolute change (% points)","At up to 1 month","SUBGROUP_AND_OVERALL","Horsley 2017","2016",0,0,-0.23,4.126,0,6,-3.03,4.3683,0,7,0,0,100,2.8,-1.822906,7.422906,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
5,3,"Adverse events at up to 1 month","Nasopharyngitis","SUBGROUP_AND_OVERALL","Horsley 2017","2016",0,0,0,0,1,7,0,0,1,6,0,0,100,0.833333,0.015844,43.8304,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
5,3,"Adverse events at up to 1 month","Serious adverse events","SUBGROUP_AND_OVERALL","Horsley 2017","2016",0,0,0,0,1,7,0,0,0,6,0,0,100,3,0.035304,254.925794,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
5,3,"Adverse events at up to 1 month","Headache","SUBGROUP_AND_OVERALL","Horsley 2017","2016",0,0,0,0,1,7,0,0,4,6,0,0,100,0.083333,0.002356,2.94812,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
5,3,"Adverse events at up to 1 month","Fatigue","SUBGROUP_AND_OVERALL","Horsley 2017","2016",0,0,0,0,0,7,0,0,1,6,0,0,100,0.244444,0.002861,20.887687,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
5,3,"Adverse events at up to 1 month","Blood CK increase","SUBGROUP_AND_OVERALL","Horsley 2017","2016",0,0,0,0,0,7,0,0,0,6,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
5,3,"Adverse events at up to 1 month","Cough","SUBGROUP_AND_OVERALL","Horsley 2017","2016",0,0,0,0,0,7,0,0,2,6,0,0,100,0.12,0.001668,8.632884,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
5,3,"Adverse events at up to 1 month","Flatulence","SUBGROUP_AND_OVERALL","Horsley 2017","2016",0,0,0,0,0,6,0,0,0,7,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
5,3,"Adverse events at up to 1 month","Infective respiratory exacerbation","SUBGROUP_AND_OVERALL","Horsley 2017","2016",0,0,0,0,1,6,0,0,1,7,0,0,100,1.2,0.022815,63.115776,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
5,3,"Adverse events at up to 1 month","Rhinorrhoea","SUBGROUP_AND_OVERALL","Horsley 2017","2016",0,0,0,0,1,6,0,0,1,7,0,0,100,1.2,0.022815,63.115776,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
5,3,"Adverse events at up to 1 month","Increased sputum","SUBGROUP_AND_OVERALL","Horsley 2017","2016",0,0,0,0,2,6,0,0,0,7,0,0,100,8.333333,0.115836,599.505829,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
5,3,"Adverse events at up to 1 month","Abdominal pain","SUBGROUP_AND_OVERALL","Horsley 2017","2016",0,0,0,0,1,6,0,0,1,7,0,0,100,1.2,0.022815,63.115776,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
5,3,"Adverse events at up to 1 month","Dry mouth","SUBGROUP_AND_OVERALL","Horsley 2017","2016",0,0,0,0,0,6,0,0,1,7,0,0,100,0.333333,0.003923,28.325088,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
5,3,"Adverse events at up to 1 month","Lethargy","SUBGROUP_AND_OVERALL","Horsley 2017","2016",0,0,0,0,0,6,0,0,2,7,0,0,100,0.169231,0.002389,11.9878,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
5,3,"Adverse events at up to 1 month","Myalgia","SUBGROUP_AND_OVERALL","Horsley 2017","2016",0,0,0,0,2,6,0,0,0,7,0,0,100,8.333333,0.115836,599.505829,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
5,3,"Adverse events at up to 1 month","Nasal congestion","SUBGROUP_AND_OVERALL","Horsley 2017","2016",0,0,0,0,2,6,0,0,0,7,0,0,100,8.333333,0.115836,599.505829,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
5,3,"Adverse events at up to 1 month","Nausea","SUBGROUP_AND_OVERALL","Horsley 2017","2016",0,0,0,0,1,6,0,0,0,7,0,0,100,4.090909,0.047875,349.566669,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
5,3,"Adverse events at up to 1 month","Oropharyngeal pain","SUBGROUP_AND_OVERALL","Horsley 2017","2016",0,0,0,0,0,6,0,0,1,7,0,0,100,0.333333,0.003923,28.325088,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
5,3,"Adverse events at up to 1 month","Productive cough","SUBGROUP_AND_OVERALL","Horsley 2017","2016",0,0,0,0,1,6,0,0,0,7,0,0,100,4.090909,0.047875,349.566669,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
5,3,"Adverse events at up to 1 month","Upper respiratory tract infection","SUBGROUP_AND_OVERALL","Horsley 2017","2016",0,0,0,0,0,6,0,0,1,7,0,0,100,0.333333,0.003923,28.325088,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
5,3,"Adverse events at up to 1 month","Total number of participants experiencing at least 1 adverse event","SUBGROUP_AND_OVERALL","Horsley 2017","2016",0,0,0,0,3,7,0,0,6,6,0,0,100,0.059829,0.000895,3.999599,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
5,4,"Sweat chloride change from baseline (mmol/L)","At up to 1 month","SUBGROUP_AND_OVERALL","Horsley 2017","2016",0,0,2.1,6.3558,0,6,-5.97,6.6606,0,7,0,0,100,8.07,0.984153,15.155847,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
6,1,"Mean change in CFQ-R respiratory domain","At up to 1 month","SUBGROUP_AND_OVERALL","Horsley 2017","2016",0,0,3.29,7.3324,0,8,-5.55,7.3418,0,7,0,0,100,8.84,1.39709,16.28291,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","1::overall","CD010966_pub4_data","significance_only",TRUE,FALSE,TRUE,-0.207750252671045,-0.0819815913269149,-0.673556970156986,0.258056464814896,-0.1207064162904,-0.0432567663634297,TRUE,TRUE
6,2,"FEV1 % predicted absolute change (% points)","At up to 1 month","SUBGROUP_AND_OVERALL","Horsley 2017","2016",0,0,-2.35,4.4616,0,8,-3.03,4.3683,0,7,0,0,0,0.68,-3.795521,5.155521,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
6,3,"Adverse events at up to 1 month","Serious adverse events","SUBGROUP_AND_OVERALL","Horsley 2017","2016",0,0,0,0,0,8,0,0,1,7,0,0,0,0.254902,0.003082,21.080924,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
6,3,"Adverse events at up to 1 month","Headache","SUBGROUP_AND_OVERALL","Horsley 2017","2016",0,0,0,0,1,8,0,0,1,7,0,0,0,0.857143,0.0171,42.964207,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
6,3,"Adverse events at up to 1 month","Nasopharyngitis","SUBGROUP_AND_OVERALL","Horsley 2017","2016",0,0,0,0,2,8,0,0,0,7,0,0,0,5.769231,0.084592,393.467127,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
6,3,"Adverse events at up to 1 month","Fatigue","SUBGROUP_AND_OVERALL","Horsley 2017","2016",0,0,0,0,2,8,0,0,0,7,0,0,0,5.769231,0.084592,393.467127,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
6,3,"Adverse events at up to 1 month","Blood CK increase","SUBGROUP_AND_OVERALL","Horsley 2017","2016",0,0,0,0,2,8,0,0,0,7,0,0,0,5.769231,0.084592,393.467127,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
6,3,"Adverse events at up to 1 month","Cough","SUBGROUP_AND_OVERALL","Horsley 2017","2016",0,0,0,0,0,8,0,0,0,7,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
6,3,"Adverse events at up to 1 month","Flatulence","SUBGROUP_AND_OVERALL","Horsley 2017","2016",0,0,0,0,2,8,0,0,0,7,0,0,0,5.769231,0.084592,393.467127,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
6,3,"Adverse events at up to 1 month","Infective respiratory exacerbation","SUBGROUP_AND_OVERALL","Horsley 2017","2016",0,0,0,0,1,8,0,0,1,7,0,0,0,0.857143,0.0171,42.964207,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
6,3,"Adverse events at up to 1 month","Rhinorrhoea","SUBGROUP_AND_OVERALL","Horsley 2017","2016",0,0,0,0,0,8,0,0,1,7,0,0,0,0.254902,0.003082,21.080924,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
6,3,"Adverse events at up to 1 month","Increased sputum","SUBGROUP_AND_OVERALL","Horsley 2017","2016",0,0,0,0,1,8,0,0,0,7,0,0,0,3,0.036407,247.207769,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
6,3,"Adverse events at up to 1 month","Abdominal pain","SUBGROUP_AND_OVERALL","Horsley 2017","2016",0,0,0,0,0,8,0,0,1,7,0,0,0,0.254902,0.003082,21.080924,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
6,3,"Adverse events at up to 1 month","Dry mouth","SUBGROUP_AND_OVERALL","Horsley 2017","2016",0,0,0,0,1,8,0,0,1,7,0,0,0,0.857143,0.0171,42.964207,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
6,3,"Adverse events at up to 1 month","Lethargy","SUBGROUP_AND_OVERALL","Horsley 2017","2016",0,0,0,0,0,8,0,0,2,7,0,0,0,0.129412,0.001879,8.911515,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
6,3,"Adverse events at up to 1 month","Myalgia","SUBGROUP_AND_OVERALL","Horsley 2017","2016",0,0,0,0,0,8,0,0,0,7,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
6,3,"Adverse events at up to 1 month","Nasal congestion","SUBGROUP_AND_OVERALL","Horsley 2017","2016",0,0,0,0,0,8,0,0,0,7,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
6,3,"Adverse events at up to 1 month","Nausea","SUBGROUP_AND_OVERALL","Horsley 2017","2016",0,0,0,0,1,8,0,0,0,7,0,0,0,3,0.036407,247.207769,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
6,3,"Adverse events at up to 1 month","Oropharyngeal pain","SUBGROUP_AND_OVERALL","Horsley 2017","2016",0,0,0,0,0,8,0,0,1,7,0,0,0,0.254902,0.003082,21.080924,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
6,3,"Adverse events at up to 1 month","Productive cough","SUBGROUP_AND_OVERALL","Horsley 2017","2016",0,0,0,0,0,8,0,0,0,7,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
6,3,"Adverse events at up to 1 month","Upper respiratory tract infection","SUBGROUP_AND_OVERALL","Horsley 2017","2016",0,0,0,0,1,8,0,0,1,7,0,0,0,0.857143,0.0171,42.964207,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
6,3,"Adverse events at up to 1 month","Total number of participants experiencing at least 1 adverse event","SUBGROUP_AND_OVERALL","Horsley 2017","2016",0,0,0,0,8,8,0,0,3,7,0,0,0,21.857143,0.336467,1419.857913,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
6,4,"Sweat chloride change from baseline (mmol/L)","At up to 1 month","SUBGROUP_AND_OVERALL","Horsley 2017","2016",0,0,-2.49,6.806,0,8,-5.97,6.6606,0,7,0,0,0,3.48,-3.34559,10.30559,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
7,1,"Adverse events occurring in more than 3% of participants in all treatment groups (combined data) versus placebo at up to 1 month","Abdominal pain","SUBGROUP_AND_OVERALL","McCarty 2002","1998",0,0,0,0,0,8,0,0,3,29,0,0,100,0.445378,0.00796,24.919408,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","1::overall","CD010966_pub4_data","significance_only",TRUE,FALSE,TRUE,-0.207750252671045,-0.0819815913269149,-0.673556970156986,0.258056464814896,-0.1207064162904,-0.0432567663634297,TRUE,TRUE
7,1,"Adverse events occurring in more than 3% of participants in all treatment groups (combined data) versus placebo at up to 1 month","Asthenia","SUBGROUP_AND_OVERALL","McCarty 2002","1998",0,0,0,0,0,8,0,0,2,29,0,0,100,0.647059,0.010548,39.6934,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","1::overall","CD010966_pub4_data","significance_only",TRUE,FALSE,TRUE,-0.207750252671045,-0.0819815913269149,-0.673556970156986,0.258056464814896,-0.1207064162904,-0.0432567663634297,TRUE,TRUE
7,1,"Adverse events occurring in more than 3% of participants in all treatment groups (combined data) versus placebo at up to 1 month","Headache","SUBGROUP_AND_OVERALL","McCarty 2002","1998",0,0,0,0,0,8,0,0,4,29,0,0,100,0.333333,0.006272,17.71514,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","1::overall","CD010966_pub4_data","significance_only",TRUE,FALSE,TRUE,-0.207750252671045,-0.0819815913269149,-0.673556970156986,0.258056464814896,-0.1207064162904,-0.0432567663634297,TRUE,TRUE
7,1,"Adverse events occurring in more than 3% of participants in all treatment groups (combined data) versus placebo at up to 1 month","Pain","SUBGROUP_AND_OVERALL","McCarty 2002","1998",0,0,0,0,0,8,0,0,3,29,0,0,100,0.445378,0.00796,24.919408,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","1::overall","CD010966_pub4_data","significance_only",TRUE,FALSE,TRUE,-0.207750252671045,-0.0819815913269149,-0.673556970156986,0.258056464814896,-0.1207064162904,-0.0432567663634297,TRUE,TRUE
7,1,"Adverse events occurring in more than 3% of participants in all treatment groups (combined data) versus placebo at up to 1 month","Diarrhoea","SUBGROUP_AND_OVERALL","McCarty 2002","1998",0,0,0,0,0,8,0,0,2,29,0,0,100,0.647059,0.010548,39.6934,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","1::overall","CD010966_pub4_data","significance_only",TRUE,FALSE,TRUE,-0.207750252671045,-0.0819815913269149,-0.673556970156986,0.258056464814896,-0.1207064162904,-0.0432567663634297,TRUE,TRUE
7,1,"Adverse events occurring in more than 3% of participants in all treatment groups (combined data) versus placebo at up to 1 month","Dizziness","SUBGROUP_AND_OVERALL","McCarty 2002","1998",0,0,0,0,2,8,0,0,1,29,0,0,100,9.333333,0.32393,268.919959,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","1::overall","CD010966_pub4_data","significance_only",TRUE,FALSE,TRUE,-0.207750252671045,-0.0819815913269149,-0.673556970156986,0.258056464814896,-0.1207064162904,-0.0432567663634297,TRUE,TRUE
7,1,"Adverse events occurring in more than 3% of participants in all treatment groups (combined data) versus placebo at up to 1 month","Lung disease","SUBGROUP_AND_OVERALL","McCarty 2002","1998",0,0,0,0,0,8,0,0,3,29,0,0,100,0.445378,0.00796,24.919408,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","1::overall","CD010966_pub4_data","significance_only",TRUE,FALSE,TRUE,-0.207750252671045,-0.0819815913269149,-0.673556970156986,0.258056464814896,-0.1207064162904,-0.0432567663634297,TRUE,TRUE
7,1,"Adverse events occurring in more than 3% of participants in all treatment groups (combined data) versus placebo at up to 1 month","Rhinitis","SUBGROUP_AND_OVERALL","McCarty 2002","1998",0,0,0,0,0,8,0,0,3,29,0,0,100,0.445378,0.00796,24.919408,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","1::overall","CD010966_pub4_data","significance_only",TRUE,FALSE,TRUE,-0.207750252671045,-0.0819815913269149,-0.673556970156986,0.258056464814896,-0.1207064162904,-0.0432567663634297,TRUE,TRUE
8,1,"Adverse events at up to 1 month","Bad taste in mouth","SUBGROUP_AND_OVERALL","Rubenstein 1998","1997",0,0,0,0,1,9,0,0,2,9,0,0,100,0.4375,0.014243,13.439047,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","1::overall","CD010966_pub4_data","significance_only",TRUE,FALSE,TRUE,-0.207750252671045,-0.0819815913269149,-0.673556970156986,0.258056464814896,-0.1207064162904,-0.0432567663634297,TRUE,TRUE
8,1,"Adverse events at up to 1 month","Diarrhoea","SUBGROUP_AND_OVERALL","Rubenstein 1998","1997",0,0,0,0,1,9,0,0,0,9,0,0,100,3.352941,0.042056,267.31485,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","1::overall","CD010966_pub4_data","significance_only",TRUE,FALSE,TRUE,-0.207750252671045,-0.0819815913269149,-0.673556970156986,0.258056464814896,-0.1207064162904,-0.0432567663634297,TRUE,TRUE
8,2,"Participants requiring study drug termination or a reduced dosage at up to 1 month","30 g 4PBA","SUBGROUP_AND_OVERALL","Zeitlin 2002","2002",0,0,0,0,2,6,0,0,0,4,0,0,0,5,0.183391,136.320866,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
9,1,"Absolute change from baseline in lung clearance index 2.5 (LCI2.5)","At week 48","SUBGROUP_AND_OVERALL","Stahl 2021","(first received 10 August 2018)",0,0,-0.37,1.382775,0,35,0.32,0.975862,0,16,0,0,100,-0.69,-1.352194,-0.027806,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","1::overall","CD010966_pub4_data","significance_only",TRUE,FALSE,TRUE,-0.207750252671045,-0.0819815913269149,-0.673556970156986,0.258056464814896,-0.1207064162904,-0.0432567663634297,TRUE,TRUE
9,2,"Most common adverse events (occurring in at least 10% of participants in either group)","Infective pulmonary exacerbation of cystic fibrosis","SUBGROUP_AND_OVERALL","Stahl 2021","(first received 10 August 2018)",0,0,0,0,18,35,0,0,10,16,0,0,100,0.635294,0.129549,3.11542,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
9,2,"Most common adverse events (occurring in at least 10% of participants in either group)","Epistaxis","SUBGROUP_AND_OVERALL","Stahl 2021","(first received 10 August 2018)",0,0,0,0,2,35,0,0,2,16,0,0,100,0.424242,0.028407,6.335875,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
9,2,"Most common adverse events (occurring in at least 10% of participants in either group)","Number of serious adverse events","SUBGROUP_AND_OVERALL","Stahl 2021","(first received 10 August 2018)",0,0,0,0,7,35,0,0,2,16,0,0,100,1.75,0.188037,16.286709,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
9,2,"Most common adverse events (occurring in at least 10% of participants in either group)","Abdominal pain","SUBGROUP_AND_OVERALL","Stahl 2021","(first received 10 August 2018)",0,0,0,0,7,35,0,0,2,16,0,0,100,1.75,0.188037,16.286709,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
9,2,"Most common adverse events (occurring in at least 10% of participants in either group)","Abdominal pain upper","SUBGROUP_AND_OVERALL","Stahl 2021","(first received 10 August 2018)",0,0,0,0,1,35,0,0,2,16,0,0,100,0.205882,0.007911,5.35805,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
9,2,"Most common adverse events (occurring in at least 10% of participants in either group)","Cough","SUBGROUP_AND_OVERALL","Stahl 2021","(first received 10 August 2018)",0,0,0,0,10,35,0,0,5,16,0,0,100,0.88,0.162236,4.773288,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
9,2,"Most common adverse events (occurring in at least 10% of participants in either group)","Headache","SUBGROUP_AND_OVERALL","Stahl 2021","(first received 10 August 2018)",0,0,0,0,3,35,0,0,2,16,0,0,100,0.65625,0.054298,7.931501,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
9,2,"Most common adverse events (occurring in at least 10% of participants in either group)","Nasopharyngitis","SUBGROUP_AND_OVERALL","Stahl 2021","(first received 10 August 2018)",0,0,0,0,22,35,0,0,8,16,0,0,100,1.692308,0.351429,8.149324,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
9,2,"Most common adverse events (occurring in at least 10% of participants in either group)","Gastroenteritis","SUBGROUP_AND_OVERALL","Stahl 2021","(first received 10 August 2018)",0,0,0,0,3,35,0,0,2,16,0,0,100,0.65625,0.054298,7.931501,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
9,2,"Most common adverse events (occurring in at least 10% of participants in either group)","Bacterial disease carrier","SUBGROUP_AND_OVERALL","Stahl 2021","(first received 10 August 2018)",0,0,0,0,0,35,0,0,2,16,0,0,100,0.08169,0.001394,4.785483,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
9,2,"Most common adverse events (occurring in at least 10% of participants in either group)","Pyrexia","SUBGROUP_AND_OVERALL","Stahl 2021","(first received 10 August 2018)",0,0,0,0,6,35,0,0,3,16,0,0,100,0.896552,0.119636,6.718767,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
9,2,"Most common adverse events (occurring in at least 10% of participants in either group)","Nasal congestion","SUBGROUP_AND_OVERALL","Stahl 2021","(first received 10 August 2018)",0,0,0,0,0,35,0,0,4,16,0,0,100,0.039124,0.000767,1.995978,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
9,2,"Most common adverse events (occurring in at least 10% of participants in either group)","Productive cough","SUBGROUP_AND_OVERALL","Stahl 2021","(first received 10 August 2018)",0,0,0,0,0,35,0,0,2,16,0,0,100,0.08169,0.001394,4.785483,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
9,2,"Most common adverse events (occurring in at least 10% of participants in either group)","Nasal polyps","SUBGROUP_AND_OVERALL","Stahl 2021","(first received 10 August 2018)",0,0,0,0,1,35,0,0,2,16,0,0,100,0.205882,0.007911,5.35805,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
9,2,"Most common adverse events (occurring in at least 10% of participants in either group)","Vomiting","SUBGROUP_AND_OVERALL","Stahl 2021","(first received 10 August 2018)",0,0,0,0,2,35,0,0,2,16,0,0,100,0.424242,0.028407,6.335875,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
9,2,"Most common adverse events (occurring in at least 10% of participants in either group)","Faeces pale","SUBGROUP_AND_OVERALL","Stahl 2021","(first received 10 August 2018)",0,0,0,0,0,35,0,0,2,16,0,0,100,0.08169,0.001394,4.785483,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
9,2,"Most common adverse events (occurring in at least 10% of participants in either group)","Other (not including serious) adverse events","SUBGROUP_AND_OVERALL","Stahl 2021","(first received 10 August 2018)",0,0,0,0,33,35,0,0,16,16,0,0,100,0.406061,0.006969,23.658206,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
9,2,"Most common adverse events (occurring in at least 10% of participants in either group)","Dyspnoea","SUBGROUP_AND_OVERALL","Stahl 2021","(first received 10 August 2018)",0,0,0,0,1,35,0,0,2,16,0,0,100,0.205882,0.007911,5.35805,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
9,2,"Most common adverse events (occurring in at least 10% of participants in either group)","Diarrhoea","SUBGROUP_AND_OVERALL","Stahl 2021","(first received 10 August 2018)",0,0,0,0,4,35,0,0,1,16,0,0,100,1.935484,0.09717,38.552017,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
9,2,"Most common adverse events (occurring in at least 10% of participants in either group)","Lung infiltration","SUBGROUP_AND_OVERALL","Stahl 2021","(first received 10 August 2018)",0,0,0,0,0,35,0,0,2,16,0,0,100,0.08169,0.001394,4.785483,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
9,2,"Most common adverse events (occurring in at least 10% of participants in either group)","Pseudomonas test positive","SUBGROUP_AND_OVERALL","Stahl 2021","(first received 10 August 2018)",0,0,0,0,1,35,0,0,2,16,0,0,100,0.205882,0.007911,5.35805,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
9,2,"Most common adverse events (occurring in at least 10% of participants in either group)","Upper respiratory tract infection","SUBGROUP_AND_OVERALL","Stahl 2021","(first received 10 August 2018)",0,0,0,0,1,35,0,0,3,16,0,0,100,0.127451,0.005796,2.802791,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
9,2,"Most common adverse events (occurring in at least 10% of participants in either group)","Rhinitis","SUBGROUP_AND_OVERALL","Stahl 2021","(first received 10 August 2018)",0,0,0,0,9,35,0,0,6,16,0,0,100,0.576923,0.109494,3.039799,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
9,2,"Most common adverse events (occurring in at least 10% of participants in either group)","Constipation","SUBGROUP_AND_OVERALL","Stahl 2021","(first received 10 August 2018)",0,0,0,0,5,35,0,0,0,16,0,0,100,5.95082,0.122236,289.703836,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
9,3,"Absolute change from baseline in sweat chloride","At week 48","SUBGROUP_AND_OVERALL","Stahl 2021","(first received 10 August 2018)",0,0,-25.4,18.7,0,33,1,10.4,0,16,0,0,100,-26.4,-34.565471,-18.234529,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
9,4,"Absolute change from baseline in MRI global chest score","At week 48","SUBGROUP_AND_OVERALL","Stahl 2021","(first received 10 August 2018)",0,0,-1.7,6.6,0,32,-0.3,6.1,0,15,0,0,100,-1.4,-5.241688,2.441688,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
9,5,"Absolute change from baseline in weight-for-age z score","At week 48","SUBGROUP_AND_OVERALL","Stahl 2021","(first received 10 August 2018)",0,0,0.13,0.407555,0,35,-0.07,0.328415,0,16,0,0,100,0.2,-0.010062,0.410062,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
10,1,"Quality of life - Euro Quality of Life Scale (EuroQol) 5-Dimension-3 Level (EQ-5D-3L) Index Score (absolute change from baseline)","At 6 months","SUBGROUP_AND_OVERALL","TRAFFIC 2015","2014",0,0,0.0066,0.1005,0,175,6e-04,0.0989,0,179,0,0,44.957824,0.006,-0.014776,0.026776,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","1::overall","CD010966_pub4_data","significance_only",TRUE,FALSE,TRUE,-0.207750252671045,-0.0819815913269149,-0.673556970156986,0.258056464814896,-0.1207064162904,-0.0432567663634297,TRUE,TRUE
10,1,"Quality of life - Euro Quality of Life Scale (EuroQol) 5-Dimension-3 Level (EQ-5D-3L) Index Score (absolute change from baseline)","At 6 months","SUBGROUP_AND_OVERALL","TRANSPORT 2015","2014",0,0,0.009,0.091,0,178,0.0117,0.091,0,183,0,0,55.042176,-0.0027,-0.021476,0.016076,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","1::overall","CD010966_pub4_data","significance_only",TRUE,FALSE,TRUE,-0.207750252671045,-0.0819815913269149,-0.673556970156986,0.258056464814896,-0.1207064162904,-0.0432567663634297,TRUE,TRUE
10,2,"Quality of life - CFQ-R respiratory domain (absolute change from baseline)","At 6 months","SUBGROUP_AND_OVERALL","TRAFFIC 2015","2014",0,0,4.98,15.6279,0,176,1.1,15.7486,0,184,0,0,49.570072,3.88,0.638286,7.121714,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
10,2,"Quality of life - CFQ-R respiratory domain (absolute change from baseline)","At 6 months","SUBGROUP_AND_OVERALL","TRANSPORT 2015","2014",0,0,5.02,15.6435,0,180,2.81,15.6825,0,185,0,0,50.429928,2.21,-1.003959,5.423959,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
10,2,"Quality of life - CFQ-R respiratory domain (absolute change from baseline)","At up to 1 month","SUBGROUP_AND_OVERALL","TRAFFIC 2015","2014",0,0,4,15.18421,0,183,3,14.53356,0,184,0,0,51.703449,1,-2.041325,4.041325,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
10,2,"Quality of life - CFQ-R respiratory domain (absolute change from baseline)","At up to 1 month","SUBGROUP_AND_OVERALL","TRANSPORT 2015","2014",0,0,6.8,15.26696,0,185,1,15.69811,0,187,0,0,48.296551,5.8,2.653233,8.946767,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
10,3,"Quality of life - EQ-5D-3L VAS score (absolute change from baseline)","At 6 months","SUBGROUP_AND_OVERALL","TRAFFIC 2015","2014",0,0,3.5,13.6791,0,173,1.4,13.8189,0,180,0,0,51.895024,2.1,-0.768858,4.968858,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
10,3,"Quality of life - EQ-5D-3L VAS score (absolute change from baseline)","At 6 months","SUBGROUP_AND_OVERALL","TRANSPORT 2015","2014",0,0,5.7,14.3685,0,177,3.3,14.4351,0,182,0,0,48.104976,2.4,-0.57973,5.37973,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
10,4,"FEV1 % predicted (relative change from baseline)","At 6 months","SUBGROUP_AND_OVERALL","TRAFFIC 2015","2014",0,0,6.39,12.1256,0,176,-0.34,12.2492,0,180,0,0,52.506208,6.73,4.197949,9.262051,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
10,4,"FEV1 % predicted (relative change from baseline)","At 6 months","SUBGROUP_AND_OVERALL","TRANSPORT 2015","2014",0,0,4.42,12.9289,0,181,0,12.9866,0,183,0,0,47.493792,4.42,1.757686,7.082314,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
10,5,"FEV1 % predicted (absolute change from baseline)","At 6 months","SUBGROUP_AND_OVERALL","TRAFFIC 2015","2014",0,0,3.59,6.9649,0,176,-0.44,7.0302,0,180,0,0,51.409824,4.03,2.576187,5.483813,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
10,5,"FEV1 % predicted (absolute change from baseline)","At 6 months","SUBGROUP_AND_OVERALL","TRANSPORT 2015","2014",0,0,2.46,7.265,0,181,-0.15,7.2915,0,183,0,0,48.590176,2.61,1.1146,4.1054,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
10,5,"FEV1 % predicted (absolute change from baseline)","At up to 1 month","SUBGROUP_AND_OVERALL","TRAFFIC 2015","2014",0,0,2.5,7.592104,0,183,0,7.612819,0,184,0,0,40.09901,2.5,0.944394,4.055606,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
10,5,"FEV1 % predicted (absolute change from baseline)","At up to 1 month","SUBGROUP_AND_OVERALL","TRANSPORT 2015","2014",0,0,2.5,6.245573,0,185,0.3,6.279242,0,187,0,0,59.90099,2.2,0.927231,3.472769,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
11,1,"Quality of life - Euro Quality of Life Scale (EuroQol) 5-Dimension-3 Level (EQ-5D-3L) Index Score (absolute change from baseline)","At 6 months","SUBGROUP_AND_OVERALL","TRAFFIC 2015","2014",0,0,0.01,0.0987,0,170,6e-04,0.0989,0,179,0,0,45.079924,0.0094,-0.011337,0.030137,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","1::overall","CD010966_pub4_data","significance_only",TRUE,FALSE,TRUE,-0.207750252671045,-0.0819815913269149,-0.673556970156986,0.258056464814896,-0.1207064162904,-0.0432567663634297,TRUE,TRUE
11,1,"Quality of life - Euro Quality of Life Scale (EuroQol) 5-Dimension-3 Level (EQ-5D-3L) Index Score (absolute change from baseline)","At 6 months","SUBGROUP_AND_OVERALL","TRANSPORT 2015","2014",0,0,0.0108,0.0906,0,176,0.0117,0.091,0,183,0,0,54.920076,-9e-04,-0.019688,0.017888,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","1::overall","CD010966_pub4_data","significance_only",TRUE,FALSE,TRUE,-0.207750252671045,-0.0819815913269149,-0.673556970156986,0.258056464814896,-0.1207064162904,-0.0432567663634297,TRUE,TRUE
11,2,"Quality of life - CFQ-R respiratory domain (absolute change from baseline)","At 6 months","SUBGROUP_AND_OVERALL","TRAFFIC 2015","2014",0,0,2.6,15.6329,0,172,1.1,15.7486,0,184,0,0,45.489864,1.5,-1.761314,4.761314,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
11,2,"Quality of life - CFQ-R respiratory domain (absolute change from baseline)","At 6 months","SUBGROUP_AND_OVERALL","TRANSPORT 2015","2014",0,0,5.66,15.6402,0,179,2.81,15.6825,0,185,0,0,46.718323,2.85,-0.36815,6.06815,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
11,2,"Quality of life - CFQ-R respiratory domain (absolute change from baseline)","At 6 months","SUBGROUP_AND_OVERALL","Wilson 2021","2021",0,0,0.1,16.068295,0,30,-6.1,15.793129,0,33,0,0,7.791814,6.2,-1.680081,14.080081,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
11,2,"Quality of life - CFQ-R respiratory domain (absolute change from baseline)","At up to 1 month","SUBGROUP_AND_OVERALL","TRAFFIC 2015","2014",0,0,5,15.14266,0,182,3,14.53356,0,184,0,0,51.703457,2,-1.041324,5.041324,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
11,2,"Quality of life - CFQ-R respiratory domain (absolute change from baseline)","At up to 1 month","SUBGROUP_AND_OVERALL","TRANSPORT 2015","2014",0,0,7.4,15.34926,0,187,1,15.69811,0,187,0,0,48.296543,6.4,3.253233,9.546767,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
11,3,"Quality of life - EQ-5D-3L VAS score (absolute change from baseline)","At 6 months","SUBGROUP_AND_OVERALL","TRAFFIC 2015","2014",0,0,2.8,13.3382,0,171,1.4,13.8189,0,180,0,0,52.379686,1.4,-1.441133,4.241133,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
11,3,"Quality of life - EQ-5D-3L VAS score (absolute change from baseline)","At 6 months","SUBGROUP_AND_OVERALL","TRANSPORT 2015","2014",0,0,6.6,14.3685,0,177,3.3,14.4351,0,182,0,0,47.620314,3.3,0.32027,6.27973,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
11,4,"FEV1 % predicted (relative change from baseline)","At 6 months","SUBGROUP_AND_OVERALL","TRAFFIC 2015","2014",0,0,3.99,12.105,0,172,-0.34,12.2492,0,180,0,0,48.650014,4.33,1.785444,6.874556,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
11,4,"FEV1 % predicted (relative change from baseline)","At 6 months","SUBGROUP_AND_OVERALL","TRANSPORT 2015","2014",0,0,5.25,12.8932,0,180,0,12.9866,0,183,0,0,44.441236,5.25,2.587679,7.912321,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
11,4,"FEV1 % predicted (relative change from baseline)","At 6 months","SUBGROUP_AND_OVERALL","Wilson 2021","2021",0,0,-1.8,13.524148,0,30,-5.4,13.590784,0,32,0,0,6.90875,3.6,-3.152331,10.352331,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
11,5,"FEV1 % predicted (absolute change from baseline)","At 6 months","SUBGROUP_AND_OVERALL","TRAFFIC 2015","2014",0,0,2.16,6.9509,0,172,-0.44,7.0302,0,180,0,0,48.640738,2.6,1.139232,4.060768,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
11,5,"FEV1 % predicted (absolute change from baseline)","At 6 months","SUBGROUP_AND_OVERALL","TRANSPORT 2015","2014",0,0,2.85,7.2449,0,180,-0.15,7.2915,0,183,0,0,46.413929,3,1.504601,4.495399,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
11,5,"FEV1 % predicted (absolute change from baseline)","At 6 months","SUBGROUP_AND_OVERALL","Wilson 2021","2021",0,0,-0.6,9.23927,0,30,-4,9.152977,0,32,0,0,4.945333,3.4,-1.181246,7.981246,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
11,5,"FEV1 % predicted (absolute change from baseline)","At up to 1 month","SUBGROUP_AND_OVERALL","TRAFFIC 2015","2014",0,0,2.3,7.571332,0,182,0,7.612819,0,184,0,0,40.09901,2.3,0.744394,3.855606,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
11,5,"FEV1 % predicted (absolute change from baseline)","At up to 1 month","SUBGROUP_AND_OVERALL","TRANSPORT 2015","2014",0,0,2.8,6.279242,0,187,0.3,6.279242,0,187,0,0,59.90099,2.5,1.227231,3.772769,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
12,1,"Quality of life - Euro Quality of Life Scale (EuroQol) 5-Dimension-3 Level (EQ-5D-3L) Index Score (absolute change from baseline)","At 6 months","SUBGROUP_AND_OVERALL","TRAFFIC 2015","2014",0,0,0.008275,0.099487,0,345,6e-04,0.0989,0,179,0,0,45.107641,0.007675,-0.010217,0.025567,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","1::overall","CD010966_pub4_data","significance_only",TRUE,FALSE,TRUE,-0.207750252671045,-0.0819815913269149,-0.673556970156986,0.258056464814896,-0.1207064162904,-0.0432567663634297,TRUE,TRUE
12,1,"Quality of life - Euro Quality of Life Scale (EuroQol) 5-Dimension-3 Level (EQ-5D-3L) Index Score (absolute change from baseline)","At 6 months","SUBGROUP_AND_OVERALL","TRANSPORT 2015","2014",0,0,0.009895,0.090677,0,354,0.0117,0.091,0,183,0,0,54.892359,-0.001805,-0.018024,0.014414,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","1::overall","CD010966_pub4_data","significance_only",TRUE,FALSE,TRUE,-0.207750252671045,-0.0819815913269149,-0.673556970156986,0.258056464814896,-0.1207064162904,-0.0432567663634297,TRUE,TRUE
12,2,"Quality of life - CFQ-R respiratory domain (absolute change from baseline)","At 6 months","SUBGROUP_AND_OVERALL","TRAFFIC 2015","2014",0,0,3.803678,15.65326,0,348,1.1,15.7486,0,184,0,0,46.55066,2.703678,-0.103945,5.511301,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
12,2,"Quality of life - CFQ-R respiratory domain (absolute change from baseline)","At 6 months","SUBGROUP_AND_OVERALL","TRANSPORT 2015","2014",0,0,5.339109,15.62328,0,359,2.81,15.6825,0,185,0,0,47.539957,2.529109,-0.249148,5.307366,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
12,2,"Quality of life - CFQ-R respiratory domain (absolute change from baseline)","At 6 months","SUBGROUP_AND_OVERALL","Wilson 2021","2021",0,0,0.1,16.068295,0,30,-6.1,15.793129,0,33,0,0,5.909384,6.2,-1.680081,14.080081,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
12,2,"Quality of life - CFQ-R respiratory domain (absolute change from baseline)","At up to 1 month","SUBGROUP_AND_OVERALL","TRAFFIC 2015","2014",0,0,4.49863,15.15094,0,365,3,14.53356,0,184,0,0,52.275663,1.49863,-1.113985,4.111245,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
12,2,"Quality of life - CFQ-R respiratory domain (absolute change from baseline)","At up to 1 month","SUBGROUP_AND_OVERALL","TRANSPORT 2015","2014",0,0,7.101613,15.29069,0,372,1,15.69811,0,187,0,0,47.724337,6.101613,3.367256,8.83597,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
12,3,"Quality of life - EQ-5D-3L VAS score (absolute change from baseline)","At 6 months","SUBGROUP_AND_OVERALL","TRAFFIC 2015","2014",0,0,3.152035,13.49557,0,344,1.4,13.8189,0,180,0,0,52.060022,1.752035,-0.719657,4.223727,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
12,3,"Quality of life - EQ-5D-3L VAS score (absolute change from baseline)","At 6 months","SUBGROUP_AND_OVERALL","TRANSPORT 2015","2014",0,0,6.15,14.35521,0,354,3.3,14.4351,0,182,0,0,47.939978,2.85,0.274287,5.425713,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
12,4,"FEV1 % predicted (relative change from baseline)","At 6 months","SUBGROUP_AND_OVERALL","TRAFFIC 2015","2014",0,0,5.203793,12.15748,0,348,-0.34,12.2492,0,180,0,0,49.599707,5.543793,3.345226,7.74236,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
12,4,"FEV1 % predicted (relative change from baseline)","At 6 months","SUBGROUP_AND_OVERALL","TRANSPORT 2015","2014",0,0,4.83385,12.89986,0,361,0,12.9866,0,183,0,0,45.141926,4.83385,2.529284,7.138416,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
12,4,"FEV1 % predicted (relative change from baseline)","At 6 months","SUBGROUP_AND_OVERALL","Wilson 2021","2021",0,0,-1.8,13.524148,0,30,-5.4,13.590784,0,32,0,0,5.258367,3.6,-3.152331,10.352331,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
12,5,"FEV1 % predicted (absolute change from baseline)","At 6 months","SUBGROUP_AND_OVERALL","TRAFFIC 2015","2014",0,0,2.883218,6.984745,0,348,-0.44,7.0302,0,180,0,0,49.330159,3.323218,2.060953,4.585483,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
12,5,"FEV1 % predicted (absolute change from baseline)","At 6 months","SUBGROUP_AND_OVERALL","TRANSPORT 2015","2014",0,0,2.65446,7.247533,0,361,-0.15,7.2915,0,183,0,0,46.924888,2.80446,1.510249,4.098671,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
12,5,"FEV1 % predicted (absolute change from baseline)","At 6 months","SUBGROUP_AND_OVERALL","Wilson 2021","2021",0,0,-0.6,9.23927,0,30,-4,9.152977,0,32,0,0,3.744954,3.4,-1.181246,7.981246,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
12,5,"FEV1 % predicted (absolute change from baseline)","At up to 1 month","SUBGROUP_AND_OVERALL","TRAFFIC 2015","2014",0,0,2.400274,7.571994,0,365,0,7.612819,0,184,0,0,40.10281,2.400274,1.053656,3.746892,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
12,5,"FEV1 % predicted (absolute change from baseline)","At up to 1 month","SUBGROUP_AND_OVERALL","TRANSPORT 2015","2014",0,0,2.650806,6.255879,0,372,0.3,6.279242,0,187,0,0,59.89719,2.350806,1.24894,3.452672,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
13,1,"FEV1 % predicted (absolute change from baseline)","At 14 days (before addition of ivacaftor)","SUBGROUP_AND_OVERALL","Boyle 2014","2014",0,0,-0.1,4.2734,0,20,1.7,4.174,0,21,0,0,100,-1.8,-4.387397,0.787397,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","1::overall","CD010966_pub4_data","significance_only",TRUE,FALSE,TRUE,-0.207750252671045,-0.0819815913269149,-0.673556970156986,0.258056464814896,-0.1207064162904,-0.0432567663634297,TRUE,TRUE
13,1,"FEV1 % predicted (absolute change from baseline)","At 21 days","SUBGROUP_AND_OVERALL","Boyle 2014","2014",0,0,3.1,6.6953,0,20,0.3,6.9891,0,21,0,0,100,2.8,-1.388744,6.988744,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","1::overall","CD010966_pub4_data","significance_only",TRUE,FALSE,TRUE,-0.207750252671045,-0.0819815913269149,-0.673556970156986,0.258056464814896,-0.1207064162904,-0.0432567663634297,TRUE,TRUE
13,2,"Adverse events occurring in 10% or more participants (from days 15 to 21)","Cough","SUBGROUP_AND_OVERALL","Boyle 2014","2014",0,0,0,0,4,20,0,0,4,21,0,0,100,1.0625,0.139492,8.092991,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
13,2,"Adverse events occurring in 10% or more participants (from days 15 to 21)","Oropharyngeal pain","SUBGROUP_AND_OVERALL","Boyle 2014","2014",0,0,0,0,1,20,0,0,2,21,0,0,100,0.5,0.019126,13.071082,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
13,2,"Adverse events occurring in 10% or more participants (from days 15 to 21)","Nasal congestion","SUBGROUP_AND_OVERALL","Boyle 2014","2014",0,0,0,0,1,20,0,0,2,21,0,0,100,0.5,0.019126,13.071082,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
13,2,"Adverse events occurring in 10% or more participants (from days 15 to 21)","Dizziness","SUBGROUP_AND_OVERALL","Boyle 2014","2014",0,0,0,0,2,20,0,0,0,21,0,0,100,5.810811,0.098916,341.355548,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
13,2,"Adverse events occurring in 10% or more participants (from days 15 to 21)","Prothrombin time prolonged","SUBGROUP_AND_OVERALL","Boyle 2014","2014",0,0,0,0,2,20,0,0,0,21,0,0,100,5.810811,0.098916,341.355548,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
13,2,"Adverse events occurring in 10% or more participants (from days 15 to 21)","Upper respiratory tract infection","SUBGROUP_AND_OVERALL","Boyle 2014","2014",0,0,0,0,2,20,0,0,0,21,0,0,100,5.810811,0.098916,341.355548,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
13,2,"Adverse events occurring in 10% or more participants (from days 15 to 21)","Pulmonary exacerbation","SUBGROUP_AND_OVERALL","Boyle 2014","2014",0,0,0,0,2,20,0,0,1,21,0,0,100,2.222222,0.08498,58.110965,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
13,3,"Sweat chloride concentration (mmol/L) (change from baseline)","At 14 days (before addition of ivacaftor)","SUBGROUP_AND_OVERALL","Boyle 2014","2014",0,0,-4.8,7.3908,0,17,-1.7,8.8462,0,17,0,0,100,-3.1,-8.579641,2.379641,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
13,3,"Sweat chloride concentration (mmol/L) (change from baseline)","At 21 days","SUBGROUP_AND_OVERALL","Boyle 2014","2014",0,0,-6.7,9.5302,0,17,-1.7,9.8142,0,16,0,0,100,-5,-11.606718,1.606718,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
14,1,"FEV1 % predicted (absolute change from baseline)","At 14 days (before addition of ivacaftor)","SUBGROUP_AND_OVERALL","Boyle 2014","2014",0,0,-0.3,4.487,0,20,1.7,4.174,0,21,0,0,100,-2,-4.655943,0.655943,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","1::overall","CD010966_pub4_data","significance_only",TRUE,FALSE,TRUE,-0.207750252671045,-0.0819815913269149,-0.673556970156986,0.258056464814896,-0.1207064162904,-0.0432567663634297,TRUE,TRUE
14,1,"FEV1 % predicted (absolute change from baseline)","At 21 days","SUBGROUP_AND_OVERALL","Boyle 2014","2014",0,0,0.5,6.9891,0,18,0.3,6.9891,0,21,0,0,100,0.2,-4.200031,4.600031,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","1::overall","CD010966_pub4_data","significance_only",TRUE,FALSE,TRUE,-0.207750252671045,-0.0819815913269149,-0.673556970156986,0.258056464814896,-0.1207064162904,-0.0432567663634297,TRUE,TRUE
14,2,"Adverse events occurring in 10% or more participants (from days 15 to 21)","Cough","SUBGROUP_AND_OVERALL","Boyle 2014","2014",0,0,0,0,1,20,0,0,4,21,0,0,100,0.223684,0.011075,4.517659,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
14,2,"Adverse events occurring in 10% or more participants (from days 15 to 21)","Oropharyngeal pain","SUBGROUP_AND_OVERALL","Boyle 2014","2014",0,0,0,0,2,20,0,0,2,21,0,0,100,1.055556,0.070122,15.889441,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
14,2,"Adverse events occurring in 10% or more participants (from days 15 to 21)","Nasal congestion","SUBGROUP_AND_OVERALL","Boyle 2014","2014",0,0,0,0,3,20,0,0,2,21,0,0,100,1.676471,0.137103,20.499545,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
14,2,"Adverse events occurring in 10% or more participants (from days 15 to 21)","Dizziness","SUBGROUP_AND_OVERALL","Boyle 2014","2014",0,0,0,0,1,20,0,0,0,21,0,0,100,3.307692,0.045662,239.606071,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
14,2,"Adverse events occurring in 10% or more participants (from days 15 to 21)","Prothrombin time prolonged","SUBGROUP_AND_OVERALL","Boyle 2014","2014",0,0,0,0,0,20,0,0,0,21,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
14,2,"Adverse events occurring in 10% or more participants (from days 15 to 21)","Upper respiratory tract infection","SUBGROUP_AND_OVERALL","Boyle 2014","2014",0,0,0,0,0,20,0,0,0,21,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
14,2,"Adverse events occurring in 10% or more participants (from days 15 to 21)","Pulmonary exacerbation","SUBGROUP_AND_OVERALL","Boyle 2014","2014",0,0,0,0,1,20,0,0,1,21,0,0,100,1.052632,0.025128,44.095717,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
14,3,"Sweat chloride concentration (mmol/L) (change from baseline)","At 14 days (before addition of ivacaftor)","SUBGROUP_AND_OVERALL","Boyle 2014","2014",0,0,-4.1,7.7798,0,17,-1.7,8.8462,0,17,0,0,100,-2.4,-7.999999,3.199999,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
14,3,"Sweat chloride concentration (mmol/L) (change from baseline)","At 21 days","SUBGROUP_AND_OVERALL","Boyle 2014","2014",0,0,-12.6,9.8142,0,17,-1.7,9.8142,0,16,0,0,100,-10.9,-17.600011,-4.199989,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
15,1,"Quality of life - CFQ-R respiratory domain (absolute change from baseline)","At 6 months","SUBGROUP_AND_OVERALL","Ratjen 2017","2017",2.5,1.3266,0,0,0,103,0,0,0,101,0,0,100,2.5,-0.100088,5.100088,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","1::overall","CD010966_pub4_data","significance_only",TRUE,FALSE,TRUE,-0.207750252671045,-0.0819815913269149,-0.673556970156986,0.258056464814896,-0.1207064162904,-0.0432567663634297,TRUE,TRUE
15,2,"FEV1 % predicted (absolute change from baseline)","At 6 months","SUBGROUP_AND_OVERALL","Ratjen 2017","2017",2.4,1.0204,0,0,0,103,0,0,0,101,0,0,100,2.4,0.400053,4.399947,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
15,3,"LCI2.5 (absolute change from baseline)","At 6 months","SUBGROUP_AND_OVERALL","Ratjen 2017","2017",-1.1,0.1531,0,0,0,103,0,0,0,101,0,0,100,-1.1,-1.40007,-0.79993,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
15,4,"Treatment-emergent adverse events with incidence > 10% in any treatment group (at 6 months)","Any adverse event","SUBGROUP_AND_OVERALL","Ratjen 2017","2017",0,0,0,0,98,103,0,0,98,101,0,0,100,0.6,0.088249,4.079388,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
15,4,"Treatment-emergent adverse events with incidence > 10% in any treatment group (at 6 months)","Any serious adverse event","SUBGROUP_AND_OVERALL","Ratjen 2017","2017",0,0,0,0,13,103,0,0,11,101,0,0,100,1.181818,0.384472,3.63276,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
15,4,"Treatment-emergent adverse events with incidence > 10% in any treatment group (at 6 months)","Productive cough","SUBGROUP_AND_OVERALL","Ratjen 2017","2017",0,0,0,0,18,103,0,0,6,101,0,0,100,3.352941,0.938131,11.983626,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
15,4,"Treatment-emergent adverse events with incidence > 10% in any treatment group (at 6 months)","Nasal congestion","SUBGROUP_AND_OVERALL","Ratjen 2017","2017",0,0,0,0,17,103,0,0,8,101,0,0,100,2.297965,0.713443,7.401632,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
15,4,"Treatment-emergent adverse events with incidence > 10% in any treatment group (at 6 months)","Oropharyngeal pain","SUBGROUP_AND_OVERALL","Ratjen 2017","2017",0,0,0,0,15,103,0,0,10,101,0,0,100,1.551136,0.506167,4.75342,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
15,4,"Treatment-emergent adverse events with incidence > 10% in any treatment group (at 6 months)","Pyrexia","SUBGROUP_AND_OVERALL","Ratjen 2017","2017",0,0,0,0,15,103,0,0,20,101,0,0,100,0.690341,0.262987,1.812144,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
15,4,"Treatment-emergent adverse events with incidence > 10% in any treatment group (at 6 months)","Upper abdominal pain","SUBGROUP_AND_OVERALL","Ratjen 2017","2017",0,0,0,0,13,103,0,0,7,101,0,0,100,1.939683,0.546958,6.878721,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
15,4,"Treatment-emergent adverse events with incidence > 10% in any treatment group (at 6 months)","Headache","SUBGROUP_AND_OVERALL","Ratjen 2017","2017",0,0,0,0,13,103,0,0,9,101,0,0,100,1.476543,0.453513,4.807315,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
15,4,"Treatment-emergent adverse events with incidence > 10% in any treatment group (at 6 months)","Upper respiratory tract infection","SUBGROUP_AND_OVERALL","Ratjen 2017","2017",0,0,0,0,13,103,0,0,10,101,0,0,100,1.314444,0.416564,4.147657,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
15,4,"Treatment-emergent adverse events with incidence > 10% in any treatment group (at 6 months)","Sputum increased","SUBGROUP_AND_OVERALL","Ratjen 2017","2017",0,0,0,0,11,103,0,0,2,101,0,0,100,5.918478,0.789145,44.387751,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
15,4,"Treatment-emergent adverse events with incidence > 10% in any treatment group (at 6 months)","Abdominal pain","SUBGROUP_AND_OVERALL","Ratjen 2017","2017",0,0,0,0,10,103,0,0,10,101,0,0,100,0.978495,0.290927,3.291041,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
15,4,"Treatment-emergent adverse events with incidence > 10% in any treatment group (at 6 months)","Nausea","SUBGROUP_AND_OVERALL","Ratjen 2017","2017",0,0,0,0,10,103,0,0,9,101,0,0,100,1.099164,0.317241,3.808337,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
15,4,"Treatment-emergent adverse events with incidence > 10% in any treatment group (at 6 months)","Rhinorrhoea","SUBGROUP_AND_OVERALL","Ratjen 2017","2017",0,0,0,0,10,103,0,0,5,101,0,0,100,2.064516,0.479566,8.887669,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
15,4,"Treatment-emergent adverse events with incidence > 10% in any treatment group (at 6 months)","Vomiting","SUBGROUP_AND_OVERALL","Ratjen 2017","2017",0,0,0,0,10,103,0,0,10,101,0,0,100,0.978495,0.290927,3.291041,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
15,4,"Treatment-emergent adverse events with incidence > 10% in any treatment group (at 6 months)","Fatigue","SUBGROUP_AND_OVERALL","Ratjen 2017","2017",0,0,0,0,9,103,0,0,11,101,0,0,100,0.783366,0.231625,2.64937,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
15,4,"Treatment-emergent adverse events with incidence > 10% in any treatment group (at 6 months)","Respiratory events","SUBGROUP_AND_OVERALL","Ratjen 2017","2017",0,0,0,0,19,103,0,0,13,101,0,0,100,1.531136,0.559367,4.19112,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
15,4,"Treatment-emergent adverse events with incidence > 10% in any treatment group (at 6 months)","Cough","SUBGROUP_AND_OVERALL","Ratjen 2017","2017",0,0,0,0,46,103,0,0,47,101,0,0,100,0.927212,0.449366,1.913188,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
15,4,"Treatment-emergent adverse events with incidence > 10% in any treatment group (at 6 months)","Pulmonary exacerbation","SUBGROUP_AND_OVERALL","Ratjen 2017","2017",0,0,0,0,20,103,0,0,18,101,0,0,100,1.111111,0.439497,2.809046,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
15,5,"Sweat chloride concentration (absolute change from baseline)","At up to 1 month","SUBGROUP_AND_OVERALL","Ratjen 2017","2017",-20.8,1.3266,0,0,0,103,0,0,0,101,0,0,100,-20.8,-23.400088,-18.199912,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
16,1,"FEV1 % predicted (absolute change from baseline)","At 21 days","SUBGROUP_AND_OVERALL","Boyle 2014","2014",0,0,1.868421,6.869761,0,38,0.3,6.9891,0,21,0,0,100,1.568421,-2.133789,5.270631,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","1::overall","CD010966_pub4_data","significance_only",TRUE,FALSE,TRUE,-0.207750252671045,-0.0819815913269149,-0.673556970156986,0.258056464814896,-0.1207064162904,-0.0432567663634297,TRUE,TRUE
16,2,"Adverse events occurring in 10% or more participants (from days 15 to 21)","Cough","SUBGROUP_AND_OVERALL","Boyle 2014","2014",0,0,0,0,5,40,0,0,4,21,0,0,100,0.607143,0.091881,4.011952,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
16,2,"Adverse events occurring in 10% or more participants (from days 15 to 21)","Pulmonary exacerbation","SUBGROUP_AND_OVERALL","Boyle 2014","2014",0,0,0,0,3,40,0,0,1,21,0,0,100,1.621622,0.076109,34.551305,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
16,2,"Adverse events occurring in 10% or more participants (from days 15 to 21)","Oropharyngeal pain","SUBGROUP_AND_OVERALL","Boyle 2014","2014",0,0,0,0,3,40,0,0,2,21,0,0,100,0.77027,0.065728,9.02688,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
16,2,"Adverse events occurring in 10% or more participants (from days 15 to 21)","Nasal congestion","SUBGROUP_AND_OVERALL","Boyle 2014","2014",0,0,0,0,4,40,0,0,2,21,0,0,100,1.055556,0.100943,11.037936,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
16,2,"Adverse events occurring in 10% or more participants (from days 15 to 21)","Dizziness","SUBGROUP_AND_OVERALL","Boyle 2014","2014",0,0,0,0,3,40,0,0,0,21,0,0,100,4.013333,0.076803,209.716724,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
16,2,"Adverse events occurring in 10% or more participants (from days 15 to 21)","Prothrombin time prolonged","SUBGROUP_AND_OVERALL","Boyle 2014","2014",0,0,0,0,2,40,0,0,0,21,0,0,100,2.792208,0.048634,160.308896,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
16,2,"Adverse events occurring in 10% or more participants (from days 15 to 21)","Upper respiratory tract infection","SUBGROUP_AND_OVERALL","Boyle 2014","2014",0,0,0,0,2,40,0,0,0,21,0,0,100,2.792208,0.048634,160.308896,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
16,3,"Sweat chloride concentration (mmol/L) (change from baseline)","At 21 days","SUBGROUP_AND_OVERALL","Boyle 2014","2014",0,0,-9.65,9.985105,0,34,-1.7,9.8142,0,16,0,0,100,-7.95,-13.814299,-2.085701,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
17,1,"Absolute change from baseline in CFQ-R respiratory domain score","At 3 months","SUBGROUP_AND_OVERALL","NCT02070744","2014",0,0,5.6,9.052485,0,6,-4.6,8.29532,0,5,0,0,100,10.2,-0.063248,20.463248,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","1::overall","CD010966_pub4_data","significance_only",TRUE,FALSE,TRUE,-0.207750252671045,-0.0819815913269149,-0.673556970156986,0.258056464814896,-0.1207064162904,-0.0432567663634297,TRUE,TRUE
17,2,"Relative change from baseline in % predicted FEV1","At 3 months","SUBGROUP_AND_OVERALL","NCT02070744","2014",0,0,2.6,8.1472,0,6,1,7.44968,0,5,0,0,100,1.6,-7.626905,10.826905,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
17,3,"Absolute change from baseline in % predicted FEV1","At 3 months","SUBGROUP_AND_OVERALL","NCT02070744","2014",0,0,0.9,3.859217,0,6,-0.1,3.503363,0,5,0,0,100,1,-3.354901,5.354901,"The doses of both groups are the same but the timings of administration between each active arm differs.","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
17,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Nausea","SUBGROUP_AND_OVERALL","NCT02070744","2014",0,0,0,0,2,15,0,0,0,13,0,0,100,5,0.081893,305.275187,"Two VX-661 50 mg tablets once daily plus 150 mg ivacaftor tablet twice daily","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
17,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Musculoskeletal pain","SUBGROUP_AND_OVERALL","NCT02070744","2014",0,0,0,0,1,6,0,0,0,5,0,0,100,3,0.033866,265.749879,"50 mg VX-661 twice daily plus 150 mg ivacaftor twice daily","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
17,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Headache","SUBGROUP_AND_OVERALL","NCT02070744","2014",0,0,0,0,2,15,0,0,1,13,0,0,68.699187,1.846154,0.066812,51.013213,"Two VX-661 50 mg tablets once daily plus 150 mg ivacaftor tablet twice daily","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
17,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Headache","SUBGROUP_AND_OVERALL","NCT02070744","2014",0,0,0,0,1,6,0,0,0,5,0,0,31.300813,3,0.033866,265.749879,"50 mg VX-661 twice daily plus 150 mg ivacaftor twice daily","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
17,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Muscle strain","SUBGROUP_AND_OVERALL","NCT02070744","2014",0,0,0,0,1,6,0,0,0,5,0,0,100,3,0.033866,265.749879,"50 mg VX-661 twice daily plus 150 mg ivacaftor twice daily","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
17,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Aspartate aminotransferase increased","SUBGROUP_AND_OVERALL","NCT02070744","2014",0,0,0,0,0,6,0,0,1,5,0,0,100,0.230769,0.002581,20.630996,"50 mg VX-661 twice daily plus 150 mg ivacaftor twice daily","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
17,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Chronic sinusitis","SUBGROUP_AND_OVERALL","NCT02070744","2014",0,0,0,0,1,6,0,0,0,5,0,0,100,3,0.033866,265.749879,"50 mg VX-661 twice daily plus 150 mg ivacaftor twice daily","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
17,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Dyspepsia","SUBGROUP_AND_OVERALL","NCT02070744","2014",0,0,0,0,1,6,0,0,1,5,0,0,100,0.8,0.014194,45.090295,"50 mg VX-661 twice daily plus 150 mg ivacaftor twice daily","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
17,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Fatigue","SUBGROUP_AND_OVERALL","NCT02070744","2014",0,0,0,0,1,6,0,0,1,5,0,0,100,0.8,0.014194,45.090295,"50 mg VX-661 twice daily plus 150 mg ivacaftor twice daily","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
17,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Nasopharyngitis","SUBGROUP_AND_OVERALL","NCT02070744","2014",0,0,0,0,2,15,0,0,0,13,0,0,100,5,0.081893,305.275187,"Two VX-661 50 mg tablets once daily plus 150 mg ivacaftor tablet twice daily","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
17,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Oxygen saturation decreased","SUBGROUP_AND_OVERALL","NCT02070744","2014",0,0,0,0,0,6,0,0,1,5,0,0,100,0.230769,0.002581,20.630996,"50 mg VX-661 twice daily plus 150 mg ivacaftor twice daily","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
17,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Tinnitus","SUBGROUP_AND_OVERALL","NCT02070744","2014",0,0,0,0,1,6,0,0,0,5,0,0,100,3,0.033866,265.749879,"50 mg VX-661 twice daily plus 150 mg ivacaftor twice daily","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
17,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Diarrhoea","SUBGROUP_AND_OVERALL","NCT02070744","2014",0,0,0,0,3,15,0,0,1,13,0,0,66.95279,3,0.127949,70.340379,"Two VX-661 50 mg tablets once daily plus 150 mg ivacaftor tablet twice daily","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
17,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Diarrhoea","SUBGROUP_AND_OVERALL","NCT02070744","2014",0,0,0,0,1,6,0,0,0,5,0,0,33.04721,3,0.033866,265.749879,"50 mg VX-661 twice daily plus 150 mg ivacaftor twice daily","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
17,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Non-cardiac chest pain","SUBGROUP_AND_OVERALL","NCT02070744","2014",0,0,0,0,0,6,0,0,1,5,0,0,100,0.230769,0.002581,20.630996,"50 mg VX-661 twice daily plus 150 mg ivacaftor twice daily","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
17,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Acute sinusitis","SUBGROUP_AND_OVERALL","NCT02070744","2014",0,0,0,0,0,6,0,0,1,5,0,0,100,0.230769,0.002581,20.630996,"50 mg VX-661 twice daily plus 150 mg ivacaftor twice daily","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
17,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Breath sounds abnormal","SUBGROUP_AND_OVERALL","NCT02070744","2014",0,0,0,0,1,6,0,0,0,5,0,0,100,3,0.033866,265.749879,"50 mg VX-661 twice daily plus 150 mg ivacaftor twice daily","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
17,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Vitamin D decreased","SUBGROUP_AND_OVERALL","NCT02070744","2014",0,0,0,0,0,15,0,0,2,13,0,0,100,0.148387,0.002424,9.084105,"Two VX-661 50 mg tablets once daily plus 150 mg ivacaftor tablet twice daily","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
17,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Iron deficiency","SUBGROUP_AND_OVERALL","NCT02070744","2014",0,0,0,0,1,6,0,0,0,5,0,0,100,3,0.033866,265.749879,"50 mg VX-661 twice daily plus 150 mg ivacaftor twice daily","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
17,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Back pain","SUBGROUP_AND_OVERALL","NCT02070744","2014",0,0,0,0,0,15,0,0,2,13,0,0,85.927505,0.148387,0.002424,9.084105,"Two VX-661 50 mg tablets once daily plus 150 mg ivacaftor tablet twice daily","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
17,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Back pain","SUBGROUP_AND_OVERALL","NCT02070744","2014",0,0,0,0,1,6,0,0,0,5,0,0,14.072495,3,0.033866,265.749879,"50 mg VX-661 twice daily plus 150 mg ivacaftor twice daily","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
17,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Pulmonary function test decreased","SUBGROUP_AND_OVERALL","NCT02070744","2014",0,0,0,0,2,15,0,0,1,13,0,0,50.530035,1.846154,0.066812,51.013213,"Two VX-661 50 mg tablets once daily plus 150 mg ivacaftor tablet twice daily","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
17,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Pulmonary function test decreased","SUBGROUP_AND_OVERALL","NCT02070744","2014",0,0,0,0,1,6,0,0,1,5,0,0,49.469965,0.8,0.014194,45.090295,"50 mg VX-661 twice daily plus 150 mg ivacaftor twice daily","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
17,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Weight decreased","SUBGROUP_AND_OVERALL","NCT02070744","2014",0,0,0,0,2,15,0,0,1,13,0,0,100,1.846154,0.066812,51.013213,"Two VX-661 50 mg tablets once daily plus 150 mg ivacaftor tablet twice daily","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
17,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Alanine aminotransferase increased","SUBGROUP_AND_OVERALL","NCT02070744","2014",0,0,0,0,0,6,0,0,1,5,0,0,100,0.230769,0.002581,20.630996,"50 mg VX-661 twice daily plus 150 mg ivacaftor twice daily","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
17,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Heart rate increased","SUBGROUP_AND_OVERALL","NCT02070744","2014",0,0,0,0,0,6,0,0,1,5,0,0,100,0.230769,0.002581,20.630996,"50 mg VX-661 twice daily plus 150 mg ivacaftor twice daily","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
17,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Forced expiratory volume decreased","SUBGROUP_AND_OVERALL","NCT02070744","2014",0,0,0,0,0,15,0,0,2,13,0,0,63.265306,0.148387,0.002424,9.084105,"Two VX-661 50 mg tablets once daily plus 150 mg ivacaftor tablet twice daily","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
17,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Forced expiratory volume decreased","SUBGROUP_AND_OVERALL","NCT02070744","2014",0,0,0,0,0,6,0,0,1,5,0,0,36.734694,0.230769,0.002581,20.630996,"50 mg VX-661 twice daily plus 150 mg ivacaftor twice daily","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
17,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Testicular pain","SUBGROUP_AND_OVERALL","NCT02070744","2014",0,0,0,0,1,6,0,0,0,5,0,0,100,3,0.033866,265.749879,"50 mg VX-661 twice daily plus 150 mg ivacaftor twice daily","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
17,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Amenorrhoea","SUBGROUP_AND_OVERALL","NCT02070744","2014",0,0,0,0,0,6,0,0,1,5,0,0,100,0.230769,0.002581,20.630996,"50 mg VX-661 twice daily plus 150 mg ivacaftor twice daily","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
17,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Haemoptysis","SUBGROUP_AND_OVERALL","NCT02070744","2014",0,0,0,0,3,15,0,0,3,13,0,0,100,0.833333,0.077528,8.957362,"Two VX-661 50 mg tablets once daily plus 150 mg ivacaftor tablet twice daily","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
17,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Nasal congestion","SUBGROUP_AND_OVERALL","NCT02070744","2014",0,0,0,0,1,15,0,0,3,13,0,0,87.640449,0.238095,0.010104,5.610572,"Two VX-661 50 mg tablets once daily plus 150 mg ivacaftor tablet twice daily","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
17,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Nasal congestion","SUBGROUP_AND_OVERALL","NCT02070744","2014",0,0,0,0,1,6,0,0,0,5,0,0,12.359551,3,0.033866,265.749879,"50 mg VX-661 twice daily plus 150 mg ivacaftor twice daily","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
17,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Respiration abnormal","SUBGROUP_AND_OVERALL","NCT02070744","2014",0,0,0,0,2,15,0,0,0,13,0,0,33.110368,5,0.081893,305.275187,"Two VX-661 50 mg tablets once daily plus 150 mg ivacaftor tablet twice daily","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
17,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Respiration abnormal","SUBGROUP_AND_OVERALL","NCT02070744","2014",0,0,0,0,1,6,0,0,1,5,0,0,66.889632,0.8,0.014194,45.090295,"50 mg VX-661 twice daily plus 150 mg ivacaftor twice daily","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
17,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Sinus congestion","SUBGROUP_AND_OVERALL","NCT02070744","2014",0,0,0,0,1,6,0,0,0,5,0,0,100,3,0.033866,265.749879,"50 mg VX-661 twice daily plus 150 mg ivacaftor twice daily","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
17,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Rales","SUBGROUP_AND_OVERALL","NCT02070744","2014",0,0,0,0,0,6,0,0,1,5,0,0,100,0.230769,0.002581,20.630996,"50 mg VX-661 twice daily plus 150 mg ivacaftor twice daily","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
17,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Epistaxis","SUBGROUP_AND_OVERALL","NCT02070744","2014",0,0,0,0,1,6,0,0,0,5,0,0,100,3,0.033866,265.749879,"50 mg VX-661 twice daily plus 150 mg ivacaftor twice daily","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
17,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Paranasal sinus hypersecretion","SUBGROUP_AND_OVERALL","NCT02070744","2014",0,0,0,0,1,6,0,0,0,5,0,0,100,3,0.033866,265.749879,"50 mg VX-661 twice daily plus 150 mg ivacaftor twice daily","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
17,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Nasal oedema","SUBGROUP_AND_OVERALL","NCT02070744","2014",0,0,0,0,1,6,0,0,0,5,0,0,100,3,0.033866,265.749879,"50 mg VX-661 twice daily plus 150 mg ivacaftor twice daily","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
17,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Sputum increased","SUBGROUP_AND_OVERALL","NCT02070744","2014",0,0,0,0,1,15,0,0,2,13,0,0,44.444444,0.392857,0.014188,10.878089,"Two VX-661 50 mg tablets once daily plus 150 mg ivacaftor tablet twice daily","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
17,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Sputum increased","SUBGROUP_AND_OVERALL","NCT02070744","2014",0,0,0,0,0,6,0,0,2,5,0,0,55.555556,0.107692,0.001403,8.265181,"50 mg VX-661 twice daily plus 150 mg ivacaftor twice daily","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
17,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Lower respiratory tract congestion","SUBGROUP_AND_OVERALL","NCT02070744","2014",0,0,0,0,1,6,0,0,0,5,0,0,100,3,0.033866,265.749879,"50 mg VX-661 twice daily plus 150 mg ivacaftor twice daily","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
17,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Cough","SUBGROUP_AND_OVERALL","NCT02070744","2014",0,0,0,0,4,15,0,0,5,13,0,0,78.266494,0.581818,0.071108,4.76055,"Two VX-661 50 mg tablets once daily plus 150 mg ivacaftor tablet twice daily","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
17,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Cough","SUBGROUP_AND_OVERALL","NCT02070744","2014",0,0,0,0,3,6,0,0,2,5,0,0,21.733506,1.5,0.063975,35.17019,"50 mg VX-661 twice daily plus 150 mg ivacaftor twice daily","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
17,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Number of participants with serious adverse events","SUBGROUP_AND_OVERALL","NCT02070744","2014",0,0,0,0,4,15,0,0,5,13,0,0,68.361582,0.581818,0.071108,4.76055,"Two VX-661 50 mg tablets once daily plus 150 mg ivacaftor tablet twice daily","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
17,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Number of participants with serious adverse events","SUBGROUP_AND_OVERALL","NCT02070744","2014",0,0,0,0,1,6,0,0,2,5,0,0,31.638418,0.3,0.00762,11.810996,"50 mg VX-661 twice daily plus 150 mg ivacaftor twice daily","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
17,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Hyposmia","SUBGROUP_AND_OVERALL","NCT02070744","2014",0,0,0,0,1,6,0,0,0,5,0,0,100,3,0.033866,265.749879,"50 mg VX-661 twice daily plus 150 mg ivacaftor twice daily","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
17,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Productive cough","SUBGROUP_AND_OVERALL","NCT02070744","2014",0,0,0,0,1,6,0,0,0,5,0,0,100,3,0.033866,265.749879,"50 mg VX-661 twice daily plus 150 mg ivacaftor twice daily","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
17,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Sputum discoloured","SUBGROUP_AND_OVERALL","NCT02070744","2014",0,0,0,0,0,6,0,0,1,5,0,0,100,0.230769,0.002581,20.630996,"50 mg VX-661 twice daily plus 150 mg ivacaftor twice daily","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
17,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Rash","SUBGROUP_AND_OVERALL","NCT02070744","2014",0,0,0,0,1,6,0,0,0,5,0,0,100,3,0.033866,265.749879,"50 mg VX-661 twice daily plus 150 mg ivacaftor twice daily","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
17,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Muscle spasms","SUBGROUP_AND_OVERALL","NCT02070744","2014",0,0,0,0,1,6,0,0,0,5,0,0,100,3,0.033866,265.749879,"50 mg VX-661 twice daily plus 150 mg ivacaftor twice daily","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
17,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Sinus headache","SUBGROUP_AND_OVERALL","NCT02070744","2014",0,0,0,0,0,6,0,0,1,5,0,0,100,0.230769,0.002581,20.630996,"50 mg VX-661 twice daily plus 150 mg ivacaftor twice daily","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
17,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Infective pulmonary exacerbation of cystic fibrosis","SUBGROUP_AND_OVERALL","NCT02070744","2014",0,0,0,0,1,6,0,0,5,5,0,0,57.579878,0.024793,0.00028,2.19628,"50 mg VX-661 twice daily plus 150 mg ivacaftor twice daily","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
17,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Infective pulmonary exacerbation of cystic fibrosis","SUBGROUP_AND_OVERALL","NCT02070744","2014",0,0,0,0,9,15,0,0,8,13,0,0,42.420122,0.9375,0.126897,6.926146,"Two VX-661 50 mg tablets once daily plus 150 mg ivacaftor tablet twice daily","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
17,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Pneumothorax","SUBGROUP_AND_OVERALL","NCT02070744","2014",0,0,0,0,0,15,0,0,2,13,0,0,100,0.148387,0.002424,9.084105,"Two VX-661 50 mg tablets once daily plus 150 mg ivacaftor tablet twice daily","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
17,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Dyspnoea","SUBGROUP_AND_OVERALL","NCT02070744","2014",0,0,0,0,2,15,0,0,1,13,0,0,33.806147,1.846154,0.066812,51.013213,"Two VX-661 50 mg tablets once daily plus 150 mg ivacaftor tablet twice daily","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
17,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Dyspnoea","SUBGROUP_AND_OVERALL","NCT02070744","2014",0,0,0,0,1,6,0,0,2,5,0,0,66.193853,0.3,0.00762,11.810996,"50 mg VX-661 twice daily plus 150 mg ivacaftor twice daily","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
17,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Number of participants with treatment-emergent adverse events","SUBGROUP_AND_OVERALL","NCT02070744","2014",0,0,0,0,15,15,0,0,13,13,0,0,NA,NA,NA,NA,"Two VX-661 50 mg tablets once daily plus 150 mg ivacaftor tablet twice daily","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
17,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Number of participants with treatment-emergent adverse events","SUBGROUP_AND_OVERALL","NCT02070744","2014",0,0,0,0,6,6,0,0,5,5,0,0,NA,NA,NA,NA,"50 mg VX-661 twice daily plus 150 mg ivacaftor twice daily","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
17,5,"Absolute change from baseline in sweat chloride","At 3 months","SUBGROUP_AND_OVERALL","NCT02070744","2014",0,0,-10.6,4.832225,0,5,2.9,4.791957,0,5,0,0,100,-13.5,-19.465072,-7.534928,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
18,1,"CFQ-R respiratory domain (absolute change from baseline)","At 1 month","SUBGROUP_AND_OVERALL","Taylor-Cousar 2017","2017",5.1,1.0771,0,0,0,248,0,0,0,256,0,0,100,5.1,2.988923,7.211077,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","1::overall","CD010966_pub4_data","significance_only",TRUE,FALSE,TRUE,-0.207750252671045,-0.0819815913269149,-0.673556970156986,0.258056464814896,-0.1207064162904,-0.0432567663634297,TRUE,TRUE
18,1,"CFQ-R respiratory domain (absolute change from baseline)","Up to and including 6 months","SUBGROUP_AND_OVERALL","McKone 2021","2021",2.8,0.213043,0,0,0,76,0,0,0,73,0,0,93.570811,2.8,2.382443,3.217557,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","1::overall","CD010966_pub4_data","significance_only",TRUE,FALSE,TRUE,-0.207750252671045,-0.0819815913269149,-0.673556970156986,0.258056464814896,-0.1207064162904,-0.0432567663634297,TRUE,TRUE
18,1,"CFQ-R respiratory domain (absolute change from baseline)","Up to and including 6 months","SUBGROUP_AND_OVERALL","Munck 2020","2020 Jun 13 [epub ahead of print]",2.1,1.88423,0,0,0,83,0,0,0,85,0,0,1.196209,2.1,-1.593023,5.793023,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","1::overall","CD010966_pub4_data","significance_only",TRUE,FALSE,TRUE,-0.207750252671045,-0.0819815913269149,-0.673556970156986,0.258056464814896,-0.1207064162904,-0.0432567663634297,TRUE,TRUE
18,1,"CFQ-R respiratory domain (absolute change from baseline)","Up to and including 6 months","SUBGROUP_AND_OVERALL","NCT02070744","2014",0.6,4.1557,0,0,0,15,0,0,0,13,0,0,0.245916,0.6,-7.545022,8.745022,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","1::overall","CD010966_pub4_data","significance_only",TRUE,FALSE,TRUE,-0.207750252671045,-0.0819815913269149,-0.673556970156986,0.258056464814896,-0.1207064162904,-0.0432567663634297,TRUE,TRUE
18,1,"CFQ-R respiratory domain (absolute change from baseline)","Up to and including 6 months","SUBGROUP_AND_OVERALL","Schwarz 2021","2018",1,3.013098,0,0,0,50,0,0,0,47,0,0,0.467787,1,-4.905564,6.905564,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","1::overall","CD010966_pub4_data","significance_only",TRUE,FALSE,TRUE,-0.207750252671045,-0.0819815913269149,-0.673556970156986,0.258056464814896,-0.1207064162904,-0.0432567663634297,TRUE,TRUE
18,1,"CFQ-R respiratory domain (absolute change from baseline)","Up to and including 6 months","SUBGROUP_AND_OVERALL","Taylor-Cousar 2017","2017",5.1,0.9694,0,0,0,248,0,0,0,256,0,0,4.519276,5.1,3.200011,6.999989,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","1::overall","CD010966_pub4_data","significance_only",TRUE,FALSE,TRUE,-0.207750252671045,-0.0819815913269149,-0.673556970156986,0.258056464814896,-0.1207064162904,-0.0432567663634297,TRUE,TRUE
18,2,"CFQ-R physical functioning domain (absolute change from baseline)","At 6 months","SUBGROUP_AND_OVERALL","Taylor-Cousar 2017","2017",3.8,0.9694,0,0,0,248,0,0,0,256,0,0,100,3.8,1.900011,5.699989,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
18,3,"CFQ-R treatment burden domain (absolute change from baseline)","At 6 months","SUBGROUP_AND_OVERALL","Taylor-Cousar 2017","2017",3.4,0.9184,0,0,0,248,0,0,0,256,0,0,100,3.4,1.599969,5.200031,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
18,4,"CFQ-R health perceptions domain (absolute change from baseline)","At 6 months","SUBGROUP_AND_OVERALL","Taylor-Cousar 2017","2017",3.2,1.0204,0,0,0,248,0,0,0,256,0,0,100,3.2,1.200053,5.199947,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
18,5,"CFQ-R vitality domain (absolute change from baseline)","At 6 months","SUBGROUP_AND_OVERALL","Taylor-Cousar 2017","2017",2.3,1.1225,0,0,0,248,0,0,0,256,0,0,100,2.3,0.09994,4.50006,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
18,16,"Most common adverse events (occurring in at least 10% of participants in either group)","Cough","SUBGROUP_AND_OVERALL","Donaldson 2018","2018",0,0,0,0,2,14,0,0,0,4,0,0,0.57616,1.8,0.026083,124.219173,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","16::overall","CD010966_pub4_data","significance_only",TRUE,TRUE,FALSE,-0.207976073333071,-0.000957071316611077,-0.321521973251102,-0.0944301734150395,-0.0202428771011532,0.018328734467931,TRUE,TRUE
18,16,"Most common adverse events (occurring in at least 10% of participants in either group)","Cough","SUBGROUP_AND_OVERALL","McKone 2021","2021",0,0,0,0,12,76,0,0,12,75,0,0,9.37729,0.984375,0.312736,3.098443,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","16::overall","CD010966_pub4_data","significance_only",TRUE,TRUE,FALSE,-0.207976073333071,-0.000957071316611077,-0.321521973251102,-0.0944301734150395,-0.0202428771011532,0.018328734467931,TRUE,TRUE
18,16,"Most common adverse events (occurring in at least 10% of participants in either group)","Cough","SUBGROUP_AND_OVERALL","Munck 2020","2020 Jun 13 [epub ahead of print]",0,0,0,0,19,83,0,0,28,85,0,0,19.666262,0.604353,0.246226,1.48336,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","16::overall","CD010966_pub4_data","significance_only",TRUE,TRUE,FALSE,-0.207976073333071,-0.000957071316611077,-0.321521973251102,-0.0944301734150395,-0.0202428771011532,0.018328734467931,TRUE,TRUE
18,16,"Most common adverse events (occurring in at least 10% of participants in either group)","Cough","SUBGROUP_AND_OVERALL","NCT02508207","2015",0,0,0,0,8,27,0,0,0,7,0,0,0.499339,6.538462,0.131249,325.727554,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","16::overall","CD010966_pub4_data","significance_only",TRUE,TRUE,FALSE,-0.207976073333071,-0.000957071316611077,-0.321521973251102,-0.0944301734150395,-0.0202428771011532,0.018328734467931,TRUE,TRUE
18,16,"Most common adverse events (occurring in at least 10% of participants in either group)","Cough","SUBGROUP_AND_OVERALL","NCT02730208","2018",0,0,0,0,12,20,0,0,13,21,0,0,4.676733,0.923077,0.177303,4.805728,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","16::overall","CD010966_pub4_data","significance_only",TRUE,TRUE,FALSE,-0.207976073333071,-0.000957071316611077,-0.321521973251102,-0.0944301734150395,-0.0202428771011532,0.018328734467931,TRUE,TRUE
18,16,"Most common adverse events (occurring in at least 10% of participants in either group)","Cough","SUBGROUP_AND_OVERALL","Schwarz 2021","2018",0,0,0,0,9,50,0,0,8,47,0,0,6.234408,1.070122,0.269794,4.244578,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","16::overall","CD010966_pub4_data","significance_only",TRUE,TRUE,FALSE,-0.207976073333071,-0.000957071316611077,-0.321521973251102,-0.0944301734150395,-0.0202428771011532,0.018328734467931,TRUE,TRUE
18,16,"Most common adverse events (occurring in at least 10% of participants in either group)","Cough","SUBGROUP_AND_OVERALL","Taylor-Cousar 2017","2017",0,0,0,0,66,251,0,0,88,258,0,0,58.969808,0.689189,0.417673,1.13721,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","16::overall","CD010966_pub4_data","significance_only",TRUE,TRUE,FALSE,-0.207976073333071,-0.000957071316611077,-0.321521973251102,-0.0944301734150395,-0.0202428771011532,0.018328734467931,TRUE,TRUE
18,16,"Most common adverse events (occurring in at least 10% of participants in either group)","Pulmonary exacerbation","SUBGROUP_AND_OVERALL","Donaldson 2018","2018",0,0,0,0,2,14,0,0,1,4,0,0,1.137791,0.5,0.014133,17.688718,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","16::overall","CD010966_pub4_data","significance_only",TRUE,TRUE,FALSE,-0.207976073333071,-0.000957071316611077,-0.321521973251102,-0.0944301734150395,-0.0202428771011532,0.018328734467931,TRUE,TRUE
18,16,"Most common adverse events (occurring in at least 10% of participants in either group)","Pulmonary exacerbation","SUBGROUP_AND_OVERALL","McKone 2021","2021",0,0,0,0,8,76,0,0,9,75,0,0,6.917169,0.862745,0.22854,3.256895,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","16::overall","CD010966_pub4_data","significance_only",TRUE,TRUE,FALSE,-0.207976073333071,-0.000957071316611077,-0.321521973251102,-0.0944301734150395,-0.0202428771011532,0.018328734467931,TRUE,TRUE
18,16,"Most common adverse events (occurring in at least 10% of participants in either group)","Pulmonary exacerbation","SUBGROUP_AND_OVERALL","Munck 2020","2020 Jun 13 [epub ahead of print]",0,0,0,0,23,83,0,0,27,85,0,0,16.457341,0.823457,0.344536,1.968101,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","16::overall","CD010966_pub4_data","significance_only",TRUE,TRUE,FALSE,-0.207976073333071,-0.000957071316611077,-0.321521973251102,-0.0944301734150395,-0.0202428771011532,0.018328734467931,TRUE,TRUE
18,16,"Most common adverse events (occurring in at least 10% of participants in either group)","Pulmonary exacerbation","SUBGROUP_AND_OVERALL","NCT02508207","2015",0,0,0,0,7,27,0,0,0,7,0,0,0.485932,5.487805,0.108935,276.459147,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","16::overall","CD010966_pub4_data","significance_only",TRUE,TRUE,FALSE,-0.207976073333071,-0.000957071316611077,-0.321521973251102,-0.0944301734150395,-0.0202428771011532,0.018328734467931,TRUE,TRUE
18,16,"Most common adverse events (occurring in at least 10% of participants in either group)","Pulmonary exacerbation","SUBGROUP_AND_OVERALL","NCT02730208","2018",0,0,0,0,10,20,0,0,15,21,0,0,6.243978,0.4,0.073394,2.180006,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","16::overall","CD010966_pub4_data","significance_only",TRUE,TRUE,FALSE,-0.207976073333071,-0.000957071316611077,-0.321521973251102,-0.0944301734150395,-0.0202428771011532,0.018328734467931,TRUE,TRUE
18,16,"Most common adverse events (occurring in at least 10% of participants in either group)","Pulmonary exacerbation","SUBGROUP_AND_OVERALL","Schwarz 2021","2018",0,0,0,0,7,50,0,0,16,47,0,0,12.105163,0.315407,0.084626,1.175539,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","16::overall","CD010966_pub4_data","significance_only",TRUE,TRUE,FALSE,-0.207976073333071,-0.000957071316611077,-0.321521973251102,-0.0944301734150395,-0.0202428771011532,0.018328734467931,TRUE,TRUE
18,16,"Most common adverse events (occurring in at least 10% of participants in either group)","Pulmonary exacerbation","SUBGROUP_AND_OVERALL","Taylor-Cousar 2017","2017",0,0,0,0,75,251,0,0,96,258,0,0,56.652626,0.719105,0.442292,1.169166,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","16::overall","CD010966_pub4_data","significance_only",TRUE,TRUE,FALSE,-0.207976073333071,-0.000957071316611077,-0.321521973251102,-0.0944301734150395,-0.0202428771011532,0.018328734467931,TRUE,TRUE
18,16,"Most common adverse events (occurring in at least 10% of participants in either group)","Headache","SUBGROUP_AND_OVERALL","Donaldson 2018","2018",0,0,0,0,1,14,0,0,0,4,0,0,1.653312,1,0.011869,84.254483,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","16::overall","CD010966_pub4_data","significance_only",TRUE,TRUE,FALSE,-0.207976073333071,-0.000957071316611077,-0.321521973251102,-0.0944301734150395,-0.0202428771011532,0.018328734467931,TRUE,TRUE
18,16,"Most common adverse events (occurring in at least 10% of participants in either group)","Headache","SUBGROUP_AND_OVERALL","NCT02730208","2018",0,0,0,0,1,20,0,0,4,21,0,0,9.080522,0.223684,0.011075,4.517659,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","16::overall","CD010966_pub4_data","significance_only",TRUE,TRUE,FALSE,-0.207976073333071,-0.000957071316611077,-0.321521973251102,-0.0944301734150395,-0.0202428771011532,0.018328734467931,TRUE,TRUE
18,16,"Most common adverse events (occurring in at least 10% of participants in either group)","Headache","SUBGROUP_AND_OVERALL","Schwarz 2021","2018",0,0,0,0,6,50,0,0,7,47,0,0,15.554644,0.779221,0.167119,3.63324,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","16::overall","CD010966_pub4_data","significance_only",TRUE,TRUE,FALSE,-0.207976073333071,-0.000957071316611077,-0.321521973251102,-0.0944301734150395,-0.0202428771011532,0.018328734467931,TRUE,TRUE
18,16,"Most common adverse events (occurring in at least 10% of participants in either group)","Headache","SUBGROUP_AND_OVERALL","Taylor-Cousar 2017","2017",0,0,0,0,44,251,0,0,37,258,0,0,73.711522,1.269617,0.678728,2.374925,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","16::overall","CD010966_pub4_data","significance_only",TRUE,TRUE,FALSE,-0.207976073333071,-0.000957071316611077,-0.321521973251102,-0.0944301734150395,-0.0202428771011532,0.018328734467931,TRUE,TRUE
18,16,"Most common adverse events (occurring in at least 10% of participants in either group)","Nasal congestion or nasopharyngitis","SUBGROUP_AND_OVERALL","Donaldson 2018","2018",0,0,0,0,1,14,0,0,1,4,0,0,3.126294,0.230769,0.004231,12.586667,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","16::overall","CD010966_pub4_data","significance_only",TRUE,TRUE,FALSE,-0.207976073333071,-0.000957071316611077,-0.321521973251102,-0.0944301734150395,-0.0202428771011532,0.018328734467931,TRUE,TRUE
18,16,"Most common adverse events (occurring in at least 10% of participants in either group)","Nasal congestion or nasopharyngitis","SUBGROUP_AND_OVERALL","Munck 2020","2020 Jun 13 [epub ahead of print]",0,0,0,0,9,83,0,0,13,85,0,0,24.787044,0.673597,0.203783,2.226545,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","16::overall","CD010966_pub4_data","significance_only",TRUE,TRUE,FALSE,-0.207976073333071,-0.000957071316611077,-0.321521973251102,-0.0944301734150395,-0.0202428771011532,0.018328734467931,TRUE,TRUE
18,16,"Most common adverse events (occurring in at least 10% of participants in either group)","Nasal congestion or nasopharyngitis","SUBGROUP_AND_OVERALL","NCT02730208","2018",0,0,0,0,3,20,0,0,1,21,0,0,1.794833,3.529412,0.160065,77.823263,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","16::overall","CD010966_pub4_data","significance_only",TRUE,TRUE,FALSE,-0.207976073333071,-0.000957071316611077,-0.321521973251102,-0.0944301734150395,-0.0202428771011532,0.018328734467931,TRUE,TRUE
18,16,"Most common adverse events (occurring in at least 10% of participants in either group)","Nasal congestion or nasopharyngitis","SUBGROUP_AND_OVERALL","Schwarz 2021","2018",0,0,0,0,6,50,0,0,0,47,0,0,0.972868,13.876404,0.3048,631.740316,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","16::overall","CD010966_pub4_data","significance_only",TRUE,TRUE,FALSE,-0.207976073333071,-0.000957071316611077,-0.321521973251102,-0.0944301734150395,-0.0202428771011532,0.018328734467931,TRUE,TRUE
18,16,"Most common adverse events (occurring in at least 10% of participants in either group)","Nasal congestion or nasopharyngitis","SUBGROUP_AND_OVERALL","Taylor-Cousar 2017","2017",0,0,0,0,42,251,0,0,39,258,0,0,69.318962,1.12845,0.60425,2.107408,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","16::overall","CD010966_pub4_data","significance_only",TRUE,TRUE,FALSE,-0.207976073333071,-0.000957071316611077,-0.321521973251102,-0.0944301734150395,-0.0202428771011532,0.018328734467931,TRUE,TRUE
18,16,"Most common adverse events (occurring in at least 10% of participants in either group)","Increased sputum","SUBGROUP_AND_OVERALL","Munck 2020","2020 Jun 13 [epub ahead of print]",0,0,0,0,7,83,0,0,12,85,0,0,20.813087,0.560307,0.153353,2.047192,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","16::overall","CD010966_pub4_data","significance_only",TRUE,TRUE,FALSE,-0.207976073333071,-0.000957071316611077,-0.321521973251102,-0.0944301734150395,-0.0202428771011532,0.018328734467931,TRUE,TRUE
18,16,"Most common adverse events (occurring in at least 10% of participants in either group)","Increased sputum","SUBGROUP_AND_OVERALL","NCT02730208","2018",0,0,0,0,2,20,0,0,1,21,0,0,1.683215,2.222222,0.08498,58.110965,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","16::overall","CD010966_pub4_data","significance_only",TRUE,TRUE,FALSE,-0.207976073333071,-0.000957071316611077,-0.321521973251102,-0.0944301734150395,-0.0202428771011532,0.018328734467931,TRUE,TRUE
18,16,"Most common adverse events (occurring in at least 10% of participants in either group)","Increased sputum","SUBGROUP_AND_OVERALL","Schwarz 2021","2018",0,0,0,0,2,50,0,0,5,47,0,0,9.48616,0.35,0.037909,3.231448,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","16::overall","CD010966_pub4_data","significance_only",TRUE,TRUE,FALSE,-0.207976073333071,-0.000957071316611077,-0.321521973251102,-0.0944301734150395,-0.0202428771011532,0.018328734467931,TRUE,TRUE
18,16,"Most common adverse events (occurring in at least 10% of participants in either group)","Increased sputum","SUBGROUP_AND_OVERALL","Taylor-Cousar 2017","2017",0,0,0,0,36,251,0,0,42,258,0,0,68.017538,0.86113,0.456117,1.625775,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","16::overall","CD010966_pub4_data","significance_only",TRUE,TRUE,FALSE,-0.207976073333071,-0.000957071316611077,-0.321521973251102,-0.0944301734150395,-0.0202428771011532,0.018328734467931,TRUE,TRUE
18,16,"Most common adverse events (occurring in at least 10% of participants in either group)","Haemoptysis","SUBGROUP_AND_OVERALL","Donaldson 2018","2018",0,0,0,0,1,14,0,0,0,4,0,0,1.657525,1,0.011869,84.254483,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","16::overall","CD010966_pub4_data","significance_only",TRUE,TRUE,FALSE,-0.207976073333071,-0.000957071316611077,-0.321521973251102,-0.0944301734150395,-0.0202428771011532,0.018328734467931,TRUE,TRUE
18,16,"Most common adverse events (occurring in at least 10% of participants in either group)","Haemoptysis","SUBGROUP_AND_OVERALL","Munck 2020","2020 Jun 13 [epub ahead of print]",0,0,0,0,10,83,0,0,7,85,0,0,14.938185,1.526419,0.40093,5.811378,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","16::overall","CD010966_pub4_data","significance_only",TRUE,TRUE,FALSE,-0.207976073333071,-0.000957071316611077,-0.321521973251102,-0.0944301734150395,-0.0202428771011532,0.018328734467931,TRUE,TRUE
18,16,"Most common adverse events (occurring in at least 10% of participants in either group)","Haemoptysis","SUBGROUP_AND_OVERALL","NCT02508207","2015",0,0,0,0,3,27,0,0,0,7,0,0,1.671167,2.142857,0.037712,121.760832,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","16::overall","CD010966_pub4_data","significance_only",TRUE,TRUE,FALSE,-0.207976073333071,-0.000957071316611077,-0.321521973251102,-0.0944301734150395,-0.0202428771011532,0.018328734467931,TRUE,TRUE
18,16,"Most common adverse events (occurring in at least 10% of participants in either group)","Haemoptysis","SUBGROUP_AND_OVERALL","NCT02730208","2018",0,0,0,0,4,20,0,0,3,21,0,0,5.749679,1.5,0.173467,12.970732,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","16::overall","CD010966_pub4_data","significance_only",TRUE,TRUE,FALSE,-0.207976073333071,-0.000957071316611077,-0.321521973251102,-0.0944301734150395,-0.0202428771011532,0.018328734467931,TRUE,TRUE
18,16,"Most common adverse events (occurring in at least 10% of participants in either group)","Haemoptysis","SUBGROUP_AND_OVERALL","Taylor-Cousar 2017","2017",0,0,0,0,26,251,0,0,35,258,0,0,75.983445,0.736254,0.362001,1.497427,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","16::overall","CD010966_pub4_data","significance_only",TRUE,TRUE,FALSE,-0.207976073333071,-0.000957071316611077,-0.321521973251102,-0.0944301734150395,-0.0202428771011532,0.018328734467931,TRUE,TRUE
18,16,"Most common adverse events (occurring in at least 10% of participants in either group)","Pyrexia","SUBGROUP_AND_OVERALL","Donaldson 2018","2018",0,0,0,0,1,14,0,0,0,4,0,0,2.222381,1,0.011869,84.254483,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","16::overall","CD010966_pub4_data","significance_only",TRUE,TRUE,FALSE,-0.207976073333071,-0.000957071316611077,-0.321521973251102,-0.0944301734150395,-0.0202428771011532,0.018328734467931,TRUE,TRUE
18,16,"Most common adverse events (occurring in at least 10% of participants in either group)","Pyrexia","SUBGROUP_AND_OVERALL","NCT02730208","2018",0,0,0,0,3,20,0,0,2,21,0,0,5.460593,1.676471,0.137103,20.499545,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","16::overall","CD010966_pub4_data","significance_only",TRUE,TRUE,FALSE,-0.207976073333071,-0.000957071316611077,-0.321521973251102,-0.0944301734150395,-0.0202428771011532,0.018328734467931,TRUE,TRUE
18,16,"Most common adverse events (occurring in at least 10% of participants in either group)","Pyrexia","SUBGROUP_AND_OVERALL","Taylor-Cousar 2017","2017",0,0,0,0,28,251,0,0,32,258,0,0,92.317026,0.886771,0.436187,1.802811,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","16::overall","CD010966_pub4_data","significance_only",TRUE,TRUE,FALSE,-0.207976073333071,-0.000957071316611077,-0.321521973251102,-0.0944301734150395,-0.0202428771011532,0.018328734467931,TRUE,TRUE
18,16,"Most common adverse events (occurring in at least 10% of participants in either group)","Oropharyngeal pain","SUBGROUP_AND_OVERALL","NCT02730208","2018",0,0,0,0,2,20,0,0,2,21,0,0,6.305466,1.055556,0.070122,15.889441,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","16::overall","CD010966_pub4_data","significance_only",TRUE,TRUE,FALSE,-0.207976073333071,-0.000957071316611077,-0.321521973251102,-0.0944301734150395,-0.0202428771011532,0.018328734467931,TRUE,TRUE
18,16,"Most common adverse events (occurring in at least 10% of participants in either group)","Oropharyngeal pain","SUBGROUP_AND_OVERALL","Taylor-Cousar 2017","2017",0,0,0,0,22,251,0,0,29,258,0,0,93.694534,0.758621,0.352299,1.633571,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","16::overall","CD010966_pub4_data","significance_only",TRUE,TRUE,FALSE,-0.207976073333071,-0.000957071316611077,-0.321521973251102,-0.0944301734150395,-0.0202428771011532,0.018328734467931,TRUE,TRUE
18,16,"Most common adverse events (occurring in at least 10% of participants in either group)","Fatigue","SUBGROUP_AND_OVERALL","Donaldson 2018","2018",0,0,0,0,1,14,0,0,0,4,0,0,2.059437,1,0.011869,84.254483,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","16::overall","CD010966_pub4_data","significance_only",TRUE,TRUE,FALSE,-0.207976073333071,-0.000957071316611077,-0.321521973251102,-0.0944301734150395,-0.0202428771011532,0.018328734467931,TRUE,TRUE
18,16,"Most common adverse events (occurring in at least 10% of participants in either group)","Fatigue","SUBGROUP_AND_OVERALL","Munck 2020","2020 Jun 13 [epub ahead of print]",0,0,0,0,10,83,0,0,4,85,0,0,10.60592,2.773973,0.57162,13.461613,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","16::overall","CD010966_pub4_data","significance_only",TRUE,TRUE,FALSE,-0.207976073333071,-0.000957071316611077,-0.321521973251102,-0.0944301734150395,-0.0202428771011532,0.018328734467931,TRUE,TRUE
18,16,"Most common adverse events (occurring in at least 10% of participants in either group)","Fatigue","SUBGROUP_AND_OVERALL","Taylor-Cousar 2017","2017",0,0,0,0,16,251,0,0,31,258,0,0,87.334643,0.498559,0.217754,1.141475,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","16::overall","CD010966_pub4_data","significance_only",TRUE,TRUE,FALSE,-0.207976073333071,-0.000957071316611077,-0.321521973251102,-0.0944301734150395,-0.0202428771011532,0.018328734467931,TRUE,TRUE
18,16,"Most common adverse events (occurring in at least 10% of participants in either group)","Dyspnoea","SUBGROUP_AND_OVERALL","Schwarz 2021","2018",0,0,0,0,5,50,0,0,5,47,0,0,100,0.933333,0.167081,5.213703,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","16::overall","CD010966_pub4_data","significance_only",TRUE,TRUE,FALSE,-0.207976073333071,-0.000957071316611077,-0.321521973251102,-0.0944301734150395,-0.0202428771011532,0.018328734467931,TRUE,TRUE
18,16,"Most common adverse events (occurring in at least 10% of participants in either group)","Abdominal pain upper","SUBGROUP_AND_OVERALL","Schwarz 2021","2018",0,0,0,0,4,50,0,0,5,47,0,0,100,0.730435,0.11915,4.47786,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","16::overall","CD010966_pub4_data","significance_only",TRUE,TRUE,FALSE,-0.207976073333071,-0.000957071316611077,-0.321521973251102,-0.0944301734150395,-0.0202428771011532,0.018328734467931,TRUE,TRUE
18,16,"Most common adverse events (occurring in at least 10% of participants in either group)","Pharyngitis","SUBGROUP_AND_OVERALL","NCT02730208","2018",0,0,0,0,2,20,0,0,0,21,0,0,100,5.810811,0.098916,341.355548,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","16::overall","CD010966_pub4_data","significance_only",TRUE,TRUE,FALSE,-0.207976073333071,-0.000957071316611077,-0.321521973251102,-0.0944301734150395,-0.0202428771011532,0.018328734467931,TRUE,TRUE
18,16,"Most common adverse events (occurring in at least 10% of participants in either group)","Upper respiratory tract infection","SUBGROUP_AND_OVERALL","NCT02730208","2018",0,0,0,0,4,20,0,0,2,21,0,0,100,2.375,0.216353,26.071412,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","16::overall","CD010966_pub4_data","significance_only",TRUE,TRUE,FALSE,-0.207976073333071,-0.000957071316611077,-0.321521973251102,-0.0944301734150395,-0.0202428771011532,0.018328734467931,TRUE,TRUE
18,16,"Most common adverse events (occurring in at least 10% of participants in either group)","Migraine","SUBGROUP_AND_OVERALL","NCT02730208","2018",0,0,0,0,2,20,0,0,0,21,0,0,100,5.810811,0.098916,341.355548,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","16::overall","CD010966_pub4_data","significance_only",TRUE,TRUE,FALSE,-0.207976073333071,-0.000957071316611077,-0.321521973251102,-0.0944301734150395,-0.0202428771011532,0.018328734467931,TRUE,TRUE
18,16,"Most common adverse events (occurring in at least 10% of participants in either group)","Lower respiratory tract infection","SUBGROUP_AND_OVERALL","NCT02730208","2018",0,0,0,0,3,20,0,0,2,21,0,0,100,1.676471,0.137103,20.499545,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","16::overall","CD010966_pub4_data","significance_only",TRUE,TRUE,FALSE,-0.207976073333071,-0.000957071316611077,-0.321521973251102,-0.0944301734150395,-0.0202428771011532,0.018328734467931,TRUE,TRUE
18,16,"Most common adverse events (occurring in at least 10% of participants in either group)","Gastroenteritis","SUBGROUP_AND_OVERALL","NCT02730208","2018",0,0,0,0,2,20,0,0,1,21,0,0,100,2.222222,0.08498,58.110965,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","16::overall","CD010966_pub4_data","significance_only",TRUE,TRUE,FALSE,-0.207976073333071,-0.000957071316611077,-0.321521973251102,-0.0944301734150395,-0.0202428771011532,0.018328734467931,TRUE,TRUE
18,16,"Most common adverse events (occurring in at least 10% of participants in either group)","Influenza","SUBGROUP_AND_OVERALL","NCT02730208","2018",0,0,0,0,2,20,0,0,1,21,0,0,100,2.222222,0.08498,58.110965,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","16::overall","CD010966_pub4_data","significance_only",TRUE,TRUE,FALSE,-0.207976073333071,-0.000957071316611077,-0.321521973251102,-0.0944301734150395,-0.0202428771011532,0.018328734467931,TRUE,TRUE
18,16,"Most common adverse events (occurring in at least 10% of participants in either group)","Sunburn","SUBGROUP_AND_OVERALL","NCT02730208","2018",0,0,0,0,1,20,0,0,3,21,0,0,100,0.315789,0.014331,6.958383,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","16::overall","CD010966_pub4_data","significance_only",TRUE,TRUE,FALSE,-0.207976073333071,-0.000957071316611077,-0.321521973251102,-0.0944301734150395,-0.0202428771011532,0.018328734467931,TRUE,TRUE
18,16,"Most common adverse events (occurring in at least 10% of participants in either group)","Bacterial test positive","SUBGROUP_AND_OVERALL","NCT02730208","2018",0,0,0,0,0,20,0,0,6,21,0,0,100,0.058161,0.001203,2.812013,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","16::overall","CD010966_pub4_data","significance_only",TRUE,TRUE,FALSE,-0.207976073333071,-0.000957071316611077,-0.321521973251102,-0.0944301734150395,-0.0202428771011532,0.018328734467931,TRUE,TRUE
18,16,"Most common adverse events (occurring in at least 10% of participants in either group)","Arthralgia","SUBGROUP_AND_OVERALL","NCT02508207","2015",0,0,0,0,0,27,0,0,1,7,0,0,100,0.078788,0.001013,6.127256,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","16::overall","CD010966_pub4_data","significance_only",TRUE,TRUE,FALSE,-0.207976073333071,-0.000957071316611077,-0.321521973251102,-0.0944301734150395,-0.0202428771011532,0.018328734467931,TRUE,TRUE
18,16,"Most common adverse events (occurring in at least 10% of participants in either group)","Renal impairment","SUBGROUP_AND_OVERALL","NCT02508207","2015",0,0,0,0,0,27,0,0,1,7,0,0,100,0.078788,0.001013,6.127256,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","16::overall","CD010966_pub4_data","significance_only",TRUE,TRUE,FALSE,-0.207976073333071,-0.000957071316611077,-0.321521973251102,-0.0944301734150395,-0.0202428771011532,0.018328734467931,TRUE,TRUE
18,16,"Most common adverse events (occurring in at least 10% of participants in either group)","Lung infection pseudomonal","SUBGROUP_AND_OVERALL","NCT02730208","2018",0,0,0,0,2,20,0,0,0,21,0,0,100,5.810811,0.098916,341.355548,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","16::overall","CD010966_pub4_data","significance_only",TRUE,TRUE,FALSE,-0.207976073333071,-0.000957071316611077,-0.321521973251102,-0.0944301734150395,-0.0202428771011532,0.018328734467931,TRUE,TRUE
18,16,"Most common adverse events (occurring in at least 10% of participants in either group)","Nausea","SUBGROUP_AND_OVERALL","Donaldson 2018","2018",0,0,0,0,2,14,0,0,0,4,0,0,2.877269,1.8,0.026083,124.219173,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","16::overall","CD010966_pub4_data","significance_only",TRUE,TRUE,FALSE,-0.207976073333071,-0.000957071316611077,-0.321521973251102,-0.0944301734150395,-0.0202428771011532,0.018328734467931,TRUE,TRUE
18,16,"Most common adverse events (occurring in at least 10% of participants in either group)","Nausea","SUBGROUP_AND_OVERALL","NCT02508207","2015",0,0,0,0,3,27,0,0,0,7,0,0,3.133026,2.142857,0.037712,121.760832,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","16::overall","CD010966_pub4_data","significance_only",TRUE,TRUE,FALSE,-0.207976073333071,-0.000957071316611077,-0.321521973251102,-0.0944301734150395,-0.0202428771011532,0.018328734467931,TRUE,TRUE
18,16,"Most common adverse events (occurring in at least 10% of participants in either group)","Nausea","SUBGROUP_AND_OVERALL","NCT02730208","2018",0,0,0,0,0,20,0,0,4,21,0,0,19.752784,0.094851,0.001863,4.829868,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","16::overall","CD010966_pub4_data","significance_only",TRUE,TRUE,FALSE,-0.207976073333071,-0.000957071316611077,-0.321521973251102,-0.0944301734150395,-0.0202428771011532,0.018328734467931,TRUE,TRUE
18,16,"Most common adverse events (occurring in at least 10% of participants in either group)","Nausea","SUBGROUP_AND_OVERALL","Taylor-Cousar 2017","2017",0,0,0,0,23,251,0,0,18,258,0,0,74.236922,1.345029,0.577836,3.130828,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","16::overall","CD010966_pub4_data","significance_only",TRUE,TRUE,FALSE,-0.207976073333071,-0.000957071316611077,-0.321521973251102,-0.0944301734150395,-0.0202428771011532,0.018328734467931,TRUE,TRUE
18,16,"Most common adverse events (occurring in at least 10% of participants in either group)","Number of participants with treatment-emergent adverse events","SUBGROUP_AND_OVERALL","McKone 2021","2021",0,0,0,0,50,76,0,0,54,75,0,0,27.468667,0.747863,0.301264,1.856507,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","16::overall","CD010966_pub4_data","significance_only",TRUE,TRUE,FALSE,-0.207976073333071,-0.000957071316611077,-0.321521973251102,-0.0944301734150395,-0.0202428771011532,0.018328734467931,TRUE,TRUE
18,16,"Most common adverse events (occurring in at least 10% of participants in either group)","Number of participants with treatment-emergent adverse events","SUBGROUP_AND_OVERALL","Munck 2020","2020 Jun 13 [epub ahead of print]",0,0,0,0,64,83,0,0,68,85,0,0,22.719599,0.842105,0.319255,2.221238,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","16::overall","CD010966_pub4_data","significance_only",TRUE,TRUE,FALSE,-0.207976073333071,-0.000957071316611077,-0.321521973251102,-0.0944301734150395,-0.0202428771011532,0.018328734467931,TRUE,TRUE
18,16,"Most common adverse events (occurring in at least 10% of participants in either group)","Number of participants with treatment-emergent adverse events","SUBGROUP_AND_OVERALL","NCT02508207","2015",0,0,0,0,24,27,0,0,2,7,0,0,0.521338,20,1.384108,288.99487,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","16::overall","CD010966_pub4_data","significance_only",TRUE,TRUE,FALSE,-0.207976073333071,-0.000957071316611077,-0.321521973251102,-0.0944301734150395,-0.0202428771011532,0.018328734467931,TRUE,TRUE
18,16,"Most common adverse events (occurring in at least 10% of participants in either group)","Number of participants with treatment-emergent adverse events","SUBGROUP_AND_OVERALL","NCT02730208","2018",0,0,0,0,20,20,0,0,21,21,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","16::overall","CD010966_pub4_data","significance_only",TRUE,TRUE,FALSE,-0.207976073333071,-0.000957071316611077,-0.321521973251102,-0.0944301734150395,-0.0202428771011532,0.018328734467931,TRUE,TRUE
18,16,"Most common adverse events (occurring in at least 10% of participants in either group)","Number of participants with treatment-emergent adverse events","SUBGROUP_AND_OVERALL","Schwarz 2021","2018",0,0,0,0,37,50,0,0,39,47,0,0,15.441293,0.583826,0.159161,2.141562,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","16::overall","CD010966_pub4_data","significance_only",TRUE,TRUE,FALSE,-0.207976073333071,-0.000957071316611077,-0.321521973251102,-0.0944301734150395,-0.0202428771011532,0.018328734467931,TRUE,TRUE
18,16,"Most common adverse events (occurring in at least 10% of participants in either group)","Number of participants with treatment-emergent adverse events","SUBGROUP_AND_OVERALL","Taylor-Cousar 2017","2017",0,0,0,0,227,251,0,0,243,258,0,0,33.849103,0.583848,0.242044,1.408329,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","16::overall","CD010966_pub4_data","significance_only",TRUE,TRUE,FALSE,-0.207976073333071,-0.000957071316611077,-0.321521973251102,-0.0944301734150395,-0.0202428771011532,0.018328734467931,TRUE,TRUE
18,16,"Most common adverse events (occurring in at least 10% of participants in either group)","Number of participants with serious adverse events","SUBGROUP_AND_OVERALL","McKone 2021","2021",0,0,0,0,4,76,0,0,7,75,0,0,8.869389,0.539683,0.101369,2.87323,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","16::overall","CD010966_pub4_data","significance_only",TRUE,TRUE,FALSE,-0.207976073333071,-0.000957071316611077,-0.321521973251102,-0.0944301734150395,-0.0202428771011532,0.018328734467931,TRUE,TRUE
18,16,"Most common adverse events (occurring in at least 10% of participants in either group)","Number of participants with serious adverse events","SUBGROUP_AND_OVERALL","Munck 2020","2020 Jun 13 [epub ahead of print]",0,0,0,0,11,83,0,0,14,85,0,0,15.943782,0.774802,0.251869,2.383448,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","16::overall","CD010966_pub4_data","significance_only",TRUE,TRUE,FALSE,-0.207976073333071,-0.000957071316611077,-0.321521973251102,-0.0944301734150395,-0.0202428771011532,0.018328734467931,TRUE,TRUE
18,16,"Most common adverse events (occurring in at least 10% of participants in either group)","Number of participants with serious adverse events","SUBGROUP_AND_OVERALL","NCT02508207","2015",0,0,0,0,0,27,0,0,0,7,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","16::overall","CD010966_pub4_data","significance_only",TRUE,TRUE,FALSE,-0.207976073333071,-0.000957071316611077,-0.321521973251102,-0.0944301734150395,-0.0202428771011532,0.018328734467931,TRUE,TRUE
18,16,"Most common adverse events (occurring in at least 10% of participants in either group)","Number of participants with serious adverse events","SUBGROUP_AND_OVERALL","NCT02730208","2018",0,0,0,0,8,20,0,0,13,21,0,0,10.110691,0.410256,0.078801,2.135879,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","16::overall","CD010966_pub4_data","significance_only",TRUE,TRUE,FALSE,-0.207976073333071,-0.000957071316611077,-0.321521973251102,-0.0944301734150395,-0.0202428771011532,0.018328734467931,TRUE,TRUE
18,16,"Most common adverse events (occurring in at least 10% of participants in either group)","Number of participants with serious adverse events","SUBGROUP_AND_OVERALL","Schwarz 2021","2018",0,0,0,0,5,50,0,0,9,47,0,0,11.0949,0.469136,0.100098,2.198733,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","16::overall","CD010966_pub4_data","significance_only",TRUE,TRUE,FALSE,-0.207976073333071,-0.000957071316611077,-0.321521973251102,-0.0944301734150395,-0.0202428771011532,0.018328734467931,TRUE,TRUE
18,16,"Most common adverse events (occurring in at least 10% of participants in either group)","Number of participants with serious adverse events","SUBGROUP_AND_OVERALL","Taylor-Cousar 2017","2017",0,0,0,0,31,251,0,0,47,258,0,0,53.981239,0.632592,0.331698,1.206437,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","16::overall","CD010966_pub4_data","significance_only",TRUE,TRUE,FALSE,-0.207976073333071,-0.000957071316611077,-0.321521973251102,-0.0944301734150395,-0.0202428771011532,0.018328734467931,TRUE,TRUE
19,1,"Quality of life: change in CFQ-R respiratory domain","At 1 month","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,23.1,11.2765,0,11,13.1,11.3842,0,10,0,0,100,10,0.294724,19.705276,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","1::overall","CD010966_pub4_data","significance_only",TRUE,FALSE,TRUE,-0.207750252671045,-0.0819815913269149,-0.673556970156986,0.258056464814896,-0.1207064162904,-0.0432567663634297,TRUE,TRUE
19,2,"FEV1 % predicted (relative change from baseline)","At 1 month","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,19.56,22.49,0,11,1.2,10.24,0,10,0,0,100,18.36,3.631867,33.088133,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
19,3,"FEV1 L (absolute change from baseline)","At 1 month","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0.37,0.34,0,11,0,0.15,0,10,0,0,100,0.37,0.14861,0.59139,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
19,4,"Adverse events (at 1 month)","Number experiencing moderate adverse events","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,0,11,0,0,0,10,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
19,4,"Adverse events (at 1 month)","Number experiencing severe adverse events","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,1,11,0,0,3,10,0,0,100,0.233333,0.009195,5.921409,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
19,4,"Adverse events (at 1 month)","URTI","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,0,11,0,0,1,10,0,0,100,0.275362,0.003535,21.447474,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
19,4,"Adverse events (at 1 month)","Number of participants experiencing at least one adverse event","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,10,11,0,0,9,10,0,0,100,1.111111,0.024117,51.191247,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
19,4,"Adverse events (at 1 month)","Infective pulmonary exacerbations","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,3,11,0,0,2,10,0,0,100,1.5,0.102741,21.899707,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
19,4,"Adverse events (at 1 month)","Headache","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,1,11,0,0,0,10,0,0,100,3,0.038568,233.354435,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
19,4,"Adverse events (at 1 month)","Increased sputum","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,2,11,0,0,0,10,0,0,100,5.526316,0.086789,351.891071,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
19,4,"Adverse events (at 1 month)","Nasal congestion","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,0,11,0,0,0,10,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
19,4,"Adverse events (at 1 month)","Pyrexia","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,1,11,0,0,1,10,0,0,100,0.9,0.019535,41.46491,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
19,4,"Adverse events (at 1 month)","Abnormal respiration","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,1,11,0,0,0,10,0,0,100,3,0.038568,233.354435,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
19,4,"Adverse events (at 1 month)","Raised blood creatine phosphokinase","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,1,11,0,0,0,10,0,0,100,3,0.038568,233.354435,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
19,4,"Adverse events (at 1 month)","Nausea","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,0,11,0,0,0,10,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
19,4,"Adverse events (at 1 month)","Constipation","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,0,11,0,0,0,10,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
19,4,"Adverse events (at 1 month)","Diarrhoea","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,1,11,0,0,0,10,0,0,100,3,0.038568,233.354435,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
19,4,"Adverse events (at 1 month)","Productive cough","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,2,11,0,0,0,10,0,0,100,5.526316,0.086789,351.891071,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
19,4,"Adverse events (at 1 month)","Cough","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,3,11,0,0,1,10,0,0,100,3.375,0.133917,85.057636,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
19,4,"Adverse events (at 1 month)","Oropharyngeal pain","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,0,11,0,0,0,10,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
19,4,"Adverse events (at 1 month)","Nasopharyngitis","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,2,11,0,0,1,10,0,0,100,2,0.068071,58.762108,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
19,4,"Adverse events (at 1 month)","Haemoptysis","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,2,11,0,0,0,10,0,0,100,5.526316,0.086789,351.891071,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
19,4,"Adverse events (at 1 month)","Rash","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,0,11,0,0,0,10,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
19,4,"Adverse events (at 1 month)","Fatigue","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,2,11,0,0,0,10,0,0,100,5.526316,0.086789,351.891071,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
19,4,"Adverse events (at 1 month)","Sinus congestion","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,0,11,0,0,0,10,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
19,4,"Adverse events (at 1 month)","Influenza","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,0,11,0,0,0,10,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
19,4,"Adverse events (at 1 month)","Pain","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,0,11,0,0,0,10,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
19,4,"Adverse events (at 1 month)","Rales","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,0,11,0,0,0,10,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
19,5,"Sweat chloride (change from baseline) (mmol/L)","At 1 month","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,-45.7,14.2615,0,11,2.9,14.5465,0,10,0,0,100,-48.6,-60.941565,-36.258435,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
20,1,"FEV1 % predicted (absolute change from baseline)","At up to 1 month","SUBGROUP_AND_OVERALL","Davies 2018a","2017",0,0,9.6,10.5,0,9,-0.4,1.0392,0,3,0,0,100,10,3.040064,16.959936,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","1::overall","CD010966_pub4_data","significance_only",TRUE,FALSE,TRUE,-0.207750252671045,-0.0819815913269149,-0.673556970156986,0.258056464814896,-0.1207064162904,-0.0432567663634297,TRUE,TRUE
20,2,"Adverse events (at up to 1 month)","Number experiencing severe adverse events","SUBGROUP_AND_OVERALL","Davies 2018a","2017",0,0,0,0,2,9,0,0,0,3,0,0,100,2.333333,0.030884,176.288232,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
20,2,"Adverse events (at up to 1 month)","Number experiencing moderate adverse events","SUBGROUP_AND_OVERALL","Davies 2018a","2017",0,0,0,0,0,9,0,0,0,3,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
20,2,"Adverse events (at up to 1 month)","Number of participants experiencing at least one adverse event","SUBGROUP_AND_OVERALL","Davies 2018a","2017",0,0,0,0,9,9,0,0,1,3,0,0,100,31.666667,0.322302,3111.294163,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
20,2,"Adverse events (at up to 1 month)","Infective respiratory exacerbations","SUBGROUP_AND_OVERALL","Davies 2018a","2017",0,0,0,0,2,9,0,0,0,3,0,0,100,2.333333,0.030884,176.288232,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
20,2,"Adverse events (at up to 1 month)","Insomnia","SUBGROUP_AND_OVERALL","Davies 2018a","2017",0,0,0,0,1,9,0,0,0,3,0,0,100,1.235294,0.013542,112.679468,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
20,2,"Adverse events (at up to 1 month)","Nausea","SUBGROUP_AND_OVERALL","Davies 2018a","2017",0,0,0,0,1,9,0,0,0,3,0,0,100,1.235294,0.013542,112.679468,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
20,2,"Adverse events (at up to 1 month)","Ear pain","SUBGROUP_AND_OVERALL","Davies 2018a","2017",0,0,0,0,1,9,0,0,0,3,0,0,100,1.235294,0.013542,112.679468,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
20,2,"Adverse events (at up to 1 month)","Increased sputum","SUBGROUP_AND_OVERALL","Davies 2018a","2017",0,0,0,0,1,9,0,0,0,3,0,0,100,1.235294,0.013542,112.679468,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
20,2,"Adverse events (at up to 1 month)","Tinnitus","SUBGROUP_AND_OVERALL","Davies 2018a","2017",0,0,0,0,1,9,0,0,0,3,0,0,100,1.235294,0.013542,112.679468,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
20,2,"Adverse events (at up to 1 month)","Viral URTI","SUBGROUP_AND_OVERALL","Davies 2018a","2017",0,0,0,0,1,9,0,0,0,3,0,0,100,1.235294,0.013542,112.679468,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
20,2,"Adverse events (at up to 1 month)","Abdominal discomfort","SUBGROUP_AND_OVERALL","Davies 2018a","2017",0,0,0,0,1,9,0,0,0,3,0,0,100,1.235294,0.013542,112.679468,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
20,2,"Adverse events (at up to 1 month)","Productive cough","SUBGROUP_AND_OVERALL","Davies 2018a","2017",0,0,0,0,2,9,0,0,0,3,0,0,100,2.333333,0.030884,176.288232,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
20,2,"Adverse events (at up to 1 month)","Oral candidiasis","SUBGROUP_AND_OVERALL","Davies 2018a","2017",0,0,0,0,1,9,0,0,1,3,0,0,100,0.25,0.00385,16.232673,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
20,2,"Adverse events (at up to 1 month)","Raised blood creatine phosphokinase","SUBGROUP_AND_OVERALL","Davies 2018a","2017",0,0,0,0,1,9,0,0,0,3,0,0,100,1.235294,0.013542,112.679468,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
20,2,"Adverse events (at up to 1 month)","Diarrhoea","SUBGROUP_AND_OVERALL","Davies 2018a","2017",0,0,0,0,1,9,0,0,0,3,0,0,100,1.235294,0.013542,112.679468,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
20,2,"Adverse events (at up to 1 month)","Fatigue","SUBGROUP_AND_OVERALL","Davies 2018a","2017",0,0,0,0,1,9,0,0,0,3,0,0,100,1.235294,0.013542,112.679468,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
20,2,"Adverse events (at up to 1 month)","Flatulence","SUBGROUP_AND_OVERALL","Davies 2018a","2017",0,0,0,0,1,9,0,0,0,3,0,0,100,1.235294,0.013542,112.679468,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
20,2,"Adverse events (at up to 1 month)","Cough","SUBGROUP_AND_OVERALL","Davies 2018a","2017",0,0,0,0,2,9,0,0,0,3,0,0,100,2.333333,0.030884,176.288232,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
20,2,"Adverse events (at up to 1 month)","Hypertension","SUBGROUP_AND_OVERALL","Davies 2018a","2017",0,0,0,0,1,9,0,0,0,3,0,0,100,1.235294,0.013542,112.679468,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
20,2,"Adverse events (at up to 1 month)","Photosensitivity reaction","SUBGROUP_AND_OVERALL","Davies 2018a","2017",0,0,0,0,1,9,0,0,0,3,0,0,100,1.235294,0.013542,112.679468,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
20,2,"Adverse events (at up to 1 month)","Decreased pulmonary function tests","SUBGROUP_AND_OVERALL","Davies 2018a","2017",0,0,0,0,1,9,0,0,0,3,0,0,100,1.235294,0.013542,112.679468,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
20,3,"Sweat chloride (absolute change from baseline)","At up to 1 month","SUBGROUP_AND_OVERALL","Davies 2018a","2017",0,0,-41.6,10.8,0,9,-11,12.4708,0,3,0,0,100,-30.6,-46.37744,-14.82256,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
21,1,"Quality of life: change in CFQ-R respiratory domain","At 1 month","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,17.1,11.6276,0,20,13.1,11.3842,0,10,0,0,12.743332,4,-4.703665,12.703665,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","1::overall","CD010966_pub4_data","significance_only",TRUE,FALSE,TRUE,-0.207750252671045,-0.0819815913269149,-0.673556970156986,0.258056464814896,-0.1207064162904,-0.0432567663634297,TRUE,TRUE
21,1,"Quality of life: change in CFQ-R respiratory domain","At 1 month","SUBGROUP_AND_OVERALL","NCT03447249","2018",0,0,18,16.627688,0,192,0.1,16.540859,0,190,0,0,87.256668,17.9,14.573831,21.226169,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","1::overall","CD010966_pub4_data","significance_only",TRUE,FALSE,TRUE,-0.207750252671045,-0.0819815913269149,-0.673556970156986,0.258056464814896,-0.1207064162904,-0.0432567663634297,TRUE,TRUE
21,1,"Quality of life: change in CFQ-R respiratory domain","At 6 months","SUBGROUP_AND_OVERALL","NCT03447249","2018",0,0,18.6,13.856406,0,192,-1.5,15.162454,0,190,0,0,100,20.1,17.186304,23.013696,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","1::overall","CD010966_pub4_data","significance_only",TRUE,FALSE,TRUE,-0.207750252671045,-0.0819815913269149,-0.673556970156986,0.258056464814896,-0.1207064162904,-0.0432567663634297,TRUE,TRUE
21,2,"FEV1 % predicted (relative change from baseline)","At 1 month","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,21.37,21.73,0,20,1.2,10.24,0,10,0,0,100,20.17,8.725521,31.614479,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
21,3,"FEV1 % predicted (absolute change from baseline)","At 1 month","SUBGROUP_AND_OVERALL","NCT03447249","2018",0,0,13,8.313844,0,192,-1,8.270429,0,190,0,0,100,14,12.336915,15.663085,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
21,3,"FEV1 % predicted (absolute change from baseline)","At 6 months","SUBGROUP_AND_OVERALL","NCT03447249","2018",0,0,13.4,8.313844,0,192,-0.8,8.270429,0,190,0,0,100,14.2,12.536915,15.863085,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
21,4,"FEV1 L (absolute change from baseline)","At 1 month","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0.42,0.45,0,20,0,0.15,0,10,0,0,100,0.42,0.201968,0.638032,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
21,5,"Adverse events (at 1 month)","Number of participants experiencing at least one adverse event","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,15,20,0,0,9,10,0,0,100,0.333333,0.016211,6.854221,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
21,5,"Adverse events (at 1 month)","Number experiencing moderate adverse events","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,1,20,0,0,0,10,0,0,100,1.615385,0.021477,121.497971,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
21,5,"Adverse events (at 1 month)","Number experiencing severe adverse events","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,4,20,0,0,3,10,0,0,100,0.583333,0.059217,5.746278,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
21,5,"Adverse events (at 1 month)","URTI","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,0,20,0,0,1,10,0,0,100,0.154472,0.002042,11.685542,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
21,5,"Adverse events (at 1 month)","Infective pulmonary exacerbation","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,3,20,0,0,2,10,0,0,100,0.705882,0.052542,9.483232,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
21,5,"Adverse events (at 1 month)","Productive cough","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,1,20,0,0,0,10,0,0,100,1.615385,0.021477,121.497971,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
21,5,"Adverse events (at 1 month)","Sinus congestion","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,0,20,0,0,0,10,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
21,5,"Adverse events (at 1 month)","Cough","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,6,20,0,0,1,10,0,0,100,3.857143,0.193585,76.852658,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
21,5,"Adverse events (at 1 month)","Increased sputum","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,1,20,0,0,0,10,0,0,100,1.615385,0.021477,121.497971,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
21,5,"Adverse events (at 1 month)","Nasopharyngitis","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,1,20,0,0,1,10,0,0,100,0.473684,0.010714,20.941743,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
21,5,"Adverse events (at 1 month)","Nausea","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,0,20,0,0,0,10,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
21,5,"Adverse events (at 1 month)","Abnormal respiration","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,1,20,0,0,0,10,0,0,100,1.615385,0.021477,121.497971,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
21,5,"Adverse events (at 1 month)","Diarrhoea","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,0,20,0,0,0,10,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
21,5,"Adverse events (at 1 month)","Haemoptysis","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,1,20,0,0,0,10,0,0,100,1.615385,0.021477,121.497971,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
21,5,"Adverse events (at 1 month)","Influenza","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,0,20,0,0,0,10,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
21,5,"Adverse events (at 1 month)","Constipation","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,1,20,0,0,0,10,0,0,100,1.615385,0.021477,121.497971,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
21,5,"Adverse events (at 1 month)","Fatigue","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,2,20,0,0,0,10,0,0,100,2.837838,0.046437,173.424274,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
21,5,"Adverse events (at 1 month)","Rash","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,0,20,0,0,0,10,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
21,5,"Adverse events (at 1 month)","Pain","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,0,20,0,0,0,10,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
21,5,"Adverse events (at 1 month)","Rales","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,0,20,0,0,0,10,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
21,5,"Adverse events (at 1 month)","Oropharyngeal pain","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,3,20,0,0,0,10,0,0,100,4.2,0.075252,234.413754,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
21,5,"Adverse events (at 1 month)","Raised blood creatine phosphokinase","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,1,20,0,0,0,10,0,0,100,1.615385,0.021477,121.497971,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
21,5,"Adverse events (at 1 month)","Nasal congestion","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,1,20,0,0,0,10,0,0,100,1.615385,0.021477,121.497971,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
21,5,"Adverse events (at 1 month)","Pyrexia","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,1,20,0,0,1,10,0,0,100,0.473684,0.010714,20.941743,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
21,5,"Adverse events (at 1 month)","Headache","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,4,20,0,0,0,10,0,0,100,5.727273,0.107858,304.119521,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
22,1,"Quality of life: absolute change in CFQ-R respiratory domain","At 1 month","SUBGROUP_AND_OVERALL","NCT03460990","2018",0,0,16.5,12.492398,0,54,3,12.834719,0,57,0,0,100,13.5,8.787927,18.212073,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","1::overall","CD010966_pub4_data","significance_only",TRUE,FALSE,TRUE,-0.207750252671045,-0.0819815913269149,-0.673556970156986,0.258056464814896,-0.1207064162904,-0.0432567663634297,TRUE,TRUE
22,2,"FEV1 % predicted (absolute change from baseline)","At 1 month","SUBGROUP_AND_OVERALL","NCT03460990","2018",0,0,10.2,6.613622,0,54,0.3,6.794851,0,57,0,0,100,9.9,7.405373,12.394627,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
22,3,"Most common adverse events (occurring in at least 10% of participants in either group)","Number of participants with treatment-emergent adverse events","SUBGROUP_AND_OVERALL","NCT03460990","2018",0,0,0,0,33,54,0,0,31,57,0,0,100,1.317972,0.488218,3.55794,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
22,3,"Most common adverse events (occurring in at least 10% of participants in either group)","Number of participants with serious adverse events","SUBGROUP_AND_OVERALL","NCT03460990","2018",0,0,0,0,2,54,0,0,0,57,0,0,100,5.47619,0.098251,305.224172,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
22,3,"Most common adverse events (occurring in at least 10% of participants in either group)","Infective pulmonary exacerbations","SUBGROUP_AND_OVERALL","NCT03460990","2018",0,0,0,0,2,54,0,0,9,57,0,0,100,0.205128,0.025663,1.639607,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
22,3,"Most common adverse events (occurring in at least 10% of participants in either group)","Sputum increased","SUBGROUP_AND_OVERALL","NCT03460990","2018",0,0,0,0,9,54,0,0,0,57,0,0,100,24.010989,0.552292,1043.881498,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
22,4,"Sweat chloride (absolute change from baseline)","At 1 month","SUBGROUP_AND_OVERALL","NCT03460990","2018",0,0,-47.2,13.962092,0,54,1.5,13.589702,0,57,0,0,100,-48.7,-53.829717,-43.570283,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
23,1,"Quality of life: change in CFQ-R respiratory domain","At 1 month","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,21,11.257,0,22,13.1,11.3842,0,10,0,0,100,7.9,-0.580101,16.380101,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","1::overall","CD010966_pub4_data","significance_only",TRUE,FALSE,TRUE,-0.207750252671045,-0.0819815913269149,-0.673556970156986,0.258056464814896,-0.1207064162904,-0.0432567663634297,TRUE,TRUE
23,2,"FEV1 % predicted (relative change from baseline)","At 1 month","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,25.05,16.38,0,22,1.2,10.24,0,10,0,0,100,23.85,14.51567,33.18433,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
23,3,"FEV1 L (absolute change from baseline)","At 1 month","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0.52,0.37,0,22,0,0.15,0,10,0,0,100,0.52,0.33959,0.70041,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
23,4,"Adverse events (at 1 month)","Number experiencing moderate adverse events","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,0,22,0,0,0,10,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
23,4,"Adverse events (at 1 month)","Number experiencing severe adverse events","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,1,22,0,0,3,10,0,0,100,0.111111,0.004622,2.670987,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
23,4,"Adverse events (at 1 month)","URTI","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,2,22,0,0,1,10,0,0,100,0.9,0.032543,24.890193,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
23,4,"Adverse events (at 1 month)","Number of participants experiencing at least one adverse event","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,17,22,0,0,9,10,0,0,100,0.377778,0.018531,7.701459,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
23,4,"Adverse events (at 1 month)","Infective pulmonary exacerbation","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,4,22,0,0,2,10,0,0,100,0.888889,0.074083,10.665334,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
23,4,"Adverse events (at 1 month)","Nasal congestion","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,0,22,0,0,0,10,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
23,4,"Adverse events (at 1 month)","Pyrexia","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,1,22,0,0,1,10,0,0,100,0.428571,0.009737,18.86427,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
23,4,"Adverse events (at 1 month)","Influenza","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,0,22,0,0,0,10,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
23,4,"Adverse events (at 1 month)","Pain","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,0,22,0,0,0,10,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
23,4,"Adverse events (at 1 month)","Productive cough","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,0,22,0,0,0,10,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
23,4,"Adverse events (at 1 month)","Sinus congestion","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,0,22,0,0,0,10,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
23,4,"Adverse events (at 1 month)","Nausea","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,3,22,0,0,0,10,0,0,100,3.769231,0.067861,209.356199,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
23,4,"Adverse events (at 1 month)","Abnormal respiration","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,3,22,0,0,0,10,0,0,100,3.769231,0.067861,209.356199,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
23,4,"Adverse events (at 1 month)","Constipation","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,3,22,0,0,0,10,0,0,100,3.769231,0.067861,209.356199,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
23,4,"Adverse events (at 1 month)","Haemoptysis","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,0,22,0,0,0,10,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
23,4,"Adverse events (at 1 month)","Rales","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,0,22,0,0,0,10,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
23,4,"Adverse events (at 1 month)","Cough","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,4,22,0,0,1,10,0,0,100,2,0.093228,42.905382,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
23,4,"Adverse events (at 1 month)","Headache","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,4,22,0,0,0,10,0,0,100,5.108108,0.096726,269.760524,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
23,4,"Adverse events (at 1 month)","Increased sputum","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,3,22,0,0,0,10,0,0,100,3.769231,0.067861,209.356199,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
23,4,"Adverse events (at 1 month)","Nasopharyngitis","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,3,22,0,0,1,10,0,0,100,1.421053,0.060794,33.216785,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
23,4,"Adverse events (at 1 month)","Oropharyngeal pain","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,4,22,0,0,0,10,0,0,100,5.108108,0.096726,269.760524,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
23,4,"Adverse events (at 1 month)","Raised blood creatine phosphokinase","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,3,22,0,0,0,10,0,0,100,3.769231,0.067861,209.356199,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
23,4,"Adverse events (at 1 month)","Fatigue","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,0,22,0,0,0,10,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
23,4,"Adverse events (at 1 month)","Diarrhoea","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,1,22,0,0,0,10,0,0,100,1.465116,0.019551,109.792747,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
23,4,"Adverse events (at 1 month)","Rash","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,0,22,0,0,0,10,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
23,5,"Sweat chloride (absolute change from baseline)","At 1 month","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,-51.4,15.0093,0,22,2.9,14.5465,0,10,0,0,100,-54.3,-65.2828,-43.3172,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
24,1,"Quality of life: change in CFQ-R respiratory domain","At 1 month","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,20.1,9.7581,0,18,2,9.6182,0,11,0,0,100,18.1,10.845483,25.354517,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","1::overall","CD010966_pub4_data","significance_only",TRUE,FALSE,TRUE,-0.207750252671045,-0.0819815913269149,-0.673556970156986,0.258056464814896,-0.1207064162904,-0.0432567663634297,TRUE,TRUE
24,2,"FEV1 % predicted (relative change from baseline)","At 1 month","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,17.59,14.82,0,18,1.6,4.65,0,11,0,0,100,15.99,8.612751,23.367249,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
24,3,"FEV1 L (absolute change from baseline)","At 1 month","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0.38,0.33,0,18,0.03,0.1,0,11,0,0,100,0.35,0.186498,0.513502,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
24,4,"Adverse events (at 1 month)","Number experiencing moderate adverse events","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,0,18,0,0,0,11,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
24,4,"Adverse events (at 1 month)","Number experiencing severe adverse events","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,1,18,0,0,2,11,0,0,100,0.264706,0.009488,7.385392,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
24,4,"Adverse events (at 1 month)","URTI","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,2,18,0,0,0,11,0,0,100,3.484848,0.057104,212.667052,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
24,4,"Adverse events (at 1 month)","Number of participants experiencing at least one adverse event","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,15,18,0,0,9,11,0,0,100,1.111111,0.083347,14.812338,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
24,4,"Adverse events (at 1 month)","Infective pulmonary exacerbation","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,5,18,0,0,3,11,0,0,100,1.025641,0.11266,9.337295,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
24,4,"Adverse events (at 1 month)","Cough","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,4,18,0,0,2,11,0,0,100,1.285714,0.106873,15.467541,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
24,4,"Adverse events (at 1 month)","Oropharyngeal pain","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,2,18,0,0,0,11,0,0,100,3.484848,0.057104,212.667052,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
24,4,"Adverse events (at 1 month)","Raised blood creatine phosphokinase","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,1,18,0,0,2,11,0,0,100,0.264706,0.009488,7.385392,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
24,4,"Adverse events (at 1 month)","Nausea","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,2,18,0,0,2,11,0,0,100,0.5625,0.034533,9.162487,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
24,4,"Adverse events (at 1 month)","Abnormal respiration","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,0,18,0,0,0,11,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
24,4,"Adverse events (at 1 month)","Fatigue","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,0,18,0,0,1,11,0,0,100,0.189189,0.00251,14.259805,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
24,4,"Adverse events (at 1 month)","Productive cough","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,1,18,0,0,0,11,0,0,100,1.971429,0.02626,148.001689,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
24,4,"Adverse events (at 1 month)","Headache","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,3,18,0,0,0,11,0,0,100,5.193548,0.093123,289.649366,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
24,4,"Adverse events (at 1 month)","Increased sputum","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,3,18,0,0,1,11,0,0,100,2,0.0853,46.893586,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
24,4,"Adverse events (at 1 month)","Nasal congestion","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,4,18,0,0,0,11,0,0,100,7.137931,0.134415,379.050461,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
24,4,"Adverse events (at 1 month)","Pyrexia","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,2,18,0,0,1,11,0,0,100,1.25,0.045136,34.617715,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
24,4,"Adverse events (at 1 month)","Sinus congestion","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,0,18,0,0,0,11,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
24,4,"Adverse events (at 1 month)","Rash","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,0,18,0,0,0,11,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
24,4,"Adverse events (at 1 month)","Pain","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,0,18,0,0,0,11,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
24,4,"Adverse events (at 1 month)","Rales","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,0,18,0,0,0,11,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
24,4,"Adverse events (at 1 month)","Constipation","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,0,18,0,0,0,11,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
24,4,"Adverse events (at 1 month)","Diarrhoea","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,2,18,0,0,0,11,0,0,100,3.484848,0.057104,212.667052,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
24,4,"Adverse events (at 1 month)","Haemoptysis","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,1,18,0,0,0,11,0,0,100,1.971429,0.02626,148.001689,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
24,4,"Adverse events (at 1 month)","Influenza","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,0,18,0,0,0,11,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
24,4,"Adverse events (at 1 month)","Nasopharyngitis","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,0,18,0,0,0,11,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
24,5,"Sweat chloride (change from baseline) (mmol/L)","At 1 month","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,-42.2,9.3338,0,18,3,9.2865,0,11,0,0,100,-45.2,-52.179208,-38.220792,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
25,1,"Quality of life: change in CFQ-R respiratory domain","At 1 month","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,15.1,14.3844,0,19,-5.2,14.452,0,6,0,0,100,20.3,7.050281,33.549719,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","1::overall","CD010966_pub4_data","significance_only",TRUE,FALSE,TRUE,-0.207750252671045,-0.0819815913269149,-0.673556970156986,0.258056464814896,-0.1207064162904,-0.0432567663634297,TRUE,TRUE
25,2,"FEV1 % predicted (relative change from baseline)","At 1 month","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,21.85,16.68,0,19,-11.2,10.06,0,6,0,0,100,33.05,22.047887,44.052113,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
25,3,"FEV1 L (absolute change from baseline)","At 1 month","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0.46,0.38,0,19,-0.22,0.2,0,6,0,0,100,0.68,0.445896,0.914104,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
25,4,"Adverse events (at 1 month)","Number experiencing moderate adverse events","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,2,19,0,0,0,6,0,0,100,1.857143,0.028923,119.248216,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
25,4,"Adverse events (at 1 month)","URTI","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,0,19,0,0,0,6,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
25,4,"Adverse events (at 1 month)","Number experiencing severe adverse events","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,2,19,0,0,3,6,0,0,100,0.117647,0.006795,2.036891,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
25,4,"Adverse events (at 1 month)","Number of participants experiencing at least one adverse event","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,18,19,0,0,6,6,0,0,100,0.948718,0.012036,74.780589,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
25,4,"Adverse events (at 1 month)","Headache","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,0,19,0,0,0,6,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
25,4,"Adverse events (at 1 month)","Increased sputum","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,0,19,0,0,0,6,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
25,4,"Adverse events (at 1 month)","Oropharyngeal pain","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,2,19,0,0,0,6,0,0,100,1.857143,0.028923,119.248216,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
25,4,"Adverse events (at 1 month)","Raised blood creatine phosphokinase","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,0,19,0,0,0,6,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
25,4,"Adverse events (at 1 month)","Influenza","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,2,19,0,0,0,6,0,0,100,1.857143,0.028923,119.248216,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
25,4,"Adverse events (at 1 month)","Infective respiratory exacerbation","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,2,19,0,0,3,6,0,0,100,0.117647,0.006795,2.036891,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
25,4,"Adverse events (at 1 month)","Cough","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,4,19,0,0,2,6,0,0,100,0.533333,0.037294,7.627014,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
25,4,"Adverse events (at 1 month)","Sinus congestion","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,2,19,0,0,0,6,0,0,100,1.857143,0.028923,119.248216,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
25,4,"Adverse events (at 1 month)","Pain","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,2,19,0,0,0,6,0,0,100,1.857143,0.028923,119.248216,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
25,4,"Adverse events (at 1 month)","Nasal congestion","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,0,19,0,0,0,6,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
25,4,"Adverse events (at 1 month)","Nasopharyngitis","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,0,19,0,0,0,6,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
25,4,"Adverse events (at 1 month)","Nausea","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,2,19,0,0,0,6,0,0,100,1.857143,0.028923,119.248216,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
25,4,"Adverse events (at 1 month)","Abnormal respiration","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,0,19,0,0,0,6,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
25,4,"Adverse events (at 1 month)","Pyrexia","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,3,19,0,0,0,6,0,0,100,2.757576,0.046957,161.940875,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
25,4,"Adverse events (at 1 month)","Fatigue","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,0,19,0,0,0,6,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
25,4,"Adverse events (at 1 month)","Constipation","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,0,19,0,0,0,6,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
25,4,"Adverse events (at 1 month)","Diarrhoea","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,0,19,0,0,0,6,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
25,4,"Adverse events (at 1 month)","Haemoptysis","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,0,19,0,0,0,6,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
25,4,"Adverse events (at 1 month)","Productive cough","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,0,19,0,0,0,6,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
25,4,"Adverse events (at 1 month)","Rash","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,2,19,0,0,0,6,0,0,100,1.857143,0.028923,119.248216,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
25,4,"Adverse events (at 1 month)","Rales","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,0,0,0,19,0,0,2,6,0,0,100,0.046154,0.000684,3.114056,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
25,5,"Sweat chloride (change from baseline) (mmol/L)","At 1 month","SUBGROUP_AND_OVERALL","Davies 2018b","2017",0,0,-38.1,13.0767,0,19,-1.3,12.9823,0,6,0,0,100,-36.8,-48.73649,-24.86351,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
26,1,"Quality of life: change in CFQ-R respiratory domain","At 1 month","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,20.3,15.1789,0,10,3.1,15.242,0,12,0,0,100,17.2,4.437672,29.962328,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","1::overall","CD010966_pub4_data","significance_only",TRUE,FALSE,TRUE,-0.207750252671045,-0.0819815913269149,-0.673556970156986,0.258056464814896,-0.1207064162904,-0.0432567663634297,TRUE,TRUE
26,2,"FEV1 % predicted (relative change from baseline)","At 1 month","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,19.3,13.2816,0,10,0.3,15.242,0,12,0,0,100,19,7.078009,30.921991,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
26,3,"FEV1 L (absolute change from baseline)","At 1 month","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0.42,0.37,0,10,-0.04,0.25,0,12,0,0,100,0.46,0.190561,0.729439,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
26,4,"Adverse events (at 1 month)","Infective pulmonary exacerbation","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,3,10,0,0,4,12,0,0,100,0.857143,0.07961,9.228616,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
26,4,"Adverse events (at 1 month)","Number experiencing moderate adverse events","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,0,10,0,0,0,12,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
26,4,"Adverse events (at 1 month)","Number experiencing severe adverse events","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,1,10,0,0,2,12,0,0,100,0.555556,0.019116,16.1455,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
26,4,"Adverse events (at 1 month)","Number of participants experiencing at least one adverse event","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,10,10,0,0,12,12,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
26,4,"Adverse events (at 1 month)","Fatigue","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,1,10,0,0,4,12,0,0,100,0.222222,0.009617,5.134678,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
26,4,"Adverse events (at 1 month)","Nausea","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,2,10,0,0,2,12,0,0,100,1.25,0.072239,21.629631,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
26,4,"Adverse events (at 1 month)","Diarrhoea","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,1,10,0,0,1,12,0,0,100,1.222222,0.026738,55.868278,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
26,4,"Adverse events (at 1 month)","Abnormal respiration","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,0,10,0,0,0,12,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
26,4,"Adverse events (at 1 month)","Oropharyngeal pain","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,2,10,0,0,2,12,0,0,100,1.25,0.072239,21.629631,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
26,4,"Adverse events (at 1 month)","Nasal congestion","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,2,10,0,0,2,12,0,0,100,1.25,0.072239,21.629631,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
26,4,"Adverse events (at 1 month)","Cough","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,4,10,0,0,1,12,0,0,100,7.333333,0.310286,173.316666,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
26,4,"Adverse events (at 1 month)","Increased sputum","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,3,10,0,0,3,12,0,0,100,1.285714,0.108589,15.223123,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
26,4,"Adverse events (at 1 month)","Haemoptysis","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,0,10,0,0,2,12,0,0,100,0.2,0.003166,12.633451,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
26,4,"Adverse events (at 1 month)","Increased blood creatine phosphokinase","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,0,10,0,0,0,12,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
26,4,"Adverse events (at 1 month)","Elevated AST","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,0,10,0,0,0,12,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
26,4,"Adverse events (at 1 month)","Pyrexia","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,0,10,0,0,1,12,0,0,100,0.365079,0.004723,28.218874,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
26,4,"Adverse events (at 1 month)","Headache","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,2,10,0,0,1,12,0,0,100,2.75,0.09418,80.298393,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
26,4,"Adverse events (at 1 month)","Nasopharyngitis","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,1,10,0,0,0,12,0,0,100,3.947368,0.050949,305.827583,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
26,4,"Adverse events (at 1 month)","Rhinorrhoea","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,0,10,0,0,0,12,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
26,5,"Sweat chloride (change from baseline) (mmol/L)","At 1 month","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,-38.2,13.2816,0,10,-2.2,13.51,0,12,0,0,100,-36,-47.233535,-24.766465,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
27,1,"Quality of life: change in CFQ-R respiratory sub-domain","At 1 month","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,17.6,15.4784,0,22,3.1,15.242,0,12,0,0,100,14.5,3.720212,25.279788,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","1::overall","CD010966_pub4_data","significance_only",TRUE,FALSE,TRUE,-0.207750252671045,-0.0819815913269149,-0.673556970156986,0.258056464814896,-0.1207064162904,-0.0432567663634297,TRUE,TRUE
27,2,"FEV1 % predicted (relative change from baseline)","At 1 month","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,13.8,13.1332,0,22,0.3,15.242,0,12,0,0,100,13.5,3.278093,23.721907,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
27,3,"FEV1 L (absolute change from baseline)","At 1 month","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0.34,0.25,0,22,-0.04,0.25,0,12,0,0,100,0.38,0.204157,0.555843,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
27,4,"Adverse events at (1 month)","Number of participants experiencing at least one adverse event","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,21,22,0,0,12,12,0,0,100,0.573333,0.007741,42.46351,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
27,4,"Adverse events at (1 month)","Number experiencing moderate adverse events","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,0,22,0,0,0,12,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
27,4,"Adverse events at (1 month)","Number experiencing severe adverse events","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,2,22,0,0,2,12,0,0,100,0.5,0.031574,7.917868,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
27,4,"Adverse events at (1 month)","Infective pulmonary exacerbation","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,5,22,0,0,4,12,0,0,100,0.588235,0.075674,4.572534,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
27,4,"Adverse events at (1 month)","Haemoptysis","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,5,22,0,0,2,12,0,0,100,1.470588,0.135142,16.002643,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
27,4,"Adverse events at (1 month)","Nausea","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,3,22,0,0,2,12,0,0,100,0.789474,0.061171,10.188918,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
27,4,"Adverse events at (1 month)","Headache","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,2,22,0,0,2,12,0,0,100,0.5,0.031574,7.917868,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
27,4,"Adverse events at (1 month)","Nasopharyngitis","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,0,22,0,0,0,12,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
27,4,"Adverse events at (1 month)","Cough","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,5,22,0,0,1,12,0,0,100,3.235294,0.162281,64.500092,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
27,4,"Adverse events at (1 month)","Oropharyngeal pain","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,2,22,0,0,2,12,0,0,100,0.5,0.031574,7.917868,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
27,4,"Adverse events at (1 month)","Nasal congestion","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,2,22,0,0,2,12,0,0,100,0.5,0.031574,7.917868,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
27,4,"Adverse events at (1 month)","Fatigue","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,0,22,0,0,4,12,0,0,100,0.041975,0.000786,2.240551,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
27,4,"Adverse events at (1 month)","Increased blood creatine phosphokinase","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,0,22,0,0,0,12,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
27,4,"Adverse events at (1 month)","Rhinorrhoea","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,3,22,0,0,0,12,0,0,100,4.487179,0.081811,246.112026,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
27,4,"Adverse events at (1 month)","Increased sputum","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,4,22,0,0,3,12,0,0,100,0.666667,0.071633,6.204461,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
27,4,"Adverse events at (1 month)","Pyrexia","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,5,22,0,0,1,12,0,0,100,3.235294,0.162281,64.500092,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
27,4,"Adverse events at (1 month)","Diarrhoea","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,3,22,0,0,1,12,0,0,100,1.736842,0.075907,39.741225,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
27,4,"Adverse events at (1 month)","Elevated AST","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,0,22,0,0,0,12,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
27,4,"Adverse events at (1 month)","Abnormal respiration","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,1,22,0,0,0,12,0,0,100,1.744186,0.02355,129.181852,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
27,5,"Sweat chloride (change from baseline) (mmol/L)","At 1 month","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,-33.2,13.1332,0,22,-2.2,13.51,0,12,0,0,100,-31,-40.409879,-21.590121,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
28,1,"Quality of life: CFQ-R respiratory domain (change from baseline)","At up to 1 month","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,24.4,15.1,0,21,15.1,15.242,0,12,0,0,7.937357,9.3,-1.474009,20.074009,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","1::overall","CD010966_pub4_data","significance_only",TRUE,FALSE,TRUE,-0.207750252671045,-0.0819815913269149,-0.673556970156986,0.258056464814896,-0.1207064162904,-0.0432567663634297,TRUE,TRUE
28,1,"Quality of life: CFQ-R respiratory domain (change from baseline)","At up to 1 month","SUBGROUP_AND_OVERALL","Middleton 2019","2019",0,0,18.1,16.4947,0,200,-1.9,15.8969,0,203,0,0,92.062643,20,16.836458,23.163542,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","1::overall","CD010966_pub4_data","significance_only",TRUE,FALSE,TRUE,-0.207750252671045,-0.0819815913269149,-0.673556970156986,0.258056464814896,-0.1207064162904,-0.0432567663634297,TRUE,TRUE
28,1,"Quality of life: CFQ-R respiratory domain (change from baseline)","At up to 6 months","SUBGROUP_AND_OVERALL","Middleton 2019","2019",0,0,17.5,14.3433,0,200,-2.7,25.2905,0,203,0,0,100,20.2,16.193114,24.206886,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","1::overall","CD010966_pub4_data","significance_only",TRUE,FALSE,TRUE,-0.207750252671045,-0.0819815913269149,-0.673556970156986,0.258056464814896,-0.1207064162904,-0.0432567663634297,TRUE,TRUE
28,2,"FEV1 % predicted (relative change from baseline)","At up to 1 month","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,26.2,13.2895,0,21,0.3,15.242,0,12,0,0,100,25.9,15.571544,36.228456,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
28,3,"FEV1 % predicted (absolute change from baseline)","At up to 1 month","SUBGROUP_AND_OVERALL","Middleton 2019","2019",0,0,13.6,8.606,0,200,-0.2,7.9485,0,203,0,0,100,13.8,12.181942,15.418058,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
28,3,"FEV1 % predicted (absolute change from baseline)","At up to 6 months","SUBGROUP_AND_OVERALL","Middleton 2019","2019",0,0,13.9,7.8888,0,200,-0.4,7.9087,0,203,0,0,100,14.3,12.757617,15.842383,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
28,4,"FEV1 L (absolute change from baseline)","At up to 1 month","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0.53,0.36,0,21,-0.04,0.25,0,12,0,0,100,0.57,0.360919,0.779081,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
28,5,"Adverse events (at up to 1 month)","Number experiencing moderate adverse events","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,2,21,0,0,0,12,0,0,100,3.205128,0.053216,193.039989,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
28,5,"Adverse events (at up to 1 month)","Number experiencing severe adverse events","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,0,21,0,0,2,12,0,0,100,0.097674,0.001608,5.93279,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
28,5,"Adverse events (at up to 1 month)","Number of participants experiencing at least one adverse event","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,18,21,0,0,12,12,0,0,100,0.211429,0.003846,11.623049,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
28,5,"Adverse events (at up to 1 month)","Infective pulmonary exacerbation","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,2,21,0,0,4,12,0,0,100,0.210526,0.017615,2.51615,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
28,5,"Adverse events (at up to 1 month)","Haemoptysis","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,2,21,0,0,2,12,0,0,100,0.526316,0.033131,8.360966,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
28,5,"Adverse events (at up to 1 month)","Pyrexia","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,1,21,0,0,1,12,0,0,100,0.55,0.012692,23.833132,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
28,5,"Adverse events (at up to 1 month)","Oropharyngeal pain","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,2,21,0,0,2,12,0,0,100,0.526316,0.033131,8.360966,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
28,5,"Adverse events (at up to 1 month)","Nausea","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,1,21,0,0,2,12,0,0,100,0.25,0.009141,6.837473,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
28,5,"Adverse events (at up to 1 month)","Headache","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,2,21,0,0,2,12,0,0,100,0.526316,0.033131,8.360966,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
28,5,"Adverse events (at up to 1 month)","Nasopharyngitis","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,4,21,0,0,0,12,0,0,100,6.428571,0.122974,336.058104,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
28,5,"Adverse events (at up to 1 month)","Rhinorrhoea","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,0,21,0,0,0,12,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
28,5,"Adverse events (at up to 1 month)","Fatigue","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,0,21,0,0,4,12,0,0,100,0.043928,0.000822,2.348808,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
28,5,"Adverse events (at up to 1 month)","Diarrhoea","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,0,21,0,0,1,12,0,0,100,0.178295,0.002394,13.276193,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
28,5,"Adverse events (at up to 1 month)","Cough","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,7,21,0,0,1,12,0,0,100,5.5,0.28996,104.324626,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
28,5,"Adverse events (at up to 1 month)","Increased sputum","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,5,21,0,0,3,12,0,0,100,0.9375,0.107497,8.176126,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
28,5,"Adverse events (at up to 1 month)","Nasal congestion","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,2,21,0,0,2,12,0,0,100,0.526316,0.033131,8.360966,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
28,5,"Adverse events (at up to 1 month)","Increased blood creatine phosphokinase","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,1,21,0,0,0,12,0,0,100,1.829268,0.024655,135.720447,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
28,5,"Adverse events (at up to 1 month)","Elevated AST","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,1,21,0,0,0,12,0,0,100,1.829268,0.024655,135.720447,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
28,5,"Adverse events (at up to 1 month)","Abnormal respiration","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,1,21,0,0,0,12,0,0,100,1.829268,0.024655,135.720447,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
29,1,"Quality of life: CFQ-R respiratory domain (change from baseline)","At up to 1 month","SUBGROUP_AND_OVERALL","Heijerman 2019","2019",0,0,16,14.4264,0,55,-1.4,14.3677,0,52,0,0,80.064799,17.4,11.942339,22.857661,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","1::overall","CD010966_pub4_data","significance_only",TRUE,FALSE,TRUE,-0.207750252671045,-0.0819815913269149,-0.673556970156986,0.258056464814896,-0.1207064162904,-0.0432567663634297,TRUE,TRUE
29,1,"Quality of life: CFQ-R respiratory domain (change from baseline)","At up to 1 month","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,20.7,11.4564,0,21,1.4,13.2,0,7,0,0,19.935201,19.3,8.362525,30.237475,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","1::overall","CD010966_pub4_data","significance_only",TRUE,FALSE,TRUE,-0.207750252671045,-0.0819815913269149,-0.673556970156986,0.258056464814896,-0.1207064162904,-0.0432567663634297,TRUE,TRUE
29,1,"Quality of life: CFQ-R respiratory domain (change from baseline)","At 6 months","SUBGROUP_AND_OVERALL","Sutharsan 2022","2022",0,0,17.1,13.991069,0,87,1.2,14.071247,0,88,0,0,100,15.9,11.742289,20.057711,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","1::overall","CD010966_pub4_data","significance_only",TRUE,FALSE,TRUE,-0.207750252671045,-0.0819815913269149,-0.673556970156986,0.258056464814896,-0.1207064162904,-0.0432567663634297,TRUE,TRUE
29,2,"FEV1 % predicted (relative change from baseline)","At up to 1 month","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,19.2,12.373,0,21,1.4,13.2288,0,7,0,0,100,17.8,6.662606,28.937394,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
29,3,"FEV1 % predicted (absolute change from baseline)","At up to 1 month","SUBGROUP_AND_OVERALL","Heijerman 2019","2019",0,0,10.4,6.6583,0,55,0.4,6.4655,0,52,0,0,100,10,7.513122,12.486878,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
29,3,"FEV1 % predicted (absolute change from baseline)","At 6 months","SUBGROUP_AND_OVERALL","Sutharsan 2022","2022",0,0,11.2,6.529165,0,87,1,6.566582,0,88,0,0,100,10.2,8.259735,12.140265,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
29,4,"FEV1 L (absolute change from baseline)","At up to 1 month","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0.45,0.32,0,21,-0.01,0.2,0,7,0,0,100,0.46,0.2583,0.6617,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
29,5,"Adverse events (at up to 1 month)","Number experiencing mild adverse events","SUBGROUP_AND_OVERALL","Heijerman 2019","2019",0,0,0,0,23,55,0,0,21,52,0,0,100,1.061012,0.385355,2.921322,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
29,5,"Adverse events (at up to 1 month)","Number experiencing moderate adverse events","SUBGROUP_AND_OVERALL","Heijerman 2019","2019",0,0,0,0,12,55,0,0,11,52,0,0,86.089444,1.040169,0.30914,3.49988,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
29,5,"Adverse events (at up to 1 month)","Number experiencing moderate adverse events","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,1,21,0,0,1,7,0,0,13.910556,0.3,0.00648,13.888262,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
29,5,"Adverse events (at up to 1 month)","Adverse event leading to discontinuation of trial drug","SUBGROUP_AND_OVERALL","Heijerman 2019","2019",0,0,0,0,0,55,0,0,0,52,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
29,5,"Adverse events (at up to 1 month)","Elevated transaminase","SUBGROUP_AND_OVERALL","Heijerman 2019","2019",0,0,0,0,2,55,0,0,1,52,0,0,100,1.924528,0.078846,46.975149,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
29,5,"Adverse events (at up to 1 month)","Rash","SUBGROUP_AND_OVERALL","Heijerman 2019","2019",0,0,0,0,2,55,0,0,2,52,0,0,100,0.943396,0.068311,13.028533,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
29,5,"Adverse events (at up to 1 month)","Cough","SUBGROUP_AND_OVERALL","Heijerman 2019","2019",0,0,0,0,8,55,0,0,4,52,0,0,81.72644,2.042553,0.386983,10.780893,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
29,5,"Adverse events (at up to 1 month)","Cough","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,10,21,0,0,1,7,0,0,18.27356,5.454545,0.271232,109.69219,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
29,5,"Adverse events (at up to 1 month)","Nasopharyngitis","SUBGROUP_AND_OVERALL","Heijerman 2019","2019",0,0,0,0,4,55,0,0,2,52,0,0,57.165733,1.960784,0.198784,19.340927,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
29,5,"Adverse events (at up to 1 month)","Nasopharyngitis","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,1,21,0,0,1,7,0,0,42.834267,0.3,0.00648,13.888262,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
29,5,"Adverse events (at up to 1 month)","Upper respiratory tract infection","SUBGROUP_AND_OVERALL","Heijerman 2019","2019",0,0,0,0,4,55,0,0,2,52,0,0,100,1.960784,0.198784,19.340927,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
29,5,"Adverse events (at up to 1 month)","Infective respiratory exacerbation","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,5,21,0,0,1,7,0,0,100,1.875,0.08623,40.77034,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
29,5,"Adverse events (at up to 1 month)","Headache","SUBGROUP_AND_OVERALL","Heijerman 2019","2019",0,0,0,0,3,55,0,0,4,52,0,0,64.391301,0.692308,0.090583,5.291145,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
29,5,"Adverse events (at up to 1 month)","Headache","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,0,21,0,0,1,7,0,0,35.608699,0.100775,0.001286,7.897971,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
29,5,"Adverse events (at up to 1 month)","Haemoptysis","SUBGROUP_AND_OVERALL","Heijerman 2019","2019",0,0,0,0,2,55,0,0,5,52,0,0,88.928661,0.354717,0.038679,3.253051,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
29,5,"Adverse events (at up to 1 month)","Haemoptysis","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,3,21,0,0,0,7,0,0,11.071339,2.837838,0.049404,163.010875,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
29,5,"Adverse events (at up to 1 month)","Pulmonary exacerbation","SUBGROUP_AND_OVERALL","Heijerman 2019","2019",0,0,0,0,1,55,0,0,6,52,0,0,100,0.141975,0.00838,2.405377,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
29,5,"Adverse events (at up to 1 month)","Oropharyngeal pain","SUBGROUP_AND_OVERALL","Heijerman 2019","2019",0,0,0,0,4,55,0,0,0,52,0,0,24.853499,9.174757,0.190815,441.141312,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
29,5,"Adverse events (at up to 1 month)","Oropharyngeal pain","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,1,21,0,0,1,7,0,0,75.146501,0.3,0.00648,13.888262,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
29,5,"Adverse events (at up to 1 month)","Increased sputum","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,8,21,0,0,2,7,0,0,100,1.538462,0.133257,17.761594,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
29,5,"Adverse events (at up to 1 month)","Pyrexia","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,3,21,0,0,1,7,0,0,100,1,0.040251,24.844181,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
29,5,"Adverse events (at up to 1 month)","Nausea","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,1,21,0,0,1,7,0,0,100,0.3,0.00648,13.888262,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
29,5,"Adverse events (at up to 1 month)","Nasal congestion","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,0,21,0,0,0,7,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
29,5,"Adverse events (at up to 1 month)","Increased blood creatine phosphokinase","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,4,21,0,0,0,7,0,0,100,3.857143,0.070575,210.803655,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
29,5,"Adverse events (at up to 1 month)","Fatigue","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,4,21,0,0,0,7,0,0,100,3.857143,0.070575,210.803655,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
29,5,"Adverse events (at up to 1 month)","Elevated AST","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,3,21,0,0,0,7,0,0,100,2.837838,0.049404,163.010875,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
29,5,"Adverse events (at up to 1 month)","Diarrhoea","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,0,21,0,0,0,7,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
29,5,"Adverse events (at up to 1 month)","Abnormal respiration","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,2,21,0,0,0,7,0,0,100,1.923077,0.030587,120.906803,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
29,5,"Adverse events (at up to 1 month)","Number of participants experiencing at least one adverse event","SUBGROUP_AND_OVERALL","Heijerman 2019","2019",0,0,0,0,32,55,0,0,33,52,0,0,95.206523,0.801054,0.288054,2.227661,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
29,5,"Adverse events (at up to 1 month)","Number of participants experiencing at least one adverse event","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,19,21,0,0,5,7,0,0,4.793477,3.8,0.212696,67.890467,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
29,5,"Adverse events (at up to 1 month)","Number experiencing serious adverse events","SUBGROUP_AND_OVERALL","Heijerman 2019","2019",0,0,0,0,2,55,0,0,1,52,0,0,100,1.924528,0.078846,46.975149,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
29,5,"Adverse events (at up to 1 month)","Number experiencing severe adverse events","SUBGROUP_AND_OVERALL","Heijerman 2019","2019",0,0,0,0,0,55,0,0,1,52,0,0,41.536734,0.309309,0.004475,21.377094,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
29,5,"Adverse events (at up to 1 month)","Number experiencing severe adverse events","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,0,21,0,0,1,7,0,0,58.463266,0.100775,0.001286,7.897971,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
29,5,"Adverse events (at up to 1 month)","Rhinorrhoea","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,1,21,0,0,0,7,0,0,100,1.097561,0.0142,84.830938,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
30,1,"Quality of life: change in CFQ-R respiratory domain","At 1 month","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,23.9,14.206,0,21,11.1,14.7078,0,8,0,0,100,12.8,0.934535,24.665465,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","1::overall","CD010966_pub4_data","significance_only",TRUE,FALSE,TRUE,-0.207750252671045,-0.0819815913269149,-0.673556970156986,0.258056464814896,-0.1207064162904,-0.0432567663634297,TRUE,TRUE
30,2,"FEV1 % predicted (relative change from baseline)","At 1 month","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,19.9,13.2895,0,21,1.6,13.0108,0,8,0,0,100,18.3,7.642021,28.957979,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
30,3,"FEV1 L (absolute change from baseline)","At 1 month","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0.47,0.37,0,21,0.03,0.16,0,8,0,0,100,0.44,0.246776,0.633224,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
30,4,"Adverse events (at 1 month)","Number experiencing moderate adverse events","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,0,21,0,0,0,8,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
30,4,"Adverse events (at 1 month)","URTI","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,2,21,0,0,0,8,0,0,100,2.179487,0.035105,135.313959,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
30,4,"Adverse events (at 1 month)","Number experiencing severe adverse events","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,0,21,0,0,1,8,0,0,100,0.116279,0.001507,8.971708,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
30,4,"Adverse events (at 1 month)","Number of participants experiencing at least one adverse event","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,19,21,0,0,7,8,0,0,100,1.357143,0.047424,38.837762,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
30,4,"Adverse events (at 1 month)","Infective pulmonary exacerbation","SUBGROUP_AND_OVERALL","Heijerman 2019","2019",0,0,0,0,1,55,0,0,6,52,0,0,54.947368,0.141975,0.00838,2.405377,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
30,4,"Adverse events (at 1 month)","Infective pulmonary exacerbation","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,3,21,0,0,4,8,0,0,45.052632,0.166667,0.014695,1.890338,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
30,4,"Adverse events (at 1 month)","Vomiting","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,0,21,0,0,2,8,0,0,100,0.060465,0.00095,3.849707,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
30,4,"Adverse events (at 1 month)","Cough","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,5,21,0,0,2,8,0,0,100,0.9375,0.07828,11.227747,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
30,4,"Adverse events (at 1 month)","Nausea","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,2,21,0,0,3,8,0,0,100,0.175439,0.011977,2.569718,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
30,4,"Adverse events (at 1 month)","Nasal congestion","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,3,21,0,0,1,8,0,0,100,1.166667,0.048133,28.278253,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
30,4,"Adverse events (at 1 month)","Productive cough","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,2,21,0,0,1,8,0,0,100,0.736842,0.025748,21.086431,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
30,4,"Adverse events (at 1 month)","Paranasal sinus discomfort","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,2,21,0,0,0,8,0,0,100,2.179487,0.035105,135.313959,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
30,4,"Adverse events (at 1 month)","Increased sputum","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,3,21,0,0,1,8,0,0,100,1.166667,0.048133,28.278253,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
30,4,"Adverse events (at 1 month)","Oropharyngeal pain","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,5,21,0,0,2,8,0,0,100,0.9375,0.07828,11.227747,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
30,4,"Adverse events (at 1 month)","Chest pain","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,2,21,0,0,0,8,0,0,100,2.179487,0.035105,135.313959,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
30,4,"Adverse events (at 1 month)","Sinus congestion","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,0,0,2,21,0,0,0,8,0,0,100,2.179487,0.035105,135.313959,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
30,5,"Sweat chloride (change from baseline) (mmol/L)","At 1 month","SUBGROUP_AND_OVERALL","Keating 2018","17/18",0,0,-33.6,12.8312,0,21,1,13.0108,0,8,0,0,100,-34.6,-45.154747,-24.045253,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
31,1,"Quality of life - CFQ-R respiratory domain (absolute change from baseline)","At 2 months","SUBGROUP_AND_OVERALL","Barry 2021","2021",0,0,10.3,13.648225,0,132,1.6,13.895633,0,126,0,0,100,8.7,5.337296,12.062704,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","1::overall","CD010966_pub4_data","significance_only",TRUE,FALSE,TRUE,-0.207750252671045,-0.0819815913269149,-0.673556970156986,0.258056464814896,-0.1207064162904,-0.0432567663634297,TRUE,TRUE
31,2,"FEV1 % predicted (absolute change from baseline)","At 2 months","SUBGROUP_AND_OVERALL","Barry 2021","2021",0,0,3.7,5.22698,0,132,0.2,5.104518,0,126,0,0,100,3.5,2.239248,4.760752,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
31,3,"Most common adverse events (occurring in at least 10% of participants in either group)","Number of participants with treatment-emergent adverse events","SUBGROUP_AND_OVERALL","Barry 2021","2021",0,0,0,0,88,132,0,0,83,126,0,0,100,1.036145,0.525691,2.042256,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
31,3,"Most common adverse events (occurring in at least 10% of participants in either group)","Cough","SUBGROUP_AND_OVERALL","Barry 2021","2021",0,0,0,0,3,132,0,0,18,126,0,0,100,0.139535,0.027038,0.720095,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
31,3,"Most common adverse events (occurring in at least 10% of participants in either group)","Headache","SUBGROUP_AND_OVERALL","Barry 2021","2021",0,0,0,0,11,132,0,0,19,126,0,0,100,0.511962,0.182039,1.439831,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
31,3,"Most common adverse events (occurring in at least 10% of participants in either group)","Number of participants with moderate adverse events","SUBGROUP_AND_OVERALL","Barry 2021","2021",0,0,0,0,1,132,0,0,2,126,0,0,100,0.473282,0.019856,11.281177,"As determined by number of adverse events that led to treatment discontinuation","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
31,3,"Most common adverse events (occurring in at least 10% of participants in either group)","Infective pulmonary exacerbations","SUBGROUP_AND_OVERALL","Barry 2021","2021",0,0,0,0,4,132,0,0,17,126,0,0,100,0.200368,0.046057,0.871688,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
31,3,"Most common adverse events (occurring in at least 10% of participants in either group)","Number of participants with serious adverse events","SUBGROUP_AND_OVERALL","Barry 2021","2021",0,0,0,0,5,132,0,0,11,126,0,0,100,0.411596,0.098665,1.717045,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
31,4,"Sweat chloride (absolute change from baseline)","At 2 months","SUBGROUP_AND_OVERALL","Barry 2021","2021",0,0,-22.3,12.486674,0,132,0.7,11.910542,0,126,0,0,100,-23,-25.976998,-20.023002,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
32,1,"CFQ-R respiratory domain score (absolute change from baseline)","At day 15","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,6.6,11.958809,0,6,-7.6,13.157565,0,8,0,0,100,14.2,0.98285,27.41715,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","1::overall","CD010966_pub4_data","significance_only",TRUE,FALSE,TRUE,-0.207750252671045,-0.0819815913269149,-0.673556970156986,0.258056464814896,-0.1207064162904,-0.0432567663634297,TRUE,TRUE
32,2,"FEV1 % predicted (relative change from baseline)","At day 15","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,10.3,8.29017,0,6,-2.3,9.030874,0,8,0,0,100,12.6,3.480569,21.719431,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
32,3,"FEV1 % predicted (absolute change from baseline)","At day 15","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,5.7,4.430953,0,6,-0.8,4.844376,0,8,0,0,100,6.5,1.617478,11.382522,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
32,4,"Most common adverse events (occurring in at least 10% of participants in either group) (day 43)","Ear discomfort","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,6,0,0,1,8,0,0,100,0.384615,0.004596,32.185105,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
32,4,"Most common adverse events (occurring in at least 10% of participants in either group) (day 43)","Abdominal distension","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,1,6,0,0,0,8,0,0,100,4.636364,0.054898,391.56148,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
32,4,"Most common adverse events (occurring in at least 10% of participants in either group) (day 43)","Colitis","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,6,0,0,1,8,0,0,100,0.384615,0.004596,32.185105,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
32,4,"Most common adverse events (occurring in at least 10% of participants in either group) (day 43)","Anxiety","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,6,0,0,1,8,0,0,100,0.384615,0.004596,32.185105,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
32,4,"Most common adverse events (occurring in at least 10% of participants in either group) (day 43)","Cough","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,2,6,0,0,1,8,0,0,100,3.5,0.101156,121.100214,"The values on clinicaltrials.gov for 'Cough' and 'Productive cough' have been combined here.","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
32,4,"Most common adverse events (occurring in at least 10% of participants in either group) (day 43)","Dysphonia","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,6,0,0,1,8,0,0,100,0.384615,0.004596,32.185105,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
32,4,"Most common adverse events (occurring in at least 10% of participants in either group) (day 43)","Dyspnoea","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,6,0,0,1,8,0,0,100,0.384615,0.004596,32.185105,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
32,4,"Most common adverse events (occurring in at least 10% of participants in either group) (day 43)","Lower respiratory tract congestion","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,1,6,0,0,0,8,0,0,100,4.636364,0.054898,391.56148,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
32,4,"Most common adverse events (occurring in at least 10% of participants in either group) (day 43)","Oropharyngeal pain","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,6,0,0,1,8,0,0,100,0.384615,0.004596,32.185105,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
32,4,"Most common adverse events (occurring in at least 10% of participants in either group) (day 43)","Number of participants with serious adverse events","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,6,0,0,2,8,0,0,100,0.2,0.002886,13.861379,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
32,4,"Most common adverse events (occurring in at least 10% of participants in either group) (day 43)","Diarrhoea","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,2,6,0,0,0,8,0,0,100,9.444444,0.132891,671.209388,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
32,4,"Most common adverse events (occurring in at least 10% of participants in either group) (day 43)","Vomiting","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,6,0,0,1,8,0,0,100,0.384615,0.004596,32.185105,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
32,4,"Most common adverse events (occurring in at least 10% of participants in either group) (day 43)","Upper respiratory tract infection","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,6,0,0,1,8,0,0,100,0.384615,0.004596,32.185105,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
32,4,"Most common adverse events (occurring in at least 10% of participants in either group) (day 43)","Blood alkaline phosphatase increased","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,6,0,0,1,8,0,0,100,0.384615,0.004596,32.185105,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
32,4,"Most common adverse events (occurring in at least 10% of participants in either group) (day 43)","Gamma-glutamyltransferase increased","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,6,0,0,1,8,0,0,100,0.384615,0.004596,32.185105,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
32,4,"Most common adverse events (occurring in at least 10% of participants in either group) (day 43)","Dizziness","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,1,6,0,0,1,8,0,0,100,1.4,0.027155,72.17821,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
32,4,"Most common adverse events (occurring in at least 10% of participants in either group) (day 43)","Lymphadenopathy","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,6,0,0,1,8,0,0,100,0.384615,0.004596,32.185105,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
32,4,"Most common adverse events (occurring in at least 10% of participants in either group) (day 43)","Vessel puncture site haemorrhage","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,6,0,0,1,8,0,0,100,0.384615,0.004596,32.185105,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
32,4,"Most common adverse events (occurring in at least 10% of participants in either group) (day 43)","Viral infection","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,6,0,0,1,8,0,0,100,0.384615,0.004596,32.185105,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
32,4,"Most common adverse events (occurring in at least 10% of participants in either group) (day 43)","Nausea","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,6,0,0,1,8,0,0,100,0.384615,0.004596,32.185105,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
32,4,"Most common adverse events (occurring in at least 10% of participants in either group) (day 43)","Fatigue","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,1,6,0,0,0,8,0,0,100,4.636364,0.054898,391.56148,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
32,4,"Most common adverse events (occurring in at least 10% of participants in either group) (day 43)","Viral upper respiratory tract infection","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,6,0,0,1,8,0,0,100,0.384615,0.004596,32.185105,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
32,4,"Most common adverse events (occurring in at least 10% of participants in either group) (day 43)","Aspartate aminotransferase increased","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,6,0,0,1,8,0,0,100,0.384615,0.004596,32.185105,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
32,4,"Most common adverse events (occurring in at least 10% of participants in either group) (day 43)","Hypoglycaemia","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,1,6,0,0,0,8,0,0,100,4.636364,0.054898,391.56148,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
32,4,"Most common adverse events (occurring in at least 10% of participants in either group) (day 43)","Musculoskeletal chest pain","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,1,6,0,0,0,8,0,0,100,4.636364,0.054898,391.56148,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
32,4,"Most common adverse events (occurring in at least 10% of participants in either group) (day 43)","Headache","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,1,6,0,0,0,8,0,0,100,4.636364,0.054898,391.56148,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
32,4,"Most common adverse events (occurring in at least 10% of participants in either group) (day 43)","Migraine","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,6,0,0,1,8,0,0,100,0.384615,0.004596,32.185105,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
32,4,"Most common adverse events (occurring in at least 10% of participants in either group) (day 43)","Haemoptysis","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,1,6,0,0,0,8,0,0,100,4.636364,0.054898,391.56148,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
32,4,"Most common adverse events (occurring in at least 10% of participants in either group) (day 43)","Nasal congestion","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,6,0,0,1,8,0,0,100,0.384615,0.004596,32.185105,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
32,4,"Most common adverse events (occurring in at least 10% of participants in either group) (day 43)","Sinus congestion","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,6,0,0,2,8,0,0,100,0.2,0.002886,13.861379,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
32,4,"Most common adverse events (occurring in at least 10% of participants in either group) (day 43)","Sputum increased","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,1,6,0,0,1,8,0,0,100,1.4,0.027155,72.17821,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
32,4,"Most common adverse events (occurring in at least 10% of participants in either group) (day 43)","Infective pulmonary exacerbations","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,6,0,0,4,8,0,0,100,0.076923,0.00121,4.889475,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
32,4,"Most common adverse events (occurring in at least 10% of participants in either group) (day 43)","Number of participants with treatment-emergent adverse events","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,3,6,0,0,8,8,0,0,100,0.058824,0.000861,4.017802,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
32,5,"Sweat chloride (absolute change from baseline)","At day 15","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,-19.5,9.100129,0,6,-0.1,9.987788,0,8,0,0,100,-19.4,-29.445948,-9.354052,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
33,1,"CFQ-R respiratory domain score (absolute change from baseline)","At day 15","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,21.8,13.62956,0,10,-7.6,13.157565,0,8,0,0,100,29.4,16.97057,41.82943,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","1::overall","CD010966_pub4_data","significance_only",TRUE,FALSE,TRUE,-0.207750252671045,-0.0819815913269149,-0.673556970156986,0.258056464814896,-0.1207064162904,-0.0432567663634297,TRUE,TRUE
33,2,"FEV1 % predicted (relative change from baseline)","At day 15","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,19,9.435849,0,10,-2.3,9.030874,0,8,0,0,100,21.3,12.734686,29.865314,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
33,3,"FEV1% predicted (absolute change from baseline)","At day 15","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,9.7,5.032453,0,10,-0.8,4.844376,0,8,0,0,100,10.5,5.917683,15.082317,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
33,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Vomiting","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,10,0,0,1,8,0,0,100,0.238095,0.002974,19.063812,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
33,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Vessel puncture site haemorrhage","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,10,0,0,1,8,0,0,100,0.238095,0.002974,19.063812,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
33,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Dysphonia","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,10,0,0,1,8,0,0,100,0.238095,0.002974,19.063812,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
33,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Respiration abnormal","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,1,10,0,0,0,8,0,0,100,2.684211,0.033668,213.999977,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
33,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Sinus congestion","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,10,0,0,2,8,0,0,100,0.12381,0.001871,8.19407,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
33,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Number of participants with serious adverse events","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,10,0,0,2,8,0,0,100,0.12381,0.001871,8.19407,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
33,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Upper respiratory tract infection","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,1,10,0,0,1,8,0,0,100,0.777778,0.016269,37.182388,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
33,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Dizziness","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,10,0,0,1,8,0,0,100,0.238095,0.002974,19.063812,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
33,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Headache","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,1,10,0,0,0,8,0,0,100,2.684211,0.033668,213.999977,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
33,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Cough","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,5,10,0,0,1,8,0,0,100,7,0.285483,171.639116,"The data presented on clinicaltrials.gov for 'Cough' and 'Productive cough' have been combined here.","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
33,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Wheezing","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,1,10,0,0,0,8,0,0,100,2.684211,0.033668,213.999977,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
33,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Lymphadenopathy","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,10,0,0,1,8,0,0,100,0.238095,0.002974,19.063812,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
33,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Colitis","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,10,0,0,1,8,0,0,100,0.238095,0.002974,19.063812,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
33,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Diarrhoea","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,2,10,0,0,0,8,0,0,100,5,0.076378,327.31838,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
33,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Nausea","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,10,0,0,1,8,0,0,100,0.238095,0.002974,19.063812,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
33,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Seasonal allergy","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,1,10,0,0,0,8,0,0,100,2.684211,0.033668,213.999977,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
33,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Aspartate aminotransferase increased","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,10,0,0,1,8,0,0,100,0.238095,0.002974,19.063812,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
33,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Migraine","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,10,0,0,1,8,0,0,100,0.238095,0.002974,19.063812,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
33,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Lower respiratory tract congestion","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,1,10,0,0,0,8,0,0,100,2.684211,0.033668,213.999977,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
33,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Nasal congestion","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,10,0,0,1,8,0,0,100,0.238095,0.002974,19.063812,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
33,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Oropharyngeal pain","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,10,0,0,1,8,0,0,100,0.238095,0.002974,19.063812,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
33,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Ear discomfort","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,10,0,0,1,8,0,0,100,0.238095,0.002974,19.063812,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
33,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Faeces soft","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,1,10,0,0,0,8,0,0,100,2.684211,0.033668,213.999977,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
33,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Post-tussive vomiting","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,1,10,0,0,0,8,0,0,100,2.684211,0.033668,213.999977,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
33,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Fatigue","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,2,10,0,0,0,8,0,0,100,5,0.076378,327.31838,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
33,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Blood bilirubin increased","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,1,10,0,0,0,8,0,0,100,2.684211,0.033668,213.999977,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
33,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Sinus headache","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,1,10,0,0,0,8,0,0,100,2.684211,0.033668,213.999977,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
33,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Anxiety","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,10,0,0,1,8,0,0,100,0.238095,0.002974,19.063812,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
33,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Viral upper respiratory tract infection","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,10,0,0,1,8,0,0,100,0.238095,0.002974,19.063812,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
33,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Procedural haemorrhage","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,1,10,0,0,0,8,0,0,100,2.684211,0.033668,213.999977,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
33,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Blood alkaline phosphatase increased","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,10,0,0,1,8,0,0,100,0.238095,0.002974,19.063812,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
33,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Gamma-glutamyltransferase increased","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,10,0,0,1,8,0,0,100,0.238095,0.002974,19.063812,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
33,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Insomnia","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,1,10,0,0,0,8,0,0,100,2.684211,0.033668,213.999977,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
33,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Dyspnoea","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,10,0,0,1,8,0,0,100,0.238095,0.002974,19.063812,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
33,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Dyspnoea exertional","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,1,10,0,0,0,8,0,0,100,2.684211,0.033668,213.999977,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
33,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Sputum increased","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,2,10,0,0,1,8,0,0,100,1.75,0.05697,53.756186,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
33,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Number of participants with treatment-emergent adverse events","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,7,10,0,0,8,8,0,0,100,0.12605,0.002084,7.625144,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
33,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Infective pulmonary exacerbations","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,1,10,0,0,4,8,0,0,100,0.111111,0.004225,2.921987,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
33,5,"Sweat chloride (absolute change from baseline)","At day 15","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,-13.6,10.903648,0,10,-0.1,9.987788,0,8,0,0,100,-13.5,-23.17326,-3.82674,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
34,1,"CFQ-R Respiratory domain score (absolute change from baseline)","At day 15","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,18.6,13.769351,0,10,-7.6,13.157565,0,8,0,0,100,26.2,13.711523,38.688477,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","1::overall","CD010966_pub4_data","significance_only",TRUE,FALSE,TRUE,-0.207750252671045,-0.0819815913269149,-0.673556970156986,0.258056464814896,-0.1207064162904,-0.0432567663634297,TRUE,TRUE
34,2,"FEV1 % predicted (relative change from baseline)","At day 15","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,14.8,10.554172,0,10,-2.3,9.030874,0,8,0,0,100,17.1,8.047249,26.152751,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
34,3,"FEV1 % predicted (absolute change from baseline)","At day 15","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,8,5.591614,0,10,-0.8,4.844376,0,8,0,0,100,8.8,3.975099,13.624901,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
34,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Colitis","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,10,0,0,1,8,0,0,100,0.238095,0.002974,19.063812,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
34,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Alanine aminotransferase increased","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,1,10,0,0,0,8,0,0,100,2.684211,0.033668,213.999977,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
34,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Gamma-glutamyltransferase increased","SUBGROUP_AND_OVERALL","Barry 2021","2021",0,0,0,0,1,10,0,0,1,8,0,0,100,0.777778,0.016269,37.182388,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
34,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Dysgeusia","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,1,10,0,0,0,8,0,0,100,2.684211,0.033668,213.999977,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
34,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Migraine","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,10,0,0,1,8,0,0,100,0.238095,0.002974,19.063812,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
34,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Breast tenderness","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,1,10,0,0,0,8,0,0,100,2.684211,0.033668,213.999977,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
34,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Procedural dizziness","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,1,10,0,0,0,8,0,0,100,2.684211,0.033668,213.999977,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
34,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Ear discomfort","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,10,0,0,1,8,0,0,100,0.238095,0.002974,19.063812,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
34,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Dyspepsia","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,1,10,0,0,0,8,0,0,100,2.684211,0.033668,213.999977,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
34,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Upper respiratory tract infection","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,10,0,0,1,8,0,0,100,0.238095,0.002974,19.063812,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
34,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Viral upper respiratory tract infection","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,1,10,0,0,1,8,0,0,100,0.777778,0.016269,37.182388,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
34,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Sinus headache","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,1,10,0,0,0,8,0,0,100,2.684211,0.033668,213.999977,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
34,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Cough","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,3,10,0,0,1,8,0,0,100,3,0.113164,79.530764,"Values on clinicaltrials.gov for 'Cough' and 'Productive cough' have been combined here.","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
34,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Dyspnoea","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,10,0,0,1,8,0,0,100,0.238095,0.002974,19.063812,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
34,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Oropharyngeal pain","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,10,0,0,1,8,0,0,100,0.238095,0.002974,19.063812,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
34,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Vessel puncture site haemorrhage","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,10,0,0,1,8,0,0,100,0.238095,0.002974,19.063812,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
34,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Vomiting","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,10,0,0,1,8,0,0,100,0.238095,0.002974,19.063812,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
34,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Aspartate aminotransferase increased","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,1,10,0,0,1,8,0,0,100,0.777778,0.016269,37.182388,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
34,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Anaemia","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,1,10,0,0,0,8,0,0,100,2.684211,0.033668,213.999977,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
34,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Lymphadenopathy","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,10,0,0,1,8,0,0,100,0.238095,0.002974,19.063812,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
34,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Abdominal discomfort","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,1,10,0,0,0,8,0,0,100,2.684211,0.033668,213.999977,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
34,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Diarrhoea","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,1,10,0,0,0,8,0,0,100,2.684211,0.033668,213.999977,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
34,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Fatigue","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,1,10,0,0,0,8,0,0,100,2.684211,0.033668,213.999977,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
34,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Nausea","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,10,0,0,1,8,0,0,100,0.238095,0.002974,19.063812,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
34,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Thirst","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,1,10,0,0,0,8,0,0,100,2.684211,0.033668,213.999977,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
34,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Platelet count increased","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,1,10,0,0,0,8,0,0,100,2.684211,0.033668,213.999977,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
34,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Number of participants with serious adverse events","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,1,10,0,0,2,8,0,0,100,0.333333,0.010748,10.338004,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
34,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Flatulence","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,1,10,0,0,0,8,0,0,100,2.684211,0.033668,213.999977,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
34,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Chronic sinusitis","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,1,10,0,0,0,8,0,0,100,2.684211,0.033668,213.999977,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
34,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Anxiety","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,10,0,0,1,8,0,0,100,0.238095,0.002974,19.063812,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
34,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Breast discomfort","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,1,10,0,0,0,8,0,0,100,2.684211,0.033668,213.999977,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
34,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Lower respiratory tract congestion","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,1,10,0,0,0,8,0,0,100,2.684211,0.033668,213.999977,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
34,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Nasal congestion","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,10,0,0,1,8,0,0,100,0.238095,0.002974,19.063812,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
34,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Blood alkaline phosphatase increased","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,1,10,0,0,1,8,0,0,100,0.777778,0.016269,37.182388,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
34,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Chromaturia","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,1,10,0,0,0,8,0,0,100,2.684211,0.033668,213.999977,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
34,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Haemoptysis","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,1,10,0,0,0,8,0,0,100,2.684211,0.033668,213.999977,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
34,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Pulmonary pain","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,1,10,0,0,0,8,0,0,100,2.684211,0.033668,213.999977,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
34,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Headache","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,3,10,0,0,0,8,0,0,100,7.933333,0.131145,479.909597,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
34,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Dysphonia","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,10,0,0,1,8,0,0,100,0.238095,0.002974,19.063812,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
34,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Respiratory tract congestion","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,1,10,0,0,0,8,0,0,100,2.684211,0.033668,213.999977,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
34,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Sinus congestion","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,10,0,0,2,8,0,0,100,0.12381,0.001871,8.19407,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
34,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Wheezing","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,1,10,0,0,0,8,0,0,100,2.684211,0.033668,213.999977,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
34,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Dizziness","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,10,0,0,1,8,0,0,100,0.238095,0.002974,19.063812,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
34,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Respiration abnormal","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,2,10,0,0,0,8,0,0,100,5,0.076378,327.31838,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
34,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Sputum increased","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,1,10,0,0,1,8,0,0,100,0.777778,0.016269,37.182388,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
34,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Infective pulmonary exacerbations","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,1,10,0,0,4,8,0,0,100,0.111111,0.004225,2.921987,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
34,4,"Most common adverse events (occurring in at least 10% of participants in either group)","Number of participants with treatment-emergent adverse events","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,10,10,0,0,8,8,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
34,5,"Sweat chloride (absolute change from baseline)","At day 15","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,-27.5,10.414382,0,10,-0.1,9.987788,0,8,0,0,100,-27.4,-36.863891,-17.936109,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
35,1,"CFQ-R respiratory domain score (absolute change from baseline)","At day 15","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,10.6,12.091866,0,10,5.8,8.672574,0,4,0,0,100,4.8,-6.531356,16.131356,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","1::overall","CD010966_pub4_data","significance_only",TRUE,FALSE,TRUE,-0.207750252671045,-0.0819815913269149,-0.673556970156986,0.258056464814896,-0.1207064162904,-0.0432567663634297,TRUE,TRUE
35,2,"FEV1 % predicted (relative change from baseline)","At day 15","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,13.2,13.280084,0,10,-1.4,9.898046,0,4,0,0,100,14.6,1.878506,27.321494,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
35,3,"FEV1 % predicted (absolute change from baseline)","At day 15","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,7.3,7.478784,0,10,-1,5.561759,0,4,0,0,100,8.3,1.145054,15.454946,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
35,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 71)","Weight decreased","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,10,0,0,1,4,0,0,100,0.111111,0.001238,9.969313,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
35,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 71)","Haemoptysis","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,1,10,0,0,1,4,0,0,100,0.333333,0.005941,18.701888,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
35,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 71)","Rhinorrhoea","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,10,0,0,1,4,0,0,100,0.111111,0.001238,9.969313,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
35,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 71)","Number of participants with treatment-emergent adverse events","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,6,10,0,0,3,4,0,0,100,0.5,0.016562,15.094866,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
35,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 71)","Fatigue","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,1,10,0,0,0,4,0,0,100,1.421053,0.016478,122.549445,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
35,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 71)","Gastroenteritis","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,10,0,0,1,4,0,0,100,0.111111,0.001238,9.969313,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
35,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 71)","Pneumonia","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,1,10,0,0,0,4,0,0,100,1.421053,0.016478,122.549445,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
35,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 71)","Tendon pain","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,10,0,0,1,4,0,0,100,0.111111,0.001238,9.969313,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
35,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 71)","Headache","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,10,0,0,1,4,0,0,100,0.111111,0.001238,9.969313,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
35,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 71)","Bronchospasm","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,1,10,0,0,0,4,0,0,100,1.421053,0.016478,122.549445,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
35,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 71)","Wheezing","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,10,0,0,1,4,0,0,100,0.111111,0.001238,9.969313,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
35,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 71)","Erythema","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,10,0,0,1,4,0,0,100,0.111111,0.001238,9.969313,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
35,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 71)","Nausea","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,10,0,0,1,4,0,0,100,0.111111,0.001238,9.969313,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
35,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 71)","Infective pulmonary exacerbation of cystic fibrosis","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,1,10,0,0,0,4,0,0,100,1.421053,0.016478,122.549445,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
35,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 71)","Nasopharyngitis","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,1,10,0,0,0,4,0,0,100,1.421053,0.016478,122.549445,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
35,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 71)","Incision site pain","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,1,10,0,0,0,4,0,0,100,1.421053,0.016478,122.549445,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
35,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 71)","Sputum increased","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,1,10,0,0,0,4,0,0,100,1.421053,0.016478,122.549445,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
35,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 71)","Number of participants with serious adverse events","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,10,0,0,0,4,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
35,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 71)","Eye swelling","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,1,10,0,0,0,4,0,0,100,1.421053,0.016478,122.549445,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
35,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 71)","Muscle strain","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,10,0,0,1,4,0,0,100,0.111111,0.001238,9.969313,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
35,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 71)","Arthralgia","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,10,0,0,1,4,0,0,100,0.111111,0.001238,9.969313,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
35,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 71)","Cough","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,1,10,0,0,1,4,0,0,100,0.333333,0.005941,18.701888,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
35,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 71)","Dyspnoea","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,10,0,0,1,4,0,0,100,0.111111,0.001238,9.969313,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
35,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 71)","Lower respiratory tract congestion","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,10,0,0,1,4,0,0,100,0.111111,0.001238,9.969313,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
35,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 71)","Sputum discoloured","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,1,10,0,0,0,4,0,0,100,1.421053,0.016478,122.549445,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
35,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 71)","Upper respiratory tract congestion","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,10,0,0,1,4,0,0,100,0.111111,0.001238,9.969313,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
35,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 71)","Night sweats","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,1,10,0,0,0,4,0,0,100,1.421053,0.016478,122.549445,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
35,5,"Sweat chloride (absolute change from baseline)","At day 15","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,-21.3,11.46281,0,10,3.5,7.981282,0,4,0,0,100,-24.8,-35.366518,-14.233482,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
36,1,"CFQ-R respiratory domain score (absolute change from baseline)","At 1 month","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,16.1,10.764628,0,21,4.8,9.190722,0,7,0,0,100,11.3,3.080991,19.519009,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","1::overall","CD010966_pub4_data","significance_only",TRUE,FALSE,TRUE,-0.207750252671045,-0.0819815913269149,-0.673556970156986,0.258056464814896,-0.1207064162904,-0.0432567663634297,TRUE,TRUE
36,2,"FEV1 % predicted (relative change from baseline)","Through 1 month","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,11.5,9.116981,0,21,-2,7.731019,0,7,0,0,100,13.5,6.571467,20.428533,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
36,3,"FEV1 % predicted (absolute change from baseline)","Through 1 month","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,6.5,5.492157,0,21,-2.2,4.703487,0,7,0,0,100,8.7,4.497822,12.902178,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
36,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 71)","Lower respiratory tract congestion","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,21,0,0,1,7,0,0,100,0.100775,0.001286,7.897971,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
36,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 71)","Nasopharyngitis","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,21,0,0,1,7,0,0,100,0.100775,0.001286,7.897971,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
36,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 71)","Headache","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,4,21,0,0,0,7,0,0,100,3.857143,0.070575,210.803655,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
36,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 71)","Cough","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,6,21,0,0,0,7,0,0,100,6.290323,0.121107,326.721527,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
36,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 71)","Productive cough","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,3,21,0,0,0,7,0,0,100,2.837838,0.049404,163.010875,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
36,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 71)","Sputum increased","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,6,21,0,0,1,7,0,0,100,2.4,0.113916,50.563556,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
36,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 71)","Chest discomfort","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,21,0,0,1,7,0,0,100,0.100775,0.001286,7.897971,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
36,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 71)","Infective pulmonary exacerbation of cystic fibrosis","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,5,21,0,0,3,7,0,0,100,0.416667,0.03899,4.452656,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
36,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 71)","Chromaturia","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,4,21,0,0,0,7,0,0,100,3.857143,0.070575,210.803655,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
36,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 71)","Dyspnoea","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,2,21,0,0,1,7,0,0,100,0.631579,0.021558,18.50326,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
36,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 71)","Number of participants with treatment-emergent adverse events","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,19,21,0,0,5,7,0,0,100,3.8,0.212696,67.890467,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
36,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 71)","Number of participants with serious adverse events","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,21,0,0,0,7,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
36,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 71)","Diarrhoea","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,3,21,0,0,0,7,0,0,100,2.837838,0.049404,163.010875,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
36,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 71)","Vomiting","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,21,0,0,1,7,0,0,100,0.100775,0.001286,7.897971,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
36,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 71)","Wheezing","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,0,0,0,21,0,0,1,7,0,0,100,0.100775,0.001286,7.897971,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
36,5,"Sweat chloride (absolute change from baseline)","Through 1 month","SUBGROUP_AND_OVERALL","NCT02951195","2016",0,0,-22.3,10.984314,0,21,1.6,9.082596,0,7,0,0,100,-23.9,-32.106207,-15.693793,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
37,1,"CFQ-R respiratory domain score (absolute change from baseline)","At 1 month","SUBGROUP_AND_OVERALL","NCT02951182","2016",0,0,20.7,12.970343,0,18,2.2,12.503551,0,11,0,0,100,18.5,8.98686,28.01314,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","1::overall","CD010966_pub4_data","significance_only",TRUE,FALSE,TRUE,-0.207750252671045,-0.0819815913269149,-0.673556970156986,0.258056464814896,-0.1207064162904,-0.0432567663634297,TRUE,TRUE
37,2,"FEV1 % predicted (relative change from baseline)","At 1 month","SUBGROUP_AND_OVERALL","NCT02951182","2016",0,0,21.7,11.663254,0,18,2.6,11.089459,0,11,0,0,100,19.1,10.616061,27.583939,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
37,3,"FEV1 % predicted (absolute change from baseline)","Through 1 month","SUBGROUP_AND_OVERALL","NCT02951182","2016",0,0,12,6.434899,0,18,1.4,6.102924,0,11,0,0,100,10.6,5.926231,15.273769,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
37,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 57)","Dyspnoea","SUBGROUP_AND_OVERALL","NCT02951182","2016",0,0,0,0,0,18,0,0,2,11,0,0,100,0.102703,0.001667,6.327216,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
37,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 57)","Oropharyngeal pain","SUBGROUP_AND_OVERALL","NCT02951182","2016",0,0,0,0,0,18,0,0,2,11,0,0,100,0.102703,0.001667,6.327216,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
37,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 57)","Respiration abnormal","SUBGROUP_AND_OVERALL","NCT02951182","2016",0,0,0,0,0,18,0,0,2,11,0,0,100,0.102703,0.001667,6.327216,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
37,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 57)","Number of participants with treatment-emergent adverse events","SUBGROUP_AND_OVERALL","NCT02951182","2016",0,0,0,0,15,18,0,0,9,11,0,0,100,1.111111,0.083347,14.812338,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
37,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 57)","Upper respiratory tract infection","SUBGROUP_AND_OVERALL","NCT02951182","2016",0,0,0,0,2,18,0,0,0,11,0,0,100,3.484848,0.057104,212.667052,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
37,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 57)","Alanine aminotransferase increased","SUBGROUP_AND_OVERALL","NCT02951182","2016",0,0,0,0,2,18,0,0,1,11,0,0,100,1.25,0.045136,34.617715,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
37,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 57)","Aspartate aminotransferase increased","SUBGROUP_AND_OVERALL","NCT02951182","2016",0,0,0,0,2,18,0,0,1,11,0,0,100,1.25,0.045136,34.617715,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
37,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 57)","Number of participants with serious adverse events","SUBGROUP_AND_OVERALL","NCT02951182","2016",0,0,0,0,2,18,0,0,0,11,0,0,100,3.484848,0.057104,212.667052,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
37,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 57)","Cough","SUBGROUP_AND_OVERALL","NCT02951182","2016",0,0,0,0,2,18,0,0,5,11,0,0,100,0.15,0.012525,1.79644,"Have combined the data from clinicaltrials.gov for 'Cough' and 'Productive cough' here.","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
37,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 57)","Sputum increased","SUBGROUP_AND_OVERALL","NCT02951182","2016",0,0,0,0,1,18,0,0,3,11,0,0,100,0.156863,0.006571,3.744695,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
37,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 57)","Diarrhoea","SUBGROUP_AND_OVERALL","NCT02951182","2016",0,0,0,0,2,18,0,0,1,11,0,0,100,1.25,0.045136,34.617715,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
37,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 57)","Abdominal pain","SUBGROUP_AND_OVERALL","NCT02951182","2016",0,0,0,0,2,18,0,0,0,11,0,0,100,3.484848,0.057104,212.667052,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
37,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 57)","Viral upper respiratory tract infection","SUBGROUP_AND_OVERALL","NCT02951182","2016",0,0,0,0,2,18,0,0,1,11,0,0,100,1.25,0.045136,34.617715,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
37,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 57)","Dizziness","SUBGROUP_AND_OVERALL","NCT02951182","2016",0,0,0,0,0,18,0,0,2,11,0,0,100,0.102703,0.001667,6.327216,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
37,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 57)","Infective pulmonary exacerbations","SUBGROUP_AND_OVERALL","NCT02951182","2016",0,0,0,0,3,18,0,0,2,11,0,0,100,0.9,0.067511,11.997993,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
37,5,"Sweat chloride (absolute change from baseline)","At 1 month","SUBGROUP_AND_OVERALL","NCT02951182","2016",0,0,-33.1,12.065436,0,18,1.6,11.61044,0,11,0,0,100,-34.7,-43.539903,-25.860097,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
38,1,"CFQ-R respiratory domain score (absolute change from baseline)","At one month","SUBGROUP_AND_OVERALL","NCT02951182","2016",0,0,12.3,7.798905,0,20,-7.8,6.670252,0,6,0,0,100,20.1,13.762153,26.437847,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","1::overall","CD010966_pub4_data","significance_only",TRUE,FALSE,TRUE,-0.207750252671045,-0.0819815913269149,-0.673556970156986,0.258056464814896,-0.1207064162904,-0.0432567663634297,TRUE,TRUE
38,2,"FEV1 % predicted (relative change from baseline)","At 1 month","SUBGROUP_AND_OVERALL","NCT02951182","2016",0,0,16.6,9.615089,0,20,-3.4,7.623145,0,6,0,0,100,20,12.586286,27.413714,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","2::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.102162499947729,0.0287492150521981,-0.310532954451865,0.106207954556406,0.0150973340891456,0.0424010960152505,TRUE,TRUE
38,3,"FEV1 % predicted (absolute change from baseline)","Through 1 month","SUBGROUP_AND_OVERALL","NCT02951182","2016",0,0,9.5,5.662219,0,20,-2.5,4.478598,0,6,0,0,100,12,7.641113,16.358887,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","3::overall","CD010966_pub4_data","direction_only",FALSE,FALSE,FALSE,-0.156314503905124,0.00286798264544102,-0.410530648038037,0.0979016402277896,-0.0306023682313756,0.0363383335222577,TRUE,TRUE
38,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 85)","Diarrhoea","SUBGROUP_AND_OVERALL","NCT02951182","2016",0,0,0,0,4,20,0,0,0,6,0,0,100,3.545455,0.063599,197.649942,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
38,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 85)","Abdominal pain","SUBGROUP_AND_OVERALL","NCT02951182","2016",0,0,0,0,0,20,0,0,1,6,0,0,100,0.089431,0.001115,7.171548,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
38,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 85)","Cough","SUBGROUP_AND_OVERALL","NCT02951182","2016",0,0,0,0,5,20,0,0,0,6,0,0,100,4.612903,0.085286,249.501531,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
38,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 85)","Nasal congestion","SUBGROUP_AND_OVERALL","NCT02951182","2016",0,0,0,0,2,20,0,0,0,6,0,0,100,1.756757,0.027427,112.524915,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
38,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 85)","Lower respiratory tract congestion","SUBGROUP_AND_OVERALL","NCT02951182","2016",0,0,0,0,2,20,0,0,0,6,0,0,100,1.756757,0.027427,112.524915,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
38,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 85)","Adjustment disorder","SUBGROUP_AND_OVERALL","NCT02951182","2016",0,0,0,0,0,20,0,0,1,6,0,0,100,0.089431,0.001115,7.171548,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
38,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 85)","Anorectal discomfort","SUBGROUP_AND_OVERALL","NCT02951182","2016",0,0,0,0,0,20,0,0,1,6,0,0,100,0.089431,0.001115,7.171548,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
38,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 85)","Viral upper respiratory tract infection","SUBGROUP_AND_OVERALL","NCT02951182","2016",0,0,0,0,1,20,0,0,2,6,0,0,100,0.105263,0.003314,3.343677,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
38,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 85)","Infective pulmonary exacerbation of cystic fibrosis","SUBGROUP_AND_OVERALL","NCT02951182","2016",0,0,0,0,3,20,0,0,1,6,0,0,100,0.882353,0.034206,22.76072,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
38,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 85)","Upper respiratory tract infection","SUBGROUP_AND_OVERALL","NCT02951182","2016",0,0,0,0,2,20,0,0,0,6,0,0,100,1.756757,0.027427,112.524915,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
38,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 85)","Number of participants with serious adverse events","SUBGROUP_AND_OVERALL","NCT02951182","2016",0,0,0,0,1,20,0,0,2,6,0,0,100,0.105263,0.003314,3.343677,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
38,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 85)","Sputum increased","SUBGROUP_AND_OVERALL","NCT02951182","2016",0,0,0,0,3,20,0,0,1,6,0,0,100,0.882353,0.034206,22.76072,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
38,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 85)","Number of participants with treatment-emergent adverse events","SUBGROUP_AND_OVERALL","NCT02951182","2016",0,0,0,0,15,20,0,0,6,6,0,0,100,0.216783,0.004008,11.725315,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
38,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 85)","Folliculitis","SUBGROUP_AND_OVERALL","NCT02951182","2016",0,0,0,0,0,20,0,0,1,6,0,0,100,0.089431,0.001115,7.171548,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
38,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 85)","Pharyngitis","SUBGROUP_AND_OVERALL","NCT02951182","2016",0,0,0,0,0,20,0,0,1,6,0,0,100,0.089431,0.001115,7.171548,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
38,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 85)","Alanine aminotransferase increased","SUBGROUP_AND_OVERALL","NCT02951182","2016",0,0,0,0,2,20,0,0,0,6,0,0,100,1.756757,0.027427,112.524915,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
38,4,"Most common adverse events (occurring in at least 10% of participants in either group) (at day 85)","Insomnia","SUBGROUP_AND_OVERALL","NCT02951182","2016",0,0,0,0,0,20,0,0,1,6,0,0,100,0.089431,0.001115,7.171548,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","4::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0778155637605283,0.0168192333958693,-0.195390192005482,0.0397590644844249,0.00451581171014535,0.0291226550815932,TRUE,TRUE
38,5,"Sweat chloride (absolute change from baseline)","Through 1 month","SUBGROUP_AND_OVERALL","NCT02951182","2016",0,0,-31.3,15.490976,0,20,2.1,12.387611,0,6,0,0,100,-33.4,-45.414116,-21.385884,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub4/full","10.1002/14651858.CD010966.pub4","5::overall","CD010966_pub4_data","direction_and_significance",FALSE,FALSE,TRUE,-0.0988757407469023,0.0237719933344068,-0.334396255569982,0.136644774076178,0.00663519284044899,0.0409087938283647,TRUE,TRUE
